<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="iso-abbrev">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="publisher-id">OMCL</journal-id><journal-title-group><journal-title>Oxidative Medicine and Cellular Longevity</journal-title></journal-title-group><issn pub-type="ppub">1942-0900</issn><issn pub-type="epub">1942-0994</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7576349</article-id><article-id pub-id-type="doi">10.1155/2020/2360872</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9528-0361</contrib-id><name><surname>Perc&#x000e1;rio</surname><given-names>Sandro</given-names></name><email>spercario49@gmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4125-4392</contrib-id><name><surname>da Silva Barbosa</surname><given-names>Aline</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9710-3791</contrib-id><name><surname>Varela</surname><given-names>Everton Luiz Pompeu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4700-7942</contrib-id><name><surname>Gomes</surname><given-names>Ant&#x000f4;nio Rafael Quadros</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3073-3518</contrib-id><name><surname>Ferreira</surname><given-names>Michelli Erica Souza</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6150-2413</contrib-id><name><surname>de Nazar&#x000e9; Ara&#x000fa;jo Moreira</surname><given-names>Thayana</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0804-5804</contrib-id><name><surname>Dolabela</surname><given-names>Maria Fani</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Oxidative Stress Research Laboratory, Institute of Biological Sciences, Federal University of Par&#x000e1;, Av. Augusto Corr&#x000ea;a, 01, Bel&#x000e9;m, Par&#x000e1;, Brazil 66075-110</aff><aff id="I2">
<sup>2</sup>Institute of Health Sciences, Federal University of Par&#x000e1;, Av. Augusto Corr&#x000ea;a, 01, Bel&#x000e9;m, Par&#x000e1;, Brazil 66075-110</aff><author-notes><fn fn-type="other"><p>Academic Editor: Patricia Morales</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>2360872</elocation-id><history><date date-type="received"><day>2</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>6</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Sandro Perc&#x000e1;rio et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Parkinson's disease (PD) occurs in approximately 1% of the population over 65 years of age and has become increasingly more common with advances in age. The number of individuals older than 60 years has been increasing in modern societies, as well as life expectancy in developing countries; therefore, PD may pose an impact on the economic, social, and health structures of these countries. Oxidative stress is highlighted as an important factor in the genesis of PD, involving several enzymes and signaling molecules in the underlying mechanisms of the disease. This review presents updated data on the involvement of oxidative stress in the disease, as well as the use of antioxidant supplements in its therapy.</p></abstract><funding-group><award-group><funding-source>Universidade Federal do Par&#x000e1;</funding-source></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Parkinson's disease (PD) is considered cosmopolitan and makes no distinction between social classes or between races, affecting both men and women, especially in the age range between 55 and 65 years, but it tends to occur with greater frequency in men [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>].</p><p>It is estimated that this disorder affects approximately 1% of the world population older than 65 years, representing up to 2/3 of all patients with movement disorders throughout the world [<xref rid="B3" ref-type="bibr">3</xref>]. PD has become increasingly more common with advances in age, reaching proportions of 2.6% of the population over 85 years old.</p><p>According to Silberman et al. [<xref rid="B4" ref-type="bibr">4</xref>], the number of individuals older than 60 years has been increasing, as has life expectancy in developing countries. Thus, along with health issues associated with an aging population, PD also imposes a significant impact on the economic, social, and health structures of these countries [<xref rid="B5" ref-type="bibr">5</xref>]. Therefore, a greater knowledge about the disease and an improvement of the planning of public health to minimize its impact in the future are necessary. Moreover, it is estimated that by 2020, approximately 40 million people worldwide will develop motor disorders secondary to PD [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>].</p></sec><sec id="sec2"><title>2. The Involvement of Oxidative Stress in PD</title><p>Oxidative stress is the result of many metabolic processes essential to the body. On the other hand, it can exert a toxic and deleterious role in the body [<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Oxidative changes are highlighted as an important factor in the genesis of Parkinson's disease (<xref ref-type="fig" rid="fig1">Figure 1</xref>), with the activation of glial cells being the main source of oxidative stress [<xref rid="B9" ref-type="bibr">9</xref>]. Some key enzymes are involved in the genesis of oxidative species derived from oxygen and nitrogen, namely, reduced nicotinamide adenine dinucleotide phosphate oxidase (NADPH), inducible nitric oxide synthase (iNOS), and astrocytic myeloperoxidase (MPO) [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>], as well as inflammatory factors, such as tumor necrosis factor alpha (TNF-<italic>&#x003b1;</italic>) [<xref rid="B17" ref-type="bibr">17</xref>] and cyclooxygenase-2 (COX-2) [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>During the pathogenesis of PD, the production of oxygen-reactive species damages the <italic>substantia nigra</italic> through lipid peroxidation, protein oxidation, and DNA oxidation. This phenomenon seems to be induced mainly by changes in iron content of the brain, mitochondrial dysfunction, monoamine oxidase (MAO) activation, or even by changes in the antioxidant defense system [<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>].</p><p>Additional redox pathways involved in PD are androgen receptor-induced neurodegeneration [<xref rid="B24" ref-type="bibr">24</xref>], production of oxidatively modified forms of <italic>&#x003b1;</italic>-synuclein and increased <italic>&#x003b1;</italic>-synuclein aggregation [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>], degradation of antioxidant enzyme quinone oxidoreductase 1 (NQO1) [<xref rid="B27" ref-type="bibr">27</xref>], reduction of the deglycase activity of protein DJ-1 [<xref rid="B28" ref-type="bibr">28</xref>], activation of gene LRRK2 [<xref rid="B29" ref-type="bibr">29</xref>], and tetrahydrobiopterin (BH4) and tyrosine hydroxylase (TH) metabolism impairment [<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Other evidence of oxidative stress involvement in PD was given by Colamartino et al. [<xref rid="B31" ref-type="bibr">31</xref>], who demonstrated that L-dihydroxyphenylalanine (L-DOPA) therapy decreases markers of lipid and protein peroxidation and increases total levels of reduced glutathione (GSH). In addition, L-DOPA and carbidopa can reduce damage to DNA and micronuclei induced by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) <italic>in vitro</italic>.</p><p>Indeed, increased levels of oxidative stress markers are already found in blood from PD patients [<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>] and animal models of the disease [<xref rid="B35" ref-type="bibr">35</xref>].</p><p>In this sense, Farias et al. [<xref rid="B36" ref-type="bibr">36</xref>], investigating the peripheral biomarkers of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in PD patients, found increased lipid hydroperoxides (LOOH), malondialdehyde (MDA) levels, and superoxide dismutase (SOD) activity, alongside decreased catalase (CAT) activity. Furthermore, these authors suggest that MDA may be a PD biomarker, while LOOH and SOD would be associated with late PD features.</p><p>To study oxidative changes in this neurodegenerative disease, an experimental mouse model of the disease is often used, in which damage to the dopaminergic neurons of the <italic>substantia nigra pars compacta</italic> is induced by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which promotes activation of microglial cells [<xref rid="B9" ref-type="bibr">9</xref>]. The peripheral administration of this neurotoxin promotes important gliosis, accompanied by increased activation of iNOS in the <italic>substantia nigra</italic>, as well as of NADPH oxidase and MPO.</p><p>Furthermore, protein oxidation has already been identified as a marker of oxidative damage in <italic>postmortem</italic> brain tissue from PD patients [<xref rid="B37" ref-type="bibr">37</xref>].</p><p>Abraham et al. [<xref rid="B38" ref-type="bibr">38</xref>] evaluated the possibility of oxidative damage to red blood cells of PD patients by evaluating the activity of antioxidant enzymes, verifying that the activities of SOD, CAT, glutathione peroxidase (GSH-Px), and glucose-6-phosphate dehydrogenase (G6PD) were significantly lower in PD patients. Consequently, these authors suggested the involvement of oxidative stress as a risk factor for the disease and pointed out its importance in the underlying mechanisms of neurodegeneration in PD.</p><p>Venkateshappa et al. [<xref rid="B39" ref-type="bibr">39</xref>] evaluated the redox state of the <italic>substantia nigra</italic> and <italic>caudate nucleus</italic> during physiological aging in the human brain by assessing the expression of glial fibrillary acidic protein (GFAP) and activity of mitochondrial complex 1. The authors observed a significant increase in protein oxidation, loss of mitochondrial complex 1 activity, and increase in astrocytic proliferation in the <italic>substantia nigra</italic> compared to the <italic>caudate nucleus</italic> as age increased. These changes in the <italic>substantia nigra</italic> were attributed to a significant decrease in the antioxidant function represented by SOD, GSH-Px, and GSH, and a decreasing trend of GSH and CAT with age. However, these parameters showed no significant differences in the <italic>caudate nucleus</italic>. These results led the authors to suggest that the <italic>substantia nigra</italic> suffers extensive oxidative damage, loss of antioxidants and mitochondrial function, and increased expression of GFAP during physiological aging, changes that could make it more vulnerable to neurotoxic environments, thereby contributing to selective degeneration during the evolution of PD.</p><p>The oxidative imbalance involved in PD neurodegenerative processes seems to be a multifactorial phenomenon triggered by factors such as the aging of the brain, genetic predisposition, mitochondrial dysfunction, production of free radicals, and environmental toxins [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>]. Nevertheless, some mechanisms are of key importance for the development of PD (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><sec id="sec2.1"><title>2.1. Iron and Iron-Dependent Free Radical Production</title><p>Iron also plays an important role in the oxidative changes of Parkinson's disease, as it is present in various regions of the brain, noteworthy in dopaminergic neurons of the <italic>substantia nigra</italic> [<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>]. Iron accumulation associated with neuromelanine can represent one of the causes of increased free radicals in the <italic>substantia nigra</italic> and consequently lead to oxidative stress and neurodegeneration [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B45" ref-type="bibr">45</xref>].</p><p>Being rich in this metal, dopaminergic neurons are very susceptible to Fenton's or Haber-Weiss' reactions, which convert H<sub>2</sub>O<sub>2</sub> to hydroxyl radicals, powerful oxidizing agents. Therefore, the presence of large quantities of ferrous ions (Fe<sup>2+</sup>) in the <italic>substantia nigra</italic> promotes high oxidative stress, DNA damage, and cell death by autophagy [<xref rid="B46" ref-type="bibr">46</xref>]. Additionally, under the action of SOD, free radical superoxide (O<sub>2</sub><sup>&#x02022;-</sup>) undergoes dismutation to H<sub>2</sub>O<sub>2</sub>, which, in the presence of high concentrations of iron, produces hydroxyl radicals (OH<sup>&#x02022;</sup>) through Fenton's reaction.</p><p>In this context, Hochstrasser et al. [<xref rid="B47" ref-type="bibr">47</xref>] and Olivieri et al. [<xref rid="B48" ref-type="bibr">48</xref>] studied the role of ceruloplasmin in this disease, an extracellular ferroxidase that oxidizes iron from its toxic ferrous form to the nontoxic ferric form. Analyzing the cerebrospinal fluid of patients with PD, Olivieri et al. found higher levels of ceruloplasmin oxidation in these patients than in controls or in subjects with other neurodegenerative diseases. Similarly, ceruloplasmin-deficient mice showed accumulation of iron in the central nervous system and increased lipid peroxidation [<xref rid="B49" ref-type="bibr">49</xref>], and ceruloplasmin deficiency due to copper dyshomeostasis is reported in PD patients [<xref rid="B50" ref-type="bibr">50</xref>]. Treatment with another iron chelator, lactoferrin, also offered protection against oxidative stress in MPTP-induced PD mice [<xref rid="B51" ref-type="bibr">51</xref>].</p><p>Moreover, iron can lead to the formation of Lewy bodies through the aggregation of <italic>&#x003b1;</italic>-synuclein [<xref rid="B52" ref-type="bibr">52</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>]. Alpha-synuclein is an abundant protein in presynaptic terminals and is responsible for the formation of Lewy bodies&#x02014;mainly by its iron-dependent binding to cytochrome <italic>c</italic> and mitochondrial damage&#x02014;via regulation of mitochondrial complex 1, increasing susceptibility of the <italic>substantia nigra</italic> to free radicals in PD [<xref rid="B58" ref-type="bibr">58</xref>&#x02013;<xref rid="B63" ref-type="bibr">63</xref>]. Bayir et al. [<xref rid="B61" ref-type="bibr">61</xref>] and Rostovtseva et al. [<xref rid="B64" ref-type="bibr">64</xref>] investigated the biochemical mechanism of action of <italic>&#x003b1;</italic>-synuclein and showed that this protein can bind to anionic lipids (such as cardiolipin), exerting peroxidase function while protecting <italic>nigral</italic> neurons against damage by H<sub>2</sub>O<sub>2</sub> and consequently preventing apoptosis. Shahnawaz et al. [<xref rid="B65" ref-type="bibr">65</xref>] suggest that detection of <italic>&#x003b1;</italic>-synuclein by protein misfolding cyclic amplification in cerebrospinal fluid may provide an efficient biochemical test for the diagnosis of PD.</p><p>Reinforcing the importance of iron in the underlying neuropathogenic changes of PD, the use of iron chelators in models of nigral neurodegeneration induced by proteasome inhibitors showed a decreased loss of dopaminergic neurons as well as a decreased <italic>&#x003b1;</italic>-synuclein aggregation and a consequential reduced formation of Lewy bodies [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B66" ref-type="bibr">66</xref>].</p><p>In addition, the toxic effects of oxidative stress seem to be boosted by environment-present substances, such as herbicide paraquat (1,1&#x02032;-dimethyl-4,4&#x02032;-bipiridina dichloride), frequently used in agriculture, which operates in synergism with iron when absorbed by the organism. As a consequence of paraquat poisoning, the increase in free radical production in several areas of the body, including the <italic>substantia nigra</italic>, peters out the antioxidant capacity of SOD and CAT, and promotes cell death [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B67" ref-type="bibr">67</xref>].</p></sec><sec id="sec2.2"><title>2.2. Mitochondrial Dysfunction</title><p>Mitochondrial dysfunction is commonly associated with neurodegenerative diseases. In PD, genetic mutations associated with the mitochondria and the action of toxic agents, such as rotenone and MPTP, lead to failures in the electron transport chain and the consequent increase in oxidative stress, accumulation of intracellular Ca<sup>2+</sup>, glutamate excitotoxicity, and decrease in energy production, culminating in neuronal damage and death [<xref rid="B68" ref-type="bibr">68</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>].</p><p>Deficiency of complex 1 (NADH-ubiquinone oxidoreductase), a macrocomplex in the electron transport chain encoded by mitochondrial DNA, seems to be one of the causes of oxidative stress increase and bioenergetic deficiency in PD [<xref rid="B70" ref-type="bibr">70</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>]. However, the mechanisms by which it occurs in PD are not fully elucidated. Nevertheless, it is known that the oxidation of cysteine residues by iron culminates in mitochondrial dysfunction in experimental models of the disease [<xref rid="B73" ref-type="bibr">73</xref>].</p><p>Studies that verify the toxic effects of rotenone on complex 1 demonstrate that its partial inhibition is related to increased levels of superoxide radicals. In addition, oxidative stress potentiates the deregulation of intracellular Ca<sup>2+</sup> induced by the accumulation of glutamate, leading to cell death by necrosis. Moreover, the accumulation of intracellular glutamate increases the demand for ATP, diminishing mitochondrial respiratory capacity and causing a failure in the electron transport chain [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B74" ref-type="bibr">74</xref>&#x02013;<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Alternatively, the decrease in the activity of complex 1 may be related to mechanisms of intracellular self-oxidation due to mitochondrial abnormalities or failures in complex 1 assembly [<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B76" ref-type="bibr">76</xref>].</p><p>Indeed, the association between mitochondrial dysfunction and oxidative stress seems perfectly relevant in PD, since mitochondrial heat-shock proteins, such as mortalin, mitochondrial heat-shock protein 70 (mtHsp70), and glucose-regulated protein 75 (GRP75), were found to be significantly increased in patients with the disease [<xref rid="B77" ref-type="bibr">77</xref>&#x02013;<xref rid="B79" ref-type="bibr">79</xref>].</p></sec><sec id="sec2.3"><title>2.3. Oxidative Stress-Mediated Gene Expression</title><p>Some authors attribute the regulation of PD genes to oxidative stress. Among them, the DJ-1 gene appears to be a preponderant factor for the development of PD. When active, the gene decreases the expression of oxidative stress markers and prevents neurological damage. The opposite occurs when this gene is inactivated or mutated: markers of stress increase, as well as the predisposition to disease [<xref rid="B80" ref-type="bibr">80</xref>&#x02013;<xref rid="B88" ref-type="bibr">88</xref>]. Such a mechanism seems to be related to residues of cysteine inherent to the DJ-1 gene [<xref rid="B89" ref-type="bibr">89</xref>]. In addition, this gene induces the synthesis of glutathione and inhibits the toxicity of <italic>&#x003b1;</italic>-synuclein [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B90" ref-type="bibr">90</xref>].</p><p>Steckley et al. [<xref rid="B91" ref-type="bibr">91</xref>], Qi et al. [<xref rid="B92" ref-type="bibr">92</xref>], and Feng et al. [<xref rid="B93" ref-type="bibr">93</xref>] attributed the regulation of oxidative stress and, consequently, neuronal apoptosis to the gene PUMA, one of the genes of the Bcl-2 family. This gene is responsible for the permeability of the mitochondrial membrane.</p><p>Activation of the LRRK2 gene may also be responsible for increased oxidative stress and neuronal loss in PD [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>As suggested by Chen et al. [<xref rid="B94" ref-type="bibr">94</xref>] and Haskew-Layton et al. [<xref rid="B95" ref-type="bibr">95</xref>], the negative regulation of genes related to antioxidant defenses via stimulation of nuclear factor erythroid 2 (NF-E2) is positively correlated with the destruction of astrocytes. The same happens with PTEN-induced putative kinase 1 (PINK1), a gene that inhibits mitochondrial dysfunction and is positively related to neuroprotection [<xref rid="B96" ref-type="bibr">96</xref>].</p><p>According to Cook et al. [<xref rid="B97" ref-type="bibr">97</xref>], mutations in the <italic>parkin</italic> gene and the abnormal accumulation of <italic>&#x003b1;</italic>-synuclein proteins in certain dopaminergic neurons are closely related to PD and oxidative stress. In this sense, Basso et al. [<xref rid="B98" ref-type="bibr">98</xref>], by inhibiting transglutaminase, observed a reduction in markers of oxidative stress and a decrease in neuronal death, features of PD.</p></sec><sec id="sec2.4"><title>2.4. Role of Nitric Oxide (NO)</title><p>Some studies suggest that NO plays an important role as a mediator of the neurotoxicity associated with mitochondrial damage in several neurological disorders, such as PD [<xref rid="B99" ref-type="bibr">99</xref>]. Under pathological conditions, the expression of iNOS and NADPH oxidase activity occurs in microglia, leading to high production of NO and O<sub>2</sub><sup>&#x02022;-</sup>. These two free radicals react to produce peroxynitrite radicals (ONOO<sup>&#x02212;</sup>), a highly reactive molecule that can cause damage to dopaminergic neurons.</p><p>Evidencing the importance of NO synthesis and its byproducts in the physiopathology of PD, nitration of tyrosine residues is a known marker of oxidative stress in patients with Parkinson's disease and is induced by ONOO<sup>&#x02212;</sup> [<xref rid="B100" ref-type="bibr">100</xref>&#x02013;<xref rid="B101" ref-type="bibr">101</xref>]. In this context, Sue et al. [<xref rid="B102" ref-type="bibr">102</xref>] studied the effects of ethyl pyruvate (EP), a known scavenger of reactive oxygen species, in mice treated with MPTP, demonstrating that EP mitigates iNOS expression in the <italic>substantia nigra</italic>, reducing oxidative damage.</p><p>Similarly, Yeung et al. [<xref rid="B103" ref-type="bibr">103</xref>] demonstrated that aldose reductase deficiency, a tyrosine hydroxylase cofactor involved in dopamine synthesis, can induce oxidative stress by increasing NO and nitrite (NO<sub>2</sub><sup>&#x02212;</sup>), causing the loss of dopaminergic neurons and autophagic abnormalities in animals with PD.</p><p>Notwithstanding, iNOS knockout mice are more resistant to the neurodegenerative effects of MPTP than wild-type mice [<xref rid="B10" ref-type="bibr">10</xref>]. The same effect is observed in animals treated with specific inhibitors of neuronal nitric oxide synthase (nNOS), such as 7-nitroindazole [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Conversely, Rathnayake et al. [<xref rid="B17" ref-type="bibr">17</xref>] identified that low serum NO metabolites (nitrites and nitrates (NOx)) are associated with cognitive impairment in PD patients, proposing NOx as a marker of early-stage PD.</p><p>Indeed, the dopaminergic neurotoxin MPTP is associated with the induction of iNOS in the <italic>substantia nigra</italic>, leading to the formation of ONOO<sup>&#x02212;</sup> [<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B104" ref-type="bibr">104</xref>], and the administration of MPTP in rats induces considerable gliosis in the <italic>substantia nigra</italic>, as well as a significant positive regulation over iNOS [<xref rid="B105" ref-type="bibr">105</xref>]. Moreover, in iNOS gene-deficient rats, the neurodegenerative effects of MPTP administration were less prominent, suggesting the inhibition of iNOS as a potential target for drugs in the treatment of PD [<xref rid="B105" ref-type="bibr">105</xref>]. Additionally, the use of nitric oxide synthase (NOS) inhibitors prevents dyskinesia in Parkinson's disease, at least in part via inhibition of glial cell activation and iNOS expression, showing the role of NO in the pathogenesis of PD [<xref rid="B106" ref-type="bibr">106</xref>]. Moreover, astrocytes express high levels of MPO, which produce hypochlorous acid (HOCl) from the reaction of H<sub>2</sub>O<sub>2</sub> and chloride ions (Cl<sup>&#x02212;</sup>), causing additional oxidative damage. The presence of HOCl can increase the amount of OH<sup>&#x02022;</sup>, as HOCl can also react with O<sub>2</sub><sup>&#x02022;-</sup>. Myeloperoxidase also catalyzes the conversion of nitrite from its nonreactive form (NO<sub>2</sub><sup>&#x02212;</sup>) to its free radical form (NO<sub>2</sub><sup>&#x02022;-</sup>), enhancing protein damage [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>This was also evidenced in the experimental model of neurodegeneration proposed by Ebadi and Sharma [<xref rid="B107" ref-type="bibr">107</xref>], in which the activation of iNOS, the synthesis of NO, and the generation of peroxynitrite were associated with <italic>nigrostriatal</italic> dopaminergic neurodegeneration and that animals that overexpressed the genes metallothioneins 1 and 2 showed greater protection against damage caused by oxidative stress due to iNOS activation.</p></sec><sec id="sec2.5"><title>2.5. Role of MAO, MPO, and NADPH Oxidase</title><p>In addition to the free radical-generating processes already mentioned, the reactions catalyzed by MAO are also potential free radical generators and are related to the decrease in intrinsic antioxidant defenses [<xref rid="B108" ref-type="bibr">108</xref>&#x02013;<xref rid="B109" ref-type="bibr">109</xref>].</p><p>At the intracellular level, dopamine is degraded both by MAO and by autooxidation [<xref rid="B110" ref-type="bibr">110</xref>&#x02013;<xref rid="B111" ref-type="bibr">111</xref>]. The metabolism of dopamine leads to the formation of dihydroxyphenylacetic acid (DOPAC) and H<sub>2</sub>O<sub>2</sub> [<xref rid="B112" ref-type="bibr">112</xref>]. The autooxidation of intracellular dopamine produces H<sub>2</sub>O<sub>2</sub> and dopamine-quinone, which participate in nucleophilic reactions associated with sulfhydryl groups, leading to further reduction of GSH-Px activity [<xref rid="B113" ref-type="bibr">113</xref>].</p><p>Dopamine-quinone is also capable of inhibiting the function of the dopamine transporter within synaptosomes by inhibiting the enzyme tyrosine hydroxylase, resulting in incomplete ATP synthesis [<xref rid="B114" ref-type="bibr">114</xref>&#x02013;<xref rid="B116" ref-type="bibr">116</xref>]. The ratio between GSH and oxidized glutathione (GSSG) is decreased during synaptosome degeneration, thus propitiating the formation of even more free radicals [<xref rid="B117" ref-type="bibr">117</xref>&#x02013;<xref rid="B118" ref-type="bibr">118</xref>]. Furthermore, the decrease in the GSH/GSSG ratio can impair free radical scavenging by GSH, as a reflection of constant oxidation of the GSH molecule and consequent depletion of cellular GSH [<xref rid="B119" ref-type="bibr">119</xref>]. In studies with cells in culture, GSH depletion has been related to the toxicity of dopamine and H<sub>2</sub>O<sub>2</sub> [<xref rid="B120" ref-type="bibr">120</xref>].</p><p>In addition to dopamine metabolism, MAO can metabolize MPTP by the action of MAO-B. MPTP is oxidized to dihydropyridine (MPDP<sup>+</sup>) and converted to N-methyl-4-phenylpyridine (MPP<sup>+</sup>) by autooxidation, binding to dopamine transporter proteins. Subsequently, it is retaken by dopaminergic <italic>nigral</italic> neurons [<xref rid="B121" ref-type="bibr">121</xref>]. Once in the cytosol, MPP<sup>+</sup> promotes the inhibition of complex 1, as well as the production of free radicals (through the activation of NADPH oxidase, microglial iNOS, and astroglial myeloperoxidase) and the production of proinflammatory cytokines, such as TNF-<italic>&#x003b1;</italic> and interleukin-1<italic>&#x003b2;</italic> (IL-1<italic>&#x003b2;</italic>). These phenomena contribute to the death of dopaminergic neurons in experimental models of PD [<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B122" ref-type="bibr">122</xref>].</p><p>Likewise, MPO is an important component of the PD puzzle. In <italic>postmortem</italic> mesencephalic analysis of PD patients, Choi et al. [<xref rid="B13" ref-type="bibr">13</xref>] observed significantly higher levels of MPO than in controls. In the same study, using the MPTP model of PD, they found high levels of 3-chlorotyrosine, a marker of MPO protein damage. These authors also demonstrated that MPO-deficient mice are resistant to MPTP neurotoxicity. In parallel, Maki et al. [<xref rid="B16" ref-type="bibr">16</xref>] also demonstrated that MPO plays an important role in oxidative damage to <italic>&#x003b1;</italic>-synuclein. Moreover, the prooxidant effect of MPTP in animal models of PD was minimized using paroxetine (an antidepressant drug), which promoted the reduction of astroglial MPO expression, production of ROS through NADPH oxidase, and the expression of proinflammatory cytokines, decreasing the loss of dopaminergic neurons and improving motor functions. These effects suggest the role of oxidative stress in the pathogenesis of PD, and therefore, the use of drugs designed to decrease the neurodegenerative effects caused by free radicals displays great potential for the treatment of the disease [<xref rid="B123" ref-type="bibr">123</xref>].</p><p>Furthermore, the role of NADPH oxidase in oxidative damage in PD was demonstrated through the treatment of PD-induced mice with a nonselective agonist of cannabinoid receptor. This treatment promoted suppression of O<sub>2</sub><sup>&#x02022;-</sup> production by NADPH oxidase in the <italic>microglia</italic>, and oxidative damage to nucleic acid and protein levels were reduced [<xref rid="B124" ref-type="bibr">124</xref>]. The damage to nucleic acid was evaluated by the dosage of 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative damage to the DNA. Likewise, 8-OHdG was elevated in the cerebrospinal fluid of patients with PD in comparison to control subjects [<xref rid="B32" ref-type="bibr">32</xref>].</p></sec></sec><sec id="sec3"><title>3. Antioxidant Approaches to PD</title><p>Considering all factors related to oxidative stress overstimulation in the underlying mechanisms of PD, numerous studies have suggested the potential beneficial effects of antioxidant supplementation in PD treatment, and several approaches have been attempted so far, from traditional antioxidant schemes, such as vitamin E, C, and <italic>&#x003b2;</italic>-carotene supplementation, to more innovative and bold approaches, such as the use of nanoparticles to deliver antioxidant molecules, among several others.</p><p>Indeed, several studies show that brains from PD patients present low levels of endogenous antioxidants, such as glutathione and coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) [<xref rid="B125" ref-type="bibr">125</xref>], increased oxidation of dopamine [<xref rid="B115" ref-type="bibr">115</xref>], and high levels of iron [<xref rid="B126" ref-type="bibr">126</xref>], suggesting that oxidative stress plays a crucial role in the pathology of PD. Considering the greater iron content of some areas of the brain [<xref rid="B127" ref-type="bibr">127</xref>], low levels of GSH are expected [<xref rid="B128" ref-type="bibr">128</xref>], as well as increased lipid peroxidation [<xref rid="B129" ref-type="bibr">129</xref>] and oxidation of nucleic acids [<xref rid="B130" ref-type="bibr">130</xref>].</p><p>In addition, Campolo et al. [<xref rid="B131" ref-type="bibr">131</xref>] suggest that the reduction of the total antioxidant capacity observed in the PD prodromal, and when associated with olfactory loss and cardiovascular dysautonomia, may represent a useful biomarker for an early and integrative PD diagnosis.</p><p>In this sense, antioxidants can provide a significant advance in the therapeutic treatment of PD, as it is believed that Parkinson's neurodegeneration is linked to dietary habits and that nutritional deficiency of antioxidant compounds, such as folic acid [<xref rid="B132" ref-type="bibr">132</xref>], vitamins (A, C, E, and niacin), and selenium, increases the risk of subjects developing PD [<xref rid="B133" ref-type="bibr">133</xref>&#x02013;<xref rid="B134" ref-type="bibr">134</xref>]. Thus, the therapeutic approach for the treatment of PD must include the modulation of oxidative stress using antioxidants, which, at least partially, may be provided by an adequate diet.</p><p>Several antioxidant molecules have been used both in experimental and clinical studies of PD and will be categorized and presented henceforth by its source or chemical class when appropriate.</p><sec id="sec3.1"><title>3.1. Endogenous Molecules</title><sec id="sec3.1.1"><title>3.1.1. Melatonin</title><p>A natural antioxidant capable of reducing cellular oxidative stress, melatonin protects mitochondrial functions <italic>in vitro</italic>. Low levels of melatonin were found in PD patients [<xref rid="B135" ref-type="bibr">135</xref>]. Zampol and Barros [<xref rid="B136" ref-type="bibr">136</xref>] prompted a study indicating that melatonin administration to cultured cells reversed <italic>&#x003b1;</italic>-synuclein damage to mitochondria. Additionally, Patki and Lau [<xref rid="B137" ref-type="bibr">137</xref>] investigated whether melatonin could reverse neurobehavioral deficits and mitochondrial disorders in an experimental model of PD, suggesting that, in the long term, melatonin protects not only mitochondria but also neurons in an animal model of chronic PD. Due to this factor, melatonin can potentially be effective in slowing the progression of idiopathic Parkinson's disease and reducing oxidative stress and respiratory chain inhibition in other mitochondrial diseases. In a similar study, Paul et al. [<xref rid="B138" ref-type="bibr">138</xref>] identified that the administration of melatonin protects against behavioral deficits and loss of nigral dopamine and reduces oxidative stress by eliminating OH<sup>&#x02022;</sup> radicals and boosting the activity of antioxidant enzymes in an animal model of PD. Similar results were observed by Li et al. [<xref rid="B139" ref-type="bibr">139</xref>] and Rasheed et al. [<xref rid="B140" ref-type="bibr">140</xref>]. Curiously, despite promoting the reversion of several rotenone- [<xref rid="B141" ref-type="bibr">141</xref>] and 6-OHDA-induced damage in rats [<xref rid="B142" ref-type="bibr">142</xref>], melatonin supplementation to animals was unable to improve locomotor activity. In addition, administration of melatonin to humans promoted reduction of COX-2 activity, nitrites and nitrates, and lipid peroxides that correlated with clinical improvement of PD patients [<xref rid="B143" ref-type="bibr">143</xref>]. Nevertheless, the association of melatonin with L-DOPA significantly decreased the side effects of L-DOPA therapy in mice [<xref rid="B144" ref-type="bibr">144</xref>]. A particular aspect of melatonin administration in PD lies on its effect on the occurrence of sleep disorders, a common finding in PD patients. In this regard, melatonin treatment promoted sleep improvement in animal studies [<xref rid="B145" ref-type="bibr">145</xref>&#x02013;<xref rid="B146" ref-type="bibr">146</xref>], while its effect on clinical trials is controversial [<xref rid="B147" ref-type="bibr">147</xref>&#x02013;<xref rid="B149" ref-type="bibr">149</xref>]. Notwithstanding, one meta-analysis study suggests melatonin therapy as highly indicated for the treatment of sleep disorders in PD patients [<xref rid="B150" ref-type="bibr">150</xref>].</p></sec><sec id="sec3.1.2"><title>3.1.2. Coenzyme Q</title><p>Another important antioxidant system is represented by CoQ<sub>10</sub>, a mitochondrial electron carrier that also acts in the prevention of oxidative damage [<xref rid="B151" ref-type="bibr">151</xref>&#x02013;<xref rid="B152" ref-type="bibr">152</xref>]. It also acts as a cofactor and activator of proteins of mitochondrial coupling [<xref rid="B153" ref-type="bibr">153</xref>]. However, the mechanisms by which CoQ<sub>10</sub> protects dopaminergic neurons against degeneration are still not well understood, although it is known that the reduction of CoQ<sub>10</sub> levels in PD patients induces changes in ATP synthesis and damage to the mitochondrial membrane [<xref rid="B125" ref-type="bibr">125</xref>]. In this sense, oral administration of CoQ<sub>10</sub> in animal models and in patients with PD caused a continuous decrease in mitochondrial dysfunction [<xref rid="B154" ref-type="bibr">154</xref>&#x02013;<xref rid="B155" ref-type="bibr">155</xref>], loss of dopamine and dopaminergic axons [<xref rid="B156" ref-type="bibr">156</xref>], protection of dopaminergic neurons against excitotoxin-induced neurodegeneration in PD [<xref rid="B157" ref-type="bibr">157</xref>&#x02013;<xref rid="B158" ref-type="bibr">158</xref>], and partial improvement of motor performance [<xref rid="B159" ref-type="bibr">159</xref>]. However, a clinical trial conducted with 600 patients showed no evidence of benefit for CoQ<sub>10</sub> supplementation [<xref rid="B160" ref-type="bibr">160</xref>], a result supported by a recent meta-analysis [<xref rid="B161" ref-type="bibr">161</xref>].</p></sec><sec id="sec3.1.3"><title>3.1.3. Urate</title><p>High levels of urate have been associated with a lower risk for PD [<xref rid="B162" ref-type="bibr">162</xref>], and changes in urate levels can predict the development of PD in animal models of the disease [<xref rid="B163" ref-type="bibr">163</xref>]. Coolen et al. [<xref rid="B164" ref-type="bibr">164</xref>], in a study with daily oral supplementation of 5000&#x02009;mg of ATP in humans, identified that there was an increase in uric acid. In parallel, Andreadou et al. [<xref rid="B165" ref-type="bibr">165</xref>] detected the presence of reduced serum levels of this antioxidant molecule in patients with PD and suggested the potential use of this molecule in the therapy of the disease. Indeed, feeding a 1% uric acid diet to rats reversed PD symptoms [<xref rid="B166" ref-type="bibr">166</xref>], effects that may be related to NF-E2-related factor 2 (Nrf2) bound to the antioxidant response element (Nrf2-ARE) pathway [<xref rid="B167" ref-type="bibr">167</xref>]. Moreover, administration of inosine, a urate precursor, was safe and promoted improvement of PD symptoms in humans [<xref rid="B168" ref-type="bibr">168</xref>].</p></sec><sec id="sec3.1.4"><title>3.1.4. <italic>&#x003b2;</italic>-Nicotinamide Adenine Dinucleotide (NAD)</title><p>NAD is known to decrease in PD [<xref rid="B169" ref-type="bibr">169</xref>]. To investigate whether NAD replenishment is beneficial in a 6-OHDA-induced mouse model of PD, Shan et al. [<xref rid="B170" ref-type="bibr">170</xref>] injected NAD in the striatum, resulting in less motor deficits and dopaminergic neuronal damage to the animals.</p></sec><sec id="sec3.1.5"><title>3.1.5. Kynurenic Acid (KA)</title><p>KA and quinolinic acid (QA) are metabolites of tryptophan degradation and have important neurological activities. KA/QA ratio changes are associated with neurological disorders, such as PD. KA administration prevented QA-induced brain damage in an <italic>ex vivo</italic> rat model of PD, preventing changes in Nrf2 levels, oxidative damage, and mitochondrial dysfunction [<xref rid="B171" ref-type="bibr">171</xref>].</p></sec><sec id="sec3.1.6"><title>3.1.6. L-Carnitine</title><p>Reactive gliosis and neuroinflammation are features of PD and might result from fatty acid oxidation. In this sense, L-carnitine inhibited lipopolysaccharide-induced oxidative stress in microglial cells, reversing the effects of detrimental neuroinflammation in vitro [<xref rid="B172" ref-type="bibr">172</xref>].</p></sec><sec id="sec3.1.7"><title>3.1.7. Glutamine</title><p>Glutamine has a positive role in reducing oxidative stress damage and suppressing MPTP-induced cytotoxicity in cultured PC12 cells. Moreover, glutamine restores SOD, GSH-Px, and lipid peroxidation markers to basal levels in those cells, probably through inhibition of the PI3K/Akt signaling pathway [<xref rid="B173" ref-type="bibr">173</xref>].</p></sec><sec id="sec3.1.8"><title>3.1.8. <italic>n</italic>-3 Polyunsaturated Fatty Acids</title><p>Omega-3-polyunsaturated fatty acids (<italic>n</italic>-3 PUFA) have been widely associated with beneficial effects over different neurodegenerative diseases, such as PD. Hernando et al. [<xref rid="B174" ref-type="bibr">174</xref>] tested the effects of docosahexanoic acid (DHA) and its hydroxylated derivative, DHAH, in a 6-OHDA-induced animal model of PD, showing a positive effect on Nrf2 pathway regulation in the treated group due to the potential antioxidant effect of these compounds.</p></sec><sec id="sec3.1.9"><title>3.1.9. Sulfur-Containing Antioxidants</title><p>Among the endogenous antioxidant molecules, some can easily promote a reducing environment within the cytoplasm, due to the particular aspects of the interaction between the intracellular environment and sulfur-hydrogen bonds that are present in these molecules. This provide these molecules with special antioxidant properties; thus, they are discussed as a separate group, alongside with N-acetylcysteine, an exogenous molecule, yet an important precursor of endogenous GSH synthesis.</p><p>
<italic>(1) Lipoic Acid (LA)</italic>. Lipoic acid is another potent antioxidant that promotes the removal of free radicals and increases antioxidant defenses, boosting the levels of GSH, <italic>&#x003b1;</italic>-tocopherol, and ascorbic acid. LA can promote the reduction and prevention of oxidative stress, either in its oxidized form (LA) or in its reduced form, dihydrolipoic acid (DHLA). Due to this ability to prevent neuronal damage caused by ROS in the nervous system, LA supplementation has been suggested for the therapy of neurodegenerative diseases, including PD [<xref rid="B175" ref-type="bibr">175</xref>&#x02013;<xref rid="B177" ref-type="bibr">177</xref>]. Bilska et al. [<xref rid="B178" ref-type="bibr">178</xref>] demonstrated that LA administration enhances the antioxidant defense system, slows the progression of neuronal degeneration, and improves the regeneration of injured tissues. This may be due to the increase in both GSH levels and activity of GSH-Px and glutathione-S-transferase (GST). Likewise, Zhou et al. [<xref rid="B179" ref-type="bibr">179</xref>] demonstrated that administration of alpha lipoamide, a neutral amide derivative of alpha-lipoic acid, restored the number of dopaminergic neurons in the midbrain and recovered mitochondrial function in an animal model of PD. Zhou and Cheng [<xref rid="B180" ref-type="bibr">180</xref>], in a 6-hydroxydopamine- (6-OHDA-) induced model of PD, demonstrated that LA alleviated 6-OHDA-induced cell injury, possibly by inhibiting autophagy mediated by the AMPK/mTOR pathway. These neuroprotective effects of lipoic acid were also observed for a combination of carnosine&#x02013;alpha-lipoic acid in a model of early-stage PD [<xref rid="B181" ref-type="bibr">181</xref>]. Moreover, Zhang et al. [<xref rid="B182" ref-type="bibr">182</xref>] demonstrated that LA alleviates L-DOPA-induced dyskinesia in rats, and similar results were presented by Abdin and Sarhan [<xref rid="B183" ref-type="bibr">183</xref>], who found normalization of catalepsy score and apparent preservation of striatal integrity in rotenone-induced PD in rats.</p><p>
<italic>(2) Reduced Glutathione</italic>. Among the endogenous antioxidant systems, the main antioxidant system seems to be the redox system of GSH, which protects cells against oxidative stress through three different pathways: direct scavenging of reactive oxygen species, transition metal chelation, and antioxidant cofactors (GSH is required for GSH-Px activity). The essential elements of these systems are GSH-Px, which reduces hydrogen peroxide or lipid peroxide, and GST, which combines electrons to GSH and some ATPase and, therefore, may reduce GSSG or GSH conjugates [<xref rid="B184" ref-type="bibr">184</xref>&#x02013;<xref rid="B185" ref-type="bibr">185</xref>]. According to Yamamoto et al. [<xref rid="B186" ref-type="bibr">186</xref>], the inhibition of proteasomes induces GSH synthesis to protect nerve cells from oxidative damage. On the other hand, the decrease in glutathione levels results in oxidative stress and mitochondrial dysfunction, regarded as triggering factors in PD neurodegeneration [<xref rid="B187" ref-type="bibr">187</xref>]. It is also believed that a reduced GSH/GSSG ratio can increase ROS and RNS production [<xref rid="B118" ref-type="bibr">118</xref>] through the opening of GSH redox state-dependent transition pores of mitochondrial permeability [<xref rid="B188" ref-type="bibr">188</xref>]. Furthermore, high levels of ROS and RNS may also impair the operation of complex 1 by oxidation of significant residues within the complex and consequent reduction of glutathione reductase (GR) activity, an enzyme responsible for the reduction of GSSG [<xref rid="B189" ref-type="bibr">189</xref>&#x02013;<xref rid="B190" ref-type="bibr">190</xref>]. Despite the inability of GSH to cross the blood-brain barrier [<xref rid="B191" ref-type="bibr">191</xref>], Sechi et al. [<xref rid="B192" ref-type="bibr">192</xref>] administered GSH intravenously to untreated PD patients and found significant improvement for all subjects. Alternatively, glutathione analogs were also employed. Yamamoto et al. [<xref rid="B193" ref-type="bibr">193</xref>] tested YM737&#x02014;a GSH analog&#x02014;in a rat model of PD, with better results than GSH itself. Wassef et al. [<xref rid="B194" ref-type="bibr">194</xref>], who performed studies in transgenic <italic>Drosophila melanogaster</italic> flies overexpressing <italic>&#x003b1;</italic>-synuclein and methionine sulfoxide reductase (MSRA), observed that dietary supplementation with S-methyl-L-cysteine was able to prevent or alleviate the symptoms of PD since it participates in the antioxidant mechanism of MSRA, inducing an increase in enzyme activity. Another study demonstrated that supplementation with water containing the GSH precursor N-acetyl-L-cysteine (NAC) in mice that express human <italic>&#x003b1;</italic>-synuclein promotes a decrease in <italic>&#x003b1;</italic>-synuclein in the brain and protects, at least partially, the decrease in dopamine concentrations, characteristics that were associated with the reduction in nuclear factor kappa B (NF-<italic>&#x00138;</italic>B) [<xref rid="B195" ref-type="bibr">195</xref>].</p><p>
<italic>(3) Hydrogen Sulfide</italic>. Hydrogen sulfide is a gaseous neurotransmitter with neuroprotective effects. Sarukhani et al. [<xref rid="B196" ref-type="bibr">196</xref>] investigated its activity in an acute 6-OHDA animal model of PA and concluded that hydrogen sulfide produces a significant antiparkinsonism effect, protecting against 6-OHDA neurotoxicity, as it reduces malondialdehyde overproduction.</p><p>
<italic>(4) N-Acetylcysteine</italic>. Known as an antioxidant and a GSH synthesis precursor for a long time, NAC was studied in two independent studies with similar results. Virel et al. [<xref rid="B197" ref-type="bibr">197</xref>], working with human mesenchymal cells, and Bonilla-Porras et al. [<xref rid="B198" ref-type="bibr">198</xref>], working with mice, demonstrated that 6-OHDA treatment caused GSH depletion that was not reversed by NAC cotreatment, despite the fact that this treatment improved antioxidant levels in both studies. According to the authors, this highlights the importance of GSH on brain metabolism. Moreover, Coles et al. [<xref rid="B199" ref-type="bibr">199</xref>] treated PD patients with repeated oral doses of NAC, but no changes in oxidative stress markers were observed, despite increased levels of antioxidant markers of PD patients in comparison with healthy controls.</p></sec></sec><sec id="sec3.2"><title>3.2. Vitamins</title><p>The beneficial effects of antioxidant vitamins in PD were evaluated in a series of studies that assessed dietary vitamin intake using structured questionnaires. Indeed, Miyake et al. [<xref rid="B200" ref-type="bibr">200</xref>] evaluated the relation between the intake of antioxidant vitamins present in vegetables and fruit and the risk of patients developing PD in Japan, observing that a greater consumption of vitamin E and <italic>&#x003b2;</italic>-carotene is associated with a reduction in the risk of PD in this population. Moreover, Rijk et al. [<xref rid="B201" ref-type="bibr">201</xref>], studying 5342 individuals from the Rotterdam Study, suggested that high dietary intake of vitamin E may protect against the occurrence of PD. Similar results were found by Zhang et al. [<xref rid="B202" ref-type="bibr">202</xref>], Etminan et al. [<xref rid="B203" ref-type="bibr">203</xref>], and Schirinzi et al. [<xref rid="B204" ref-type="bibr">204</xref>]. Nevertheless, other authors failed to prove the beneficial effects of dietary antioxidant vitamin intake [<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B205" ref-type="bibr">205</xref>&#x02013;<xref rid="B208" ref-type="bibr">208</xref>], suggesting that the vitamin amount provided by the diet is insufficient [<xref rid="B209" ref-type="bibr">209</xref>]. Indeed, a recent cohort study conducted by Hughes et al. [<xref rid="B210" ref-type="bibr">210</xref>] investigated the intake of vitamins C and E and carotenoids on the risk of PD development and concluded that there are still no results that support the hypothesis that ingestion, alone or a combination of these antioxidant substances, decreases the risk of developing PD. Notwithstanding, in an experimental study, vitamin A and <italic>&#x003b2;</italic>-carotene dose-dependently destabilized preformed <italic>&#x003b1;</italic>-synuclein filaments [<xref rid="B211" ref-type="bibr">211</xref>], and the treatment of PD patients with <italic>&#x003b1;</italic>-tocopherol and ascorbic acid delays disease progression [<xref rid="B212" ref-type="bibr">212</xref>]. Moreover, research using 6-aminolevulinic acid in an experimental model of PD demonstrated the neuroprotective action of vitamin E through behavioral and histochemical evidence [<xref rid="B213" ref-type="bibr">213</xref>]. Zhu [<xref rid="B132" ref-type="bibr">132</xref>] suggests that in addition to vitamin C, other antioxidants are important in the diet for the reduction of the risk of PD, such as vitamins B6 and B12, S-adenosyl-L-methionine (SAME), and folic acid, based on the regulation of catechol-O-methyltransferase (COMT), an enzyme that acts in catecholamine degradation.</p></sec><sec id="sec3.3"><title>3.3. Phenols and Polyphenols</title><sec id="sec3.3.1"><title>3.3.1. Tyrosol</title><p>A simple phenol present in extra virgin oil, tyrosol, was demonstrated to delay <italic>&#x003b1;</italic>-synuclein aggregation in a <italic>Caenorhabditis elegans</italic> model of PD. Additionally, tyrosol treatment reduced ROS levels and promoted the expression of specific chaperones and antioxidant enzymes [<xref rid="B214" ref-type="bibr">214</xref>].</p></sec><sec id="sec3.3.2"><title>3.3.2. Tricetin</title><p>Extracted from <italic>Ginkgo biloba</italic>, tricetin was demonstrated to confer neuroprotection against 6-OHDA-induced oxidative stress in a <italic>C. elegans</italic> model of PD. Moreover, it also induced the protein expression of Nrf2 and its transcriptional activation, resulting in the upregulated expression of heme oxidase-1 [<xref rid="B215" ref-type="bibr">215</xref>].</p></sec><sec id="sec3.3.3"><title>3.3.3. Chrysin</title><p>Chrysin is a natural flavonoid found in bee propolis, honey, and several plants and was investigated in both the 6-OHDA [<xref rid="B216" ref-type="bibr">216</xref>] and the MPTP [<xref rid="B217" ref-type="bibr">217</xref>] models of PD, reversing neurochemical deficits, behavioral abnormalities, and oxidative stress in those animals.</p></sec><sec id="sec3.3.4"><title>3.3.4. Acteoside</title><p>Acteoside is a flavonoid reported to have antioxidant and neuroprotective effects. Li et al. [<xref rid="B218" ref-type="bibr">218</xref>] investigated its effect in a 6-OHDA zebrafish model of PD, demonstrating its ability to reduce neural damage and even prevent neural damage. In addition, pretreatment with acteoside could upregulate antioxidant enzymes by activating the Nrf2 signaling pathway.</p></sec><sec id="sec3.3.5"><title>3.3.5. Pinostrobin</title><p>Another flavonoid with antioxidant effects, pinostrobin was also used in the MPTP zebrafish model of PD with similar results as acteoside, as it significantly enhances Nrf2 expression and upregulates heme oxygenase-1 (HO-1) expression [<xref rid="B219" ref-type="bibr">219</xref>].</p></sec><sec id="sec3.3.6"><title>3.3.6. Curcumin</title><p>Like other flavonoids, curcumin is reported to have antioxidant and neuroprotective properties. Indeed, its use in both <italic>Drosophila melanogaster</italic> and 6-OHDA-induced PD in rat models resulted in improved locomotive abilities, less severe neurodegeneration, and decreased oxidative stress markers [<xref rid="B220" ref-type="bibr">220</xref>&#x02013;<xref rid="B221" ref-type="bibr">221</xref>]. Similar results were found with demethoxycurcumin, a curcumin derivative [<xref rid="B222" ref-type="bibr">222</xref>].</p></sec><sec id="sec3.3.7"><title>3.3.7. Hesperidin</title><p>Hesperidin was reported to reduce the iron content in the heads of <italic>D. melanogaster</italic> and to restore dopamine levels and cholinergic activity, as well as to reduce Fe-induced mortality, oxidative stress, and mitochondrial dysfunction in this model of PD [<xref rid="B223" ref-type="bibr">223</xref>].</p></sec><sec id="sec3.3.8"><title>3.3.8. Naringenin</title><p>A citrus fruit flavanone, naringenin was employed in two independent studies using the MPTP-induced PD model in mice, leading to an overall reversion of PD-induced features, such as <italic>&#x003b1;</italic>-synuclein aggregation, as well as to lower oxidative stress levels and increased antioxidant parameters [<xref rid="B224" ref-type="bibr">224</xref>&#x02013;<xref rid="B225" ref-type="bibr">225</xref>].</p></sec><sec id="sec3.3.9"><title>3.3.9. Resveratrol</title><p>Resveratrol is a very promising polyphenol, showing inhibition of <italic>&#x003b1;</italic>-synuclein aggregation in PD-induced mice [<xref rid="B226" ref-type="bibr">226</xref>], increased lifespan of MPTP-treated <italic>D. melanogaster</italic> [<xref rid="B227" ref-type="bibr">227</xref>], and protection for PC12 cells from rotenone oxidative damage, an effect partially mediated through the activation of the SIR/Akt1 signaling pathway [<xref rid="B228" ref-type="bibr">228</xref>]. In all three studies, oxidative stress was decreased in the resveratrol-treated groups, whereas antioxidant status was increased.</p></sec><sec id="sec3.3.10"><title>3.3.10. Genistein</title><p>Wu et al. [<xref rid="B229" ref-type="bibr">229</xref>] investigated the effects of genistein against the rotenone-induced PD model in human SH-SY5Y cells, which express a mutant form of <italic>&#x003b1;</italic>-synuclein. The authors demonstrated that genistein was able to prevent mitochondrial oxidative damage caused by rotenone to those cells. Further investigation led the authors to conclude that genistein can reduce oxidative stress damage and cell apoptosis, activating estrogen receptors and NF-E2L2 channels.</p></sec><sec id="sec3.3.11"><title>3.3.11. Rosmarinic Acid</title><p>Qu et al. [<xref rid="B230" ref-type="bibr">230</xref>] demonstrated that rosmarinic acid protected against iron-induced <italic>&#x003b1;</italic>-synuclein aggregation by upregulating HO-1 and inhibiting <italic>&#x003b1;</italic>-synuclein expression.</p></sec><sec id="sec3.3.12"><title>3.3.12. Salidroside</title><p>Wu et al. [<xref rid="B231" ref-type="bibr">231</xref>] administered salidroside to 6-OHDA-induced PD rats and demonstrated neuroprotection against oxidative stress, an effect probably related to the regulation of the Wn/<italic>&#x003b2;</italic>-catenin signaling pathway.</p></sec><sec id="sec3.3.13"><title>3.3.13. Anacardic Acids</title><p>Anacardic acids are alkyl phenols mainly present in cashew nuts and were used to treat rotenone-induced PD in rats. Among several of the beneficial effects, the authors demonstrated that the use of anacardic acids prevented motor impairment and lipoperoxidation induced by rotenone, in part due to a modulatory action on mitochondria and SOD gene expression [<xref rid="B232" ref-type="bibr">232</xref>].</p></sec></sec><sec id="sec3.4"><title>3.4. Terpenes</title><sec id="sec3.4.1"><title>3.4.1. Thymol</title><p>Thymol is a dietary monoterpene and was tested to prevent neurotoxicity and neurodegeneration in rotenone-challenged rats. Rotenone-induced neurodegeneration is a well-established PD model with oxidative stress involvement that mimics the features of PD in humans. Thymol treatment significantly reduced dopaminergic neural loss and oxidative stress, resulting in clinical improvement to the animals and preservation of antioxidant defenses, as well as attenuation of inflammatory mediators [<xref rid="B233" ref-type="bibr">233</xref>].</p></sec><sec id="sec3.4.2"><title>3.4.2. Astragaloside IV</title><p>A triterpene extracted from the roots of <italic>Astragalus membranaceus</italic>, an herb known as <italic>Huang Qi</italic> that has been used for more than 5000 years in China, possesses anti-inflammatory and antioxidant properties in neurogenerative diseases and was employed to prevent damage caused by MPTP in rats and lipopolysaccharide-induced damage to BV2 microglial cells with promising results [<xref rid="B234" ref-type="bibr">234</xref>].</p></sec><sec id="sec3.4.3"><title>3.4.3. Carvacrol</title><p>It is a phenolic monoterpenoid that is found primarily in the essential oil from oregano. Haddadi et al. [<xref rid="B235" ref-type="bibr">235</xref>] treated 6-OHDA-induced PD in rats with carvacrol, showing that a dose of 25&#x02009;mg promoted significant memory deficit improvement in the animals.</p></sec><sec id="sec3.4.4"><title>3.4.4. <italic>&#x003b2;</italic>-Amirin</title><p>This pentacyclic triterpenoid compound is found in several medicinal plants and promotes excellent antioxidant activity, significantly reducing ROS in a <italic>C. elegans</italic> model of PD. Moreover, <italic>&#x003b2;</italic>-amirin treatment also exerted a protective effect on dopaminergic neurons, reducing cell damage and <italic>&#x003b1;</italic>-synuclein aggregation [<xref rid="B236" ref-type="bibr">236</xref>].</p></sec><sec id="sec3.4.5"><title>3.4.5. Asiatic Acid (AA)</title><p>A triterpenoid used for the treatment of depression, asiatic acid is known for its antioxidant properties. AA was tested in three different PD models: PD transgenic <italic>Drosophila</italic> flies, where it caused significant improvement in climbing ability and prolonged the lifespan&#x02014;effects attributed to AA antioxidant properties; rotenone-induced damage in SH-SY5Y cells, where it protected mitochondria from oxidative stress and apoptosis; and in an isolated mitochondria model, where AA promoted membrane integrity and ATP production against the decline in membrane potential induced by <italic>&#x003b1;</italic>-synuclein. Considering that maintaining mitochondrial integrity is essential in PD, the authors suggested AA as an excellent candidate for PD prevention and therapy [<xref rid="B237" ref-type="bibr">237</xref>].</p></sec><sec id="sec3.4.6"><title>3.4.6. Geraniol</title><p>An acyclic monoterpene found in the essential oils of several aromatic plants, geraniol was used to prevent rotenone-induced mitochondrial damage in SK-N-SH cells, ameliorating intracellular redox status, preserving membrane potential, and reducing the expression of <italic>&#x003b1;</italic>-synuclein, features that corroborate enhanced cell viability [<xref rid="B238" ref-type="bibr">238</xref>].</p></sec></sec><sec id="sec3.5"><title>3.5. Plant Extracts</title><p>Beyond using purified antioxidant molecules, several studies have considered the use of crude plant extracts to treat PD-like symptoms and the consequent morphological and biochemical modifications induced in PD models, mainly due to the synergistic effect of the antioxidant molecule content of such extracts. Some of these studies are summarized below.</p><sec id="sec3.5.1"><title>3.5.1. Grape Skin</title><p>Moderate red wine consumption is considered to confer several health benefits, including protection against neurological diseases. These health benefits are suggested to come from resveratrol, a compound from grape skin that displays anti-PD effects [<xref rid="B226" ref-type="bibr">226</xref>&#x02013;<xref rid="B228" ref-type="bibr">228</xref>]. Notwithstanding, Wu et al. [<xref rid="B239" ref-type="bibr">239</xref>] investigated the effects of grape skin extract (GSE) left from red wine production on a <italic>Drosophila</italic> model of PD, resulting in preservation of mitochondrial morphology and improvement of indirect flight muscle function, as well as in prolonged lifespan of the flies. Notably, the authors suggested that these effects of GSE are not accounted for by resveratrol alone.</p></sec><sec id="sec3.5.2"><title>3.5.2. <italic>Centella asiatica</italic></title><p>It is a well-known medicinal plant native to southern Asia, Australia, and some Pacific Islands commonly used against circulatory dysfunction in Chinese traditional medicine. Teerapattarakan et al. [<xref rid="B240" ref-type="bibr">240</xref>] used a <italic>C. asiatica</italic> extract to treat rotenone-induced PD in rats and showed significant improvement in the travelled distance of treated rats, alongside a higher number of dopaminergic neurons in the <italic>substantia nigra</italic> and <italic>striatum</italic>, decreased MDA, and increased SOD and catalase expression.</p></sec><sec id="sec3.5.3"><title>3.5.3. <italic>Dendropanax morbifenus</italic></title><p>This plant is an endemic species of South Korea that is extensively used in traditional medicine to treat several clinical complications. Park et al. [<xref rid="B241" ref-type="bibr">241</xref>] successfully used <italic>D. morbifenus</italic> leaf extracts to prevent behavioral deficits and dopaminergic neuron loss in the MPTP-induced PD mouse model. Chromatographic profiling of the extract identified chlorogenic acid as its major constituent, a well-known antioxidant agent.</p></sec><sec id="sec3.5.4"><title>3.5.4. <italic>Azadirachta indica</italic></title><p>Similar to <italic>D. morbifenus</italic>, <italic>A. indica</italic> is a medicinal plant used for more than 2,000 years in India and displays anti-PD properties. Curiously, it is called &#x0201c;<italic>arishtha</italic>&#x0201d; in Sanskrit, which means &#x0201c;the eliminator of pain.&#x0201d; Indeed, treatment with <italic>A. indica</italic> extract to 6-OHDA-induced PD rats promoted improved motor behavior and reversed several biochemical modifications induced by 6-OHDA, such as the suppression of inflammatory factors, antioxidant enzymes, and iNOS expression [<xref rid="B242" ref-type="bibr">242</xref>].</p></sec><sec id="sec3.5.5"><title>3.5.5. <italic>Zizyphus spinachristi</italic></title><p>Known as &#x0201c;Christ's thorn jujube,&#x0201d; <italic>Zizyphus spinachristi</italic> is an evergreen tree native to northern and tropical Africa and Southern and Western Asia. Fruits and leaves from the tree have been used in Ancient Egypt as food and medicine. Singh et al. [<xref rid="B243" ref-type="bibr">243</xref>] investigated the beneficial effects of <italic>Z. spinachristi</italic> fruit extract against MPTP-induced neurotoxicity in SH-SY5Y cells, demonstrating its ability to reverse cell damage and oxidative stress, effects accounting for its potent antioxidant properties.</p></sec><sec id="sec3.5.6"><title>3.5.6. <italic>Apium graveolens</italic> L.</title><p>
<italic>Apium graveolens L.</italic> is used in Chinese traditional medicine and is routinely prescribed for the treatment of gout, diabetes, and hypertension. Chonpathompikunlert et al. [<xref rid="B244" ref-type="bibr">244</xref>] tested the effect of the methanolic extract of the whole plant on the MPTP model of PD in rats and demonstrated significant improvement in behavioral performance and oxidative stress parameters, as well as an increased number of dopaminergic neurons.</p></sec><sec id="sec3.5.7"><title>3.5.7. <italic>Ginkgo biloba</italic></title><p>Another potent antioxidant tested was the extract rich in flavonoids and terpenes obtained from leaves of <italic>Ginkgo biloba</italic>, which promoted effective protection to the neurons of animals exposed to MPTP in an experimental model of PD [<xref rid="B245" ref-type="bibr">245</xref>&#x02013;<xref rid="B246" ref-type="bibr">246</xref>].</p></sec><sec id="sec3.5.8"><title>3.5.8. <italic>Aspidosperma pyrifolium</italic> Mart.</title><p>
<italic>Aspidosperma</italic> species are commonly used in folk medicine in Brazil, especially to treat malaria, and there are several ongoing studies in this regard. Among them, <italic>A. pyrifolium</italic> Mart. aqueous extract was tested against 6-OHDA-induced PD in rats, where the treated groups showed decreased PD features, including less lipid peroxidation and increased levels of dopamine, suggesting a potential for this extract in PD treatment [<xref rid="B247" ref-type="bibr">247</xref>].</p></sec><sec id="sec3.5.9"><title>3.5.9. <italic>Olea europaea</italic> L.</title><p>Leaf extract from this ordinary olive tree has shown antioxidant and neuroprotective effects, which led Sarbishegi et al. [<xref rid="B248" ref-type="bibr">248</xref>] to investigate its effect against a rotenone-induced model of PD in rats, resulting in significant improvement of oxidative markers and blockage of depletion of tyrosine hydroxylase-positive neurons caused by rotenone exposure.</p></sec><sec id="sec3.5.10"><title>3.5.10. <italic>Bacopa monnieri</italic></title><p>This plant is used in Ayurvedic medicine for the treatment of neurological disorders and displays high levels of antioxidant molecules. Tested against the MPTP-induced PD model in mice, the ethanolic extract of <italic>B. monnieri</italic> treatment promoted several anti-PD effects, including modulation of oxidative stress and nigrostriatal dopaminergic neuroprotection [<xref rid="B249" ref-type="bibr">249</xref>].</p></sec><sec id="sec3.5.11"><title>3.5.11. <italic>Hibiscus asper</italic></title><p>The methanolic extract of the leaves of <italic>Hibiscus asper</italic> was used in an experimental model of PD in rats and proved to be neuroprotective, as it provided a significant increase in the activity of antioxidant enzymes (SOD, CAT, and GSH-Px) and decreased lipid peroxidation in the brain [<xref rid="B250" ref-type="bibr">250</xref>].</p></sec><sec id="sec3.5.12"><title>3.5.12. Blackberries</title><p>The ethanolic extract of blackberries was used in both <italic>in vitro</italic> and <italic>in vivo</italic> models of PD and demonstrated dose-dependent neuroprotective effects through antiapoptotic and antioxidant effects [<xref rid="B251" ref-type="bibr">251</xref>].</p></sec><sec id="sec3.5.13"><title>3.5.13. <italic>Eplingiella fruticosa</italic></title><p>
<italic>Eplingiella fruticosa</italic> is a Brazilian aromatic plant used for pain treatment in Brazilian folk medicine, which has demonstrated potent antioxidant and anti-inflammatory properties. Beserra-Filho et al. [<xref rid="B252" ref-type="bibr">252</xref>] tested the essential oil obtained from <italic>E. fruticosa</italic> leaves against a reserpine-induced PD model in mice and demonstrated important anti-PD effects, such as modulation of oxidative stress, delayed onset of catalepsy, and protection against dopaminergic depletion in the <italic>striatum</italic>.</p></sec><sec id="sec3.5.14"><title>3.5.14. Red Ginseng</title><p>Ginseng treatment of rotenone-induced PD in rats promoted marked improvement of locomotor activity, suppression of <italic>&#x003b2;</italic>-amyloid deposition, and inhibition of the NF-<italic>&#x00138;</italic>B inflammatory pathway and oxidative stress mediators, and significantly increased tyrosine hydroxylase activity [<xref rid="B253" ref-type="bibr">253</xref>]. Moreover, <italic>Angelica sinensis</italic> extract, popularly known as &#x0201c;female ginseng,&#x0201d; also prevented the occurrence of PD-like symptoms in a <italic>C. elegans</italic> model of the disease [<xref rid="B254" ref-type="bibr">254</xref>].</p></sec><sec id="sec3.5.15"><title>3.5.15. Seaweeds</title><p>Using the 6-OHDA-induced PD model in SH-SY5Y human neuroblastoma cells, several studies demonstrated promising anti-PD effects of seaweed extracts, such as brown seaweeds <italic>Bifurcaria bifurcata</italic> [<xref rid="B255" ref-type="bibr">255</xref>], <italic>Ecklonia cava</italic> [<xref rid="B256" ref-type="bibr">256</xref>], and <italic>Sargassum hemiphyllum</italic> [<xref rid="B257" ref-type="bibr">257</xref>], as well as the red seaweed <italic>Chondrus crispus</italic>, which was tested on the <italic>C. elegans</italic> model of PD [<xref rid="B258" ref-type="bibr">258</xref>].</p></sec></sec><sec id="sec3.6"><title>3.6. Other Plant-Derived Molecules</title><sec id="sec3.6.1"><title>3.6.1. Diosgenin</title><p>This natural steroid saponin extracted from the tubers of <italic>Dioscorea</italic> wild yam was used to prevent the alterations caused in the lipopolysaccharide- (LPS-) induced PD model in rats, resulting in a significant reduction in oxidative stress markers and inactivation of the Toll-like receptor (TLR)/NF-<italic>&#x00138;</italic>B inflammatory pathway [<xref rid="B259" ref-type="bibr">259</xref>].</p></sec><sec id="sec3.6.2"><title>3.6.2. Thymoquinone</title><p>Extracted from the seeds of <italic>Nigella sativa</italic>, a plant popularly known as black cumin, thymoquinone is a bicyclic benzenoid ketone. It was employed by Ardah et al. [<xref rid="B260" ref-type="bibr">260</xref>] to prevent MPTP-induced PD in mice. Treatment with thymoquinone restored antioxidant enzymes, prevented lipid peroxidation, and attenuated the expression of proinflammatory cytokines.</p></sec><sec id="sec3.6.3"><title>3.6.3. Sulforaphane</title><p>It is an organic isothiocyanate extracted from many cruciferous vegetables, such as cabbages and broccolis. Bao et al. [<xref rid="B261" ref-type="bibr">261</xref>] investigated its effect on MPTP-induced damage in PC12 cells, reporting its ability to reduce Nrf2, HO-1, and nicotinamide quinine oxidoreductase, concluding that sulforaphane protected the cells via activation of the Nrf2-antioxidant responsive element pathway.</p></sec><sec id="sec3.6.4"><title>3.6.4. Crocin</title><p>Crocin, a saffron-active component, exhibited protective effects against malathion-induced PD in rats by reducing oxidative stress and anti-inflammatory effects and improving motor deficits and neurobehavioral impairments [<xref rid="B262" ref-type="bibr">262</xref>].</p></sec><sec id="sec3.6.5"><title>3.6.5. Spermidine</title><p>Spermidine is an antioxidant polyamine and was tested against rotenone-induced PD in rats, reversing neuroinflammation and restoring striatal neurochemistry, as well as oxidative stress markers [<xref rid="B263" ref-type="bibr">263</xref>].</p></sec><sec id="sec3.6.6"><title>3.6.6. Gastrodin</title><p>It is the glucoside of gastrodigenin and has been isolated from the orchid <italic>Gastrodia elata</italic>. Haddadi et al. [<xref rid="B264" ref-type="bibr">264</xref>], using the 6-OHDA model of PD in rats, demonstrated catalepsy prevention and motor coordination in lesioned rats. Moreover, gastrodin suppressed MPO activity, lipid peroxidation, and NO synthesis induced by 6-OHDA and increased total antioxidant capacity in the <italic>substantia nigra pars compacta</italic> of these rats.</p></sec></sec><sec id="sec3.7"><title>3.7. Drugs</title><sec id="sec3.7.1"><title>3.7.1. Paroxetine</title><p>Using a mouse experimental model, Chung et al. [<xref rid="B123" ref-type="bibr">123</xref>] studied the effects of the antioxidant paroxetine in mice that received MPTP, demonstrating that this antidepressant drug protects <italic>nigrostriatal</italic> dopaminergic neurons from oxidative damage induced by the neurotoxin. Additionally, the authors also verified that paroxetine inhibited microglial activation and, therefore, the expression of iNOS and TNF-<italic>&#x003b1;</italic>; inhibited the activation of <italic>astroglia</italic> and hence the production of MPO; and promoted attenuation of the production of oxidizing agents via NADPH oxidase. Collectively, oxidative stress reduction has enabled the increase of dopamine levels in the <italic>nucleus striatum</italic> and the improvement of the motor performance of these animals.</p></sec><sec id="sec3.7.2"><title>3.7.2. Pramipexole</title><p>Pramipexole is a novel dopamine agonist that also inhibits oxidative stress and mitochondrial apoptosis. Wang et al. [<xref rid="B265" ref-type="bibr">265</xref>] used pramipexole transdermal patches (PPX) against MPTP-induced PD in mice, showing that PPX improved dyskinesia in PD-induced mice and restored the activity of antioxidant enzymes alongside MDA reduction. Another similar study demonstrated that PPX activates Akt kinase and, therefore, is related to SPHK1 activation, which is crucial for neurite extension in neurons and directed cell movement [<xref rid="B266" ref-type="bibr">266</xref>].</p></sec><sec id="sec3.7.3"><title>3.7.3. Simvastatin</title><p>Regularly employed to reduce cholesterol levels, this hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor was tested against the 6-OHDA model of PD both in SH-SY5Y cells and mice, causing a reduction in oxidative markers, reversion of apoptosis, and inhibition of the mitogen-activated protein kinase (MAPK) pathway and NF-<italic>&#x00138;</italic>B activation in SH-SY5Y cells. Simvastatin treatment in mice decreased limb asymmetry and apomorphine-induced rotations in PD mice [<xref rid="B267" ref-type="bibr">267</xref>].</p></sec><sec id="sec3.7.4"><title>3.7.4. Methylene Blue</title><p>Clinically used for a relatively long time, methylene blue is known for its neuroprotective and antioxidant properties. Focusing on the induction of neurotrophic factors, Bhurtel et al. [<xref rid="B268" ref-type="bibr">268</xref>] studied its effects against MPTP-induced PD in both <italic>in vivo</italic> and <italic>in vitro</italic> models of the disease. According to the authors, methylene blue treatment significantly reduced the loss of dopaminergic neurons, depletion of dopamine, and glial cell activation through the activation of brain-derived neurotrophic factor (BDNF).</p></sec><sec id="sec3.7.5"><title>3.7.5. Ebselen</title><p>MPTP was also used in a study performed in the primate model of PD to observe the action of ebselen, an antioxidant with actions similar to glutathione peroxidase. It was demonstrated that ebselen could prevent both the loss of neurons and the onset of clinical symptoms of the disease in this experimental model [<xref rid="B269" ref-type="bibr">269</xref>].</p></sec><sec id="sec3.7.6"><title>3.7.6. Geranylgeranylacetone</title><p>This synthetic drug used to treat gastric ulcers was associated with glial cell-derived neurotrophic factor against the MPTP-induced PD model in mice. Treated animals displayed significant recovery in their swim, pole, and traction scores, as well as reduced neuronal apoptosis in the <italic>substantia nigra</italic> and oxidative stress markers [<xref rid="B270" ref-type="bibr">270</xref>].</p></sec><sec id="sec3.7.7"><title>3.7.7. Lactoferrin</title><p>It is a non-heme iron-binding glycoprotein belonging to the transferrin family and was tested against the MPTP model of PD in mice. Beneficial effects on both the central and peripheral systems were observed, including a reduction in oxidative stress and neuronal apoptosis [<xref rid="B51" ref-type="bibr">51</xref>].</p></sec><sec id="sec3.7.8"><title>3.7.8. Apocynin</title><p>This well-known NADPH oxidase inhibitor was used by Hou et al. [<xref rid="B271" ref-type="bibr">271</xref>] to treat mice induced to PD by pesticide exposure (paraquat and maneb), causing significant improvement of mouse learning and memory deficits, effects associated with the inhibition of signal transducers and activators of transcription 1 (STAT1) and NF-<italic>&#x00138;</italic>B pathways.</p></sec><sec id="sec3.7.9"><title>3.7.9. Norfluoxetine</title><p>Norfluoxetine is an active metabolite of the antidepressant fluoxetine that inhibits serotonin uptake. Treatment with norfluoxetine inhibited NADPH oxidase activation and nitrate production in microglial cell cultures and mitigated microglial cell activation and microglial-derived ROS production in the MPTP model of PD in mice [<xref rid="B272" ref-type="bibr">272</xref>].</p></sec><sec id="sec3.7.10"><title>3.7.10. Phenothiazine</title><p>It was formerly used as an insecticide and as a drug to treat infections with parasitic worms (anthelminthic) in livestock and humans and is the mother drug of modern antipsychotic drugs. Tapias et al. [<xref rid="B273" ref-type="bibr">273</xref>] used it against the rotenone-induced PD model in rats and rat midbrain cell cultures, demonstrating a significant reduction in protein thiol oxidation, mitochondrial dysfunction, axonal impairment, oxidative stress, and inflammatory response as a result of phenothiazine treatment.</p></sec><sec id="sec3.7.11"><title>3.7.11. Hydralazine</title><p>A potent Nrf2 activator, hydralazine was used by Guo et al. [<xref rid="B274" ref-type="bibr">274</xref>] against the MPTP-induced PD model in SH-SY5Y cells and mice, resulting in significant translocation of Nrf2, as well as upregulation of the expression of its downstream antioxidant genes. These effects resulted in substantial improvements in oxidative stress, behavioral disorders, and the loss of dopaminergic neurons in the <italic>substantia nigra</italic> and striatum of treated mice and cells, effects attributed to Nrf2 pathway activation.</p></sec></sec><sec id="sec3.8"><title>3.8. Other Synthetic Molecules</title><sec id="sec3.8.1"><title>3.8.1. Montelukast (MK)</title><p>A cysteinyl leukotriene receptor antagonist, MK later exhibited remarkable neuroprotective activity in various neurodegenerative disorders. In the rotenone-induced PD animal model, MK exhibited neuroprotective effects through the attenuation of microglial cell activation, oxidative stress inhibition, and p38 MAPK expression [<xref rid="B275" ref-type="bibr">275</xref>].</p></sec><sec id="sec3.8.2"><title>3.8.2. DDO-7263</title><p>A novel Nrf2-ARE activator, DDO-7263 was tested against MPTP-induced PD in mice, improving behavioral abnormalities induced by MPTP and significantly attenuating chemically induced dopaminergic neuron loss of tyrosine hydroxylase in the <italic>substantia nigra</italic> and <italic>striatum</italic>. In addition, DDO-7263 inhibited the secretion of inflammatory factors and protected PC12 neurons from H<sub>2</sub>O<sub>2</sub>-induced oxidative damage [<xref rid="B276" ref-type="bibr">276</xref>].</p></sec><sec id="sec3.8.3"><title>3.8.3. KMS99220</title><p>A synthetic morpholine-containing chalcone, KMS99220 confers neuroprotection due to its high binding affinity to the Nrf2 inhibitory protein Keap-1 and increased nuclear translocation of Nrf2 and gene expression of the antioxidant enzymes. It is reported to reduce <italic>&#x003b1;</italic>-synuclein aggregates in GFP-<italic>&#x003b1;</italic>-syn A53T-overexpressing cells, and in MPTP-treated mice, oral administration of KMS99220 prevented degeneration of the nigral dopaminergic neurons, induced the Nrf2 target genes, and effectively prevented the associated motor deficits [<xref rid="B277" ref-type="bibr">277</xref>].</p></sec><sec id="sec3.8.4"><title>3.8.4. M40403</title><p>A SOD-mimetic compound, it was employed with positive results in cellular and fly models of PD to reverse PD symptoms in PINK1 and Parkin phenotypes, which are known to be associated with early-onset forms of PD [<xref rid="B278" ref-type="bibr">278</xref>].</p></sec></sec><sec id="sec3.9"><title>3.9. Use of Nanoparticles to Deliver Antioxidants</title><p>Another interesting method of antioxidant treatment in PD consists of delivering antioxidant molecules through nanoparticles that can direct antioxidant effects towards specific sites of the cell or that display specific scavenging activities.</p><sec id="sec3.9.1"><title>3.9.1. Ceria Nanoparticles</title><p>Ceria nanoparticles effectively scavenge ROS, present catalase- and SOD-mimetic activities, and readily penetrate the cellular membrane and scavenge intracellular ROS in the cytosol. Moreover, triphenylphosphonium-conjugated ceria nanoparticles can scavenge mitochondrial ROS after their delivery to mitochondria. Extracellular ROS can also be scavenged through 300&#x02009;nm sized ceria nanoparticle clusters that are not subject to cellular uptake. Kwon et al. [<xref rid="B279" ref-type="bibr">279</xref>] used ceria nanoparticles to treat PD-like symptoms in the MPTP model of PD in mice, reporting inhibition of lipid peroxidation and protection of tyrosine hydroxylase in the <italic>striatum</italic> of treated mice.</p></sec><sec id="sec3.9.2"><title>3.9.2. Chitosan Nanoparticles</title><p>Raj et al. [<xref rid="B280" ref-type="bibr">280</xref>] used chitosan nanoparticles to deliver the PD drug pramipexole by the intranasal route to rotenone-induced PD rats, reporting enhanced antioxidant status and increased dopamine levels in treated animals.</p></sec><sec id="sec3.9.3"><title>3.9.3. Nanoemulsions</title><p>Nanoemulsions were also tested to deliver selegine (also known as L-deprenyl, a medication that is used in the treatment of PD), displaying high antioxidant properties that, along with the anti-PD effects of selegine, conferred significant protection to treated rats [<xref rid="B281" ref-type="bibr">281</xref>].</p></sec></sec></sec><sec id="sec4"><title>4. Final Remarks</title><p>The use of antioxidants as adjuvant PD therapy has been debated because the results of the efficacy of antioxidant substances are not yet fully clarified in human studies. Nevertheless, although there is no clarity regarding the efficacy of antioxidant use in PD patients, Agim and Cannon [<xref rid="B282" ref-type="bibr">282</xref>] point out that dietary components may act as protective factors in PD, as demonstrated in both <italic>in vivo</italic> and <italic>in vitro</italic> studies.</p><p>Indeed, as presented in the numerous reports cited in this review, <italic>in vitro</italic> studies and animal models provide vast and strong evidence for the benefits of antioxidant supplementation to treat PD and set a solid ground for its use in human studies.</p><p>Among the several antioxidant approaches reported, antioxidants derived from plants have presented remarkable results, especially those with high flavonoid content, such as purple and red fruits and seaweeds.</p><p>In this sense, Joseph et al. [<xref rid="B283" ref-type="bibr">283</xref>] believe that antioxidant-rich foods may benefit neurons during neuronal aging, reversing or delaying free radical action, which are normally produced by dopaminergic neurons of the <italic>substantia nigra</italic> of the brain.</p><p>Nevertheless, it is worth noting that free radicals exert several beneficial roles in mammalian cells, such as ATP production, phagocytosis, and cell signaling [<xref rid="B82" ref-type="bibr">82</xref>], and the indiscriminate use of antioxidants might be harmful.</p><p>In conclusion, oxidative stress plays a crucial role in the pathogenesis of Parkinson's disease, either by external factors or individual intrinsic factors. Nevertheless, the effects of oxidative stress and other factors related to the disease have not been fully elucidated thus far, and further studies are still necessary in the search for the formulation of new drugs and for more efficient use of existing drugs. However, the potential benefit of antioxidant supplements as an adjuvant therapy for Parkinson's disease is unquestionable and is aimed at improving patient quality of life.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to Dr. Michael Dean Green for language revision. Funding was provided by the Federal University of Par&#x000e1; (UFPA).</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>6-OHDA:</term><def><p>6-Hydroxydopamine</p></def></def-item><def-item><term>8-OHdG:</term><def><p>8-Hydroxy-2-deoxyguanosine</p></def></def-item><def-item><term>AA:</term><def><p>Asiatic acid</p></def></def-item><def-item><term>BDNF:</term><def><p>Brain-derived neurotrophic factor</p></def></def-item><def-item><term>BH4:</term><def><p>Tetrahydrobiopterin</p></def></def-item><def-item><term>CAT:</term><def><p>Catalase</p></def></def-item><def-item><term>Cl:</term><def><p>Chloride ion</p></def></def-item><def-item><term>COMT:</term><def><p>Catechol-O-methyltransferase</p></def></def-item><def-item><term>CoQ<sub>10</sub>:</term><def><p>Coenzyme Q<sub>10</sub></p></def></def-item><def-item><term>COX-2:</term><def><p>Cyclooxygenase-2</p></def></def-item><def-item><term>DHA:</term><def><p>Docosahexanoic acid</p></def></def-item><def-item><term>DHLA:</term><def><p>Dihydrolipoic acid</p></def></def-item><def-item><term>DOPAC:</term><def><p>Dihydroxyphenylacetic acid</p></def></def-item><def-item><term>EP:</term><def><p>Ethyl pyruvate</p></def></def-item><def-item><term>Fe<sup>2+</sup>:</term><def><p>Ferrous ion</p></def></def-item><def-item><term>G6PD:</term><def><p>Glucose-6-phosphate dehydrogenase</p></def></def-item><def-item><term>GFAP:</term><def><p>Glial fibrillary acidic protein</p></def></def-item><def-item><term>GR:</term><def><p>Glutathione reductase</p></def></def-item><def-item><term>GRP75:</term><def><p>Glucose-regulated protein 75</p></def></def-item><def-item><term>GSE:</term><def><p>Grape skin extract</p></def></def-item><def-item><term>GSH:</term><def><p>Reduced glutathione</p></def></def-item><def-item><term>GSH-Px:</term><def><p>Glutathione peroxidase</p></def></def-item><def-item><term>GSSG:</term><def><p>Oxidized glutathione</p></def></def-item><def-item><term>GST:</term><def><p>Glutathione-S-transferase</p></def></def-item><def-item><term>H<sub>2</sub>O<sub>2</sub>:</term><def><p>Hydrogen peroxide</p></def></def-item><def-item><term>HO-1:</term><def><p>Heme oxygenase-1</p></def></def-item><def-item><term>HOC:</term><def><p>Hypochlorous acid</p></def></def-item><def-item><term>IL-1<italic>&#x003b2;</italic>:</term><def><p>Interleukin 1 beta</p></def></def-item><def-item><term>iNOS:</term><def><p>Inducible nitric oxide synthase</p></def></def-item><def-item><term>KA:</term><def><p>Kynurenic acid</p></def></def-item><def-item><term>LA:</term><def><p>Lipoic acid</p></def></def-item><def-item><term>L-DOPA:</term><def><p>L-Dihydroxyphenylalanine</p></def></def-item><def-item><term>LOOH:</term><def><p>Lipid hydroperoxides</p></def></def-item><def-item><term>LPS:</term><def><p>Lipopolysaccharide</p></def></def-item><def-item><term>MAO:</term><def><p>Monoamine oxidase</p></def></def-item><def-item><term>MAPK:</term><def><p>Mitogen-activated protein kinase</p></def></def-item><def-item><term>MDA:</term><def><p>Malondialdehyde</p></def></def-item><def-item><term>MK:</term><def><p>Montelukast</p></def></def-item><def-item><term>MPDP<sup>+</sup>:</term><def><p>Dihydropyridine</p></def></def-item><def-item><term>MPO:</term><def><p>Myeloperoxidase</p></def></def-item><def-item><term>MPP<sup>+</sup>:</term><def><p>N-Methyl-4-phenylpyridine</p></def></def-item><def-item><term>MPTP:</term><def><p>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></def></def-item><def-item><term>MSRA:</term><def><p>Methionine sulfoxide reductase</p></def></def-item><def-item><term>mtHsp70:</term><def><p>Mitochondrial heat-shock protein 70</p></def></def-item><def-item><term><italic>n</italic>-3 PUFA:</term><def><p>Omega-3-polyunsaturated fatty acids</p></def></def-item><def-item><term>NAC:</term><def><p>N-Acetylcysteine</p></def></def-item><def-item><term>NAD:</term><def><p>
<italic>&#x003b2;</italic>-Nicotinamide adenine dinucleotide</p></def></def-item><def-item><term>NADPH oxidase:</term><def><p>Reduced nicotinamide adenine dinucleotide phosphate oxidase</p></def></def-item><def-item><term>NF-E2:</term><def><p>Factor nuclear erythroid 2</p></def></def-item><def-item><term>NF-<italic>&#x003ba;</italic>B:</term><def><p>Nuclear factor kappa <italic>&#x003b2;</italic></p></def></def-item><def-item><term>nNOS:</term><def><p>Neuronal nitric oxide synthase</p></def></def-item><def-item><term>NO:</term><def><p>Nitric oxide</p></def></def-item><def-item><term>NO<sub>2</sub>:</term><def><p>Nitrite</p></def></def-item><def-item><term>NO<sub>2</sub><sup>&#x02022;</sup>:</term><def><p>Free radical form of nitrite</p></def></def-item><def-item><term>NOS:</term><def><p>Nitric oxide synthase</p></def></def-item><def-item><term>NOx:</term><def><p>Nitrites and nitrates</p></def></def-item><def-item><term>NQO1:</term><def><p>Quinone oxidoreductase 1</p></def></def-item><def-item><term>Nrf2-ARE:</term><def><p>NF-E2-related factor 2 bound to the antioxidant response element pathway</p></def></def-item><def-item><term>Nrf2:</term><def><p>NF-E2-related factor 2</p></def></def-item><def-item><term>O<sub>2</sub><sup>&#x02022;</sup>:</term><def><p>Superoxide</p></def></def-item><def-item><term>OH<sup>&#x02022;</sup>:</term><def><p>Hydroxyl radical</p></def></def-item><def-item><term>ONOO<sup>:</sup>:</term><def><p>Peroxynitrite radical</p></def></def-item><def-item><term>PD:</term><def><p>Parkinson's disease</p></def></def-item><def-item><term>PINK1:</term><def><p>PTEN-induced putative kinase 1</p></def></def-item><def-item><term>PPX:</term><def><p>Pramipexole transdermal patches</p></def></def-item><def-item><term>QA:</term><def><p>Quinolinic acid</p></def></def-item><def-item><term>RNS:</term><def><p>Reactive nitrogen species</p></def></def-item><def-item><term>ROS:</term><def><p>Reactive oxygen species.</p></def></def-item><def-item><term>SAME:</term><def><p>S-Adenosyl-L-methionine</p></def></def-item><def-item><term>SOD:</term><def><p>Superoxide dismutase</p></def></def-item><def-item><term>STAT1:</term><def><p>Signal transducers and activators of transcription 1</p></def></def-item><def-item><term>TH:</term><def><p>Tyrosine hydroxylase</p></def></def-item><def-item><term>TLR:</term><def><p>Toll-like receptor</p></def></def-item><def-item><term>TNF-<italic>&#x003b1;</italic>:</term><def><p>Tumor necrosis factor alpha.</p></def></def-item></def-list></glossary><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Limongi</surname><given-names>J. C. P.</given-names></name></person-group><source><italic toggle="yes">Conhecendo Melhor a Doen&#x000e7;a de Parkinson &#x02013; Uma Abordagem Multidisciplinar com Orienta&#x000e7;&#x000f5;es Pr&#x000e1;ticas para o Dia-a-Dia</italic></source><year>2001</year><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>Plexius</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savica</surname><given-names>R.</given-names></name><name><surname>Grossardt</surname><given-names>B. R.</given-names></name><name><surname>Rocca</surname><given-names>W. A.</given-names></name><name><surname>Bower</surname><given-names>J. H.</given-names></name></person-group><article-title>Parkinson disease with and without dementia: a prevalence study and future projections</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2018</year><volume>33</volume><issue>4</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29330922</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Teive</surname><given-names>H. A. G.</given-names></name><name><surname>Meneses</surname><given-names>M. S.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Meneses</surname><given-names>M. S.</given-names></name><name><surname>Teive</surname><given-names>H. A. G.</given-names></name></person-group><article-title>Hist&#x000f3;rico</article-title><source><italic toggle="yes">Doen&#x000e7;a de Parkinson: Aspectos Cl&#x000ed;nicos e Cir&#x000fa;rgicos</italic></source><year>1996</year><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>Guanabara Koogan</publisher-name><fpage>4</fpage><lpage>14</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberman</surname><given-names>C. D.</given-names></name><name><surname>Laks</surname><given-names>J.</given-names></name><name><surname>Rodrigues</surname><given-names>C. S.</given-names></name><name><surname>Engelhardt</surname><given-names>E.</given-names></name></person-group><article-title>A review of depression as a risk factor of Parkinson&#x02019;s disease and impact cognition</article-title><source><italic toggle="yes">Revista de Psiquiatria do Rio Grande do Sul</italic></source><year>2004</year><volume>26</volume><issue>1</issue><fpage>52</fpage><lpage>60</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genc</surname><given-names>G.</given-names></name><name><surname>Abboud</surname><given-names>H.</given-names></name><name><surname>Oravivattanakul</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Socioeconomic status may impact functional outcome of deep brain stimulation surgery in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuromodulation</italic></source><year>2016</year><volume>19</volume><issue>1</issue><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/ner.12324</pub-id><pub-id pub-id-type="other">2-s2.0-84956693780</pub-id><pub-id pub-id-type="pmid">26076401</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lana</surname><given-names>R. C.</given-names></name><name><surname>&#x000c1;lvares</surname><given-names>L. M. R. S.</given-names></name><name><surname>Nasciutti-Prudente</surname><given-names>C.</given-names></name><name><surname>Goulart</surname><given-names>F. R. P.</given-names></name><name><surname>Teixeira-Salmela</surname><given-names>L. F.</given-names></name><name><surname>Cardoso</surname><given-names>F. E.</given-names></name></person-group><article-title>Percep&#x000e7;&#x000e3;o da qualidade de vida de indiv&#x000ed;duos com doen&#x000e7;a de Parkinson atrav&#x000e9;s do PDQ-39</article-title><source><italic toggle="yes">Revista Brasileira Fisioterapia</italic></source><year>2007</year><volume>11</volume><issue>5</issue><fpage>397</fpage><lpage>402</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D. P.</given-names></name></person-group><article-title>Radical-free biology of oxidative stress</article-title><source><italic toggle="yes">American Journal of Physiology-Cell Physiology</italic></source><year>2008</year><volume>295</volume><issue>4</issue><fpage>849</fpage><lpage>868</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisoschi</surname><given-names>A. M.</given-names></name><name><surname>Pop</surname><given-names>A.</given-names></name></person-group><article-title>The role of antioxidants in the chemistry of oxidative stress: a review</article-title><source><italic toggle="yes">European Journal of Medicinal Chemistry</italic></source><year>2015</year><volume>97</volume><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">25942353</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>E. C.</given-names></name><name><surname>Hunot</surname><given-names>S.</given-names></name></person-group><article-title>Neuroinflammation in Parkinson&#x02019;s disease: a target for neuroprotection?</article-title><source><italic toggle="yes">The Lancet Neurology</italic></source><year>2009</year><volume>8</volume><issue>4</issue><fpage>382</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">19296921</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberatore</surname><given-names>G. T.</given-names></name><name><surname>Jackson-Lewis</surname><given-names>V.</given-names></name><name><surname>Vukosavic</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>1999</year><volume>5</volume><issue>12</issue><fpage>1403</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/70978</pub-id><pub-id pub-id-type="other">2-s2.0-0032710609</pub-id><?supplied-pmid 10581083?><pub-id pub-id-type="pmid">10581083</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D. C.</given-names></name><name><surname>Teismann</surname><given-names>P.</given-names></name><name><surname>Tieu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2003</year><volume>100</volume><issue>10</issue><fpage>6145</fpage><lpage>6150</lpage><pub-id pub-id-type="doi">10.1073/pnas.0937239100</pub-id><pub-id pub-id-type="other">2-s2.0-0037947448</pub-id><?supplied-pmid 12721370?><pub-id pub-id-type="pmid">12721370</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H. M.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Hong</surname><given-names>J. S.</given-names></name></person-group><article-title>Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">The FASEB Journal</italic></source><year>2003</year><volume>17</volume><issue>13</issue><fpage>1954</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1096/fj.03-0109fje</pub-id><pub-id pub-id-type="other">2-s2.0-84863116750</pub-id><?supplied-pmid 12897068?><pub-id pub-id-type="pmid">12897068</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>D. K.</given-names></name><name><surname>Pennathur</surname><given-names>S.</given-names></name><name><surname>Perier</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson&#x02019;s disease in mice</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2005</year><volume>25</volume><issue>28</issue><fpage>6594</fpage><lpage>6600</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0970-05.2005</pub-id><pub-id pub-id-type="other">2-s2.0-22244434468</pub-id><?supplied-pmid 16014720?><pub-id pub-id-type="pmid">16014720</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalimoniuk</surname><given-names>M.</given-names></name><name><surname>Lukacova</surname><given-names>N.</given-names></name><name><surname>Marsala</surname><given-names>J.</given-names></name><name><surname>Langfort</surname><given-names>J.</given-names></name></person-group><article-title>Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonism in mice</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2006</year><volume>141</volume><issue>2</issue><fpage>1033</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">16716528</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group><article-title>Oxidative stress in Parkinson&#x02019;s disease: a mechanism of pathogenic and therapeutic significance</article-title><source><italic toggle="yes">Annals of the New York Academy of Sciences</italic></source><year>2008</year><volume>1147</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">19076434</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maki</surname><given-names>R. A.</given-names></name><name><surname>Holzer</surname><given-names>M.</given-names></name><name><surname>Motamedchaboki</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson&#x02019;s disease and in the hMPO-<italic>&#x003b1;</italic>-synuclein-A53T mouse model, correlating with increased nitration and aggregation of <italic>&#x003b1;</italic>-synuclein and exacerbation of motor impairment</article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>2019</year><volume>141</volume><fpage>115</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.05.033</pub-id><pub-id pub-id-type="other">2-s2.0-85067264834</pub-id><?supplied-pmid 31175983?><pub-id pub-id-type="pmid">31175983</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathnayake</surname><given-names>D.</given-names></name><name><surname>Chang</surname><given-names>T.</given-names></name><name><surname>Udagama</surname><given-names>P.</given-names></name></person-group><article-title>Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study</article-title><source><italic toggle="yes">BMC Neurology</italic></source><year>2019</year><volume>19</volume><issue>1, article 56</issue><pub-id pub-id-type="doi">10.1186/s12883-019-1286-6</pub-id><pub-id pub-id-type="other">2-s2.0-85064006043</pub-id><?supplied-pmid 30954070?><pub-id pub-id-type="pmid">30954070</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Olanow</surname><given-names>C. W.</given-names></name></person-group><article-title>Oxidative stress and the pathogenesis of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurology</italic></source><year>1996</year><volume>47</volume><issue>6, Supplement 3</issue><fpage>161S</fpage><lpage>170S</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>T. B.</given-names></name><name><surname>Betarbet</surname><given-names>R.</given-names></name><name><surname>Greenamyre</surname><given-names>J. T.</given-names></name></person-group><article-title>Environment, mitochondria, and Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">The Neuroscientist</italic></source><year>2002</year><volume>8</volume><issue>3</issue><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">12061498</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>L.</given-names></name><name><surname>Stevenson</surname><given-names>F. F.</given-names></name><name><surname>Doctrow</surname><given-names>S. R.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group><article-title>Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson&#x02019;s disease accelerate age-related neurodegeneration</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2007</year><volume>27</volume><issue>26</issue><fpage>6914</fpage><lpage>6922</lpage><pub-id pub-id-type="pmid">17596439</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Du</surname><given-names>R.-H.</given-names></name><etal/></person-group><article-title>MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Molecular Neurodegeneration</italic></source><year>2016</year><volume>11</volume><issue>1</issue><fpage>p. 28</fpage><pub-id pub-id-type="doi">10.1186/s13024-016-0094-3</pub-id><pub-id pub-id-type="other">2-s2.0-84966292082</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaki</surname><given-names>G. S.</given-names></name><name><surname>Papavassiliou</surname><given-names>A. G.</given-names></name></person-group><article-title>Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuromolecular Medicine</italic></source><year>2014</year><volume>16</volume><issue>2</issue><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">24522549</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>L. H.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2015</year><volume>284</volume><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.09.071</pub-id><pub-id pub-id-type="other">2-s2.0-84908294565</pub-id><?supplied-pmid 25301748?><pub-id pub-id-type="pmid">25301748</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenkorang</surname><given-names>M. A.</given-names></name><name><surname>Duong</surname><given-names>P.</given-names></name><name><surname>Cunningham</surname><given-names>R. L.</given-names></name></person-group><article-title>NADPH oxidase mediates membrane androgen receptor-induced neurodegeneration</article-title><source><italic toggle="yes">Endocrinology</italic></source><year>2019</year><volume>160</volume><issue>4</issue><fpage>947</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">30811529</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scudamore</surname><given-names>O.</given-names></name><name><surname>Ciossek</surname><given-names>T.</given-names></name></person-group><article-title>Increased oxidative stress exacerbates <italic>&#x003b1;</italic>-synuclein aggregation in vivo</article-title><source><italic toggle="yes">Journal of Neuropathology &#x00026; Experimental Neurology</italic></source><year>2018</year><volume>77</volume><issue>6</issue><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">29718367</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musgrove</surname><given-names>R. E.</given-names></name><name><surname>Helwig</surname><given-names>M.</given-names></name><name><surname>Bae</surname><given-names>E.-J.</given-names></name><etal/></person-group><article-title>Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular <italic>&#x003b1;</italic>-synuclein transfer</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2019</year><volume>129</volume><issue>9</issue><fpage>3738</fpage><lpage>3753</lpage><pub-id pub-id-type="pmid">31194700</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>S. S.</given-names></name><name><surname>Wang</surname><given-names>Z. H.</given-names></name><etal/></person-group><article-title>Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2019</year><volume>39</volume><issue>37</issue><fpage>7291</fpage><lpage>7305</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0625-19.2019</pub-id><pub-id pub-id-type="other">2-s2.0-85072133111</pub-id><?supplied-pmid 31358653?><pub-id pub-id-type="pmid">31358653</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Rao</surname><given-names>S. P.</given-names></name><name><surname>Kalivendi</surname><given-names>S. V.</given-names></name></person-group><article-title>The deglycase activity of DJ-1 mitigates <italic>&#x003b1;</italic>-synuclein glycation and aggregation in dopaminergic cells: role of oxidative stress mediated downregulation of DJ-1 in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>2019</year><volume>135</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">30796974</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>I.</given-names></name><name><surname>Kaganovich</surname><given-names>A.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with <italic>&#x003b1;</italic>-synuclein fibrils</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2019</year><volume>129</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.05.012</pub-id><pub-id pub-id-type="other">2-s2.0-85065914806</pub-id><?supplied-pmid 31102768?><pub-id pub-id-type="pmid">31102768</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosaki</surname><given-names>H.</given-names></name><name><surname>Yamaguchi</surname><given-names>K.</given-names></name><name><surname>Man-Yoshi</surname><given-names>K.</given-names></name><name><surname>Muramatsu</surname><given-names>S. I.</given-names></name><name><surname>Hara</surname><given-names>S.</given-names></name><name><surname>Ichinose</surname><given-names>H.</given-names></name></person-group><article-title>Administration of tetrahydrobiopterin restored the decline of dopamine in the striatum induced by an acute action of MPTP</article-title><source><italic toggle="yes">Neurochemistry International</italic></source><year>2019</year><volume>125</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">30739038</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colamartino</surname><given-names>M.</given-names></name><name><surname>Duranti</surname><given-names>G.</given-names></name><name><surname>Ceci</surname><given-names>R.</given-names></name><name><surname>Sabatini</surname><given-names>S.</given-names></name><name><surname>Testa</surname><given-names>A.</given-names></name><name><surname>Cozzi</surname><given-names>R.</given-names></name></person-group><article-title>A multi-biomarker analysis of the antioxidant efficacy of Parkinson&#x02019;s disease therapy</article-title><source><italic toggle="yes">Toxicology In Vitro</italic></source><year>2018</year><volume>47</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29080800</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isobe</surname><given-names>C.</given-names></name><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Terayama</surname><given-names>Y.</given-names></name></person-group><article-title>Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2&#x02032;-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson&#x02019;s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process</article-title><source><italic toggle="yes">Neuroscience Letters</italic></source><year>2010</year><volume>469</volume><issue>1</issue><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">19944739</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mileti&#x00107;</surname><given-names>J.</given-names></name><name><surname>Drakuli&#x00107;</surname><given-names>D.</given-names></name><name><surname>Peji&#x00107;</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prooxidant&#x02013;antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">International Journal of Neuroscience</italic></source><year>2018</year><volume>128</volume><issue>7</issue><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1080/00207454.2017.1403916</pub-id><pub-id pub-id-type="other">2-s2.0-85036562928</pub-id><?supplied-pmid 29148896?><pub-id pub-id-type="pmid">29148896</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vida</surname><given-names>C.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Garrido</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Lymphoproliferation impairment and oxidative stress in blood cells from early Parkinson&#x02019;s disease patients</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2019</year><volume>20</volume><issue>3</issue><fpage>p. 771</fpage></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben</surname><given-names>M. D.</given-names></name><name><surname>Bongiovanni</surname><given-names>R.</given-names></name><name><surname>Tuniz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Earliest mechanisms of dopaminergic neurons sufferance in a novel slow progressing ex vivo model of Parkinson disease in rat organotypic cultures of substantia nigra</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2019</year><volume>20</volume><issue>9</issue><fpage>p. 2224</fpage></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Farias</surname><given-names>C. C.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name><name><surname>Bonif&#x000e1;cio</surname><given-names>K. L.</given-names></name><etal/></person-group><article-title>Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson&#x02019;s disease and its progression: disease and staging biomarkers and new drug targets</article-title><source><italic toggle="yes">Neuroscience Letters</italic></source><year>2016</year><volume>617</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2016.02.011</pub-id><pub-id pub-id-type="other">2-s2.0-84958211385</pub-id><pub-id pub-id-type="pmid">26861200</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>Z. I.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name><name><surname>Marsden</surname><given-names>D. C.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>A generalised increase in protein carbonyls in the brain in Parkinson&#x02019;s but not incidental Lewy body disease</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1997</year><volume>69</volume><issue>3</issue><fpage>1326</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">9282961</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>S.</given-names></name><name><surname>Soundararajan</surname><given-names>C. C.</given-names></name><name><surname>Vivekanandhan</surname><given-names>S.</given-names></name><name><surname>Behari</surname><given-names>M.</given-names></name></person-group><article-title>Erythrocyte antioxidant enzymes in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Indian Journal of Medical Research</italic></source><year>2005</year><volume>121</volume><issue>2</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">15756044</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkateshappa</surname><given-names>C.</given-names></name><name><surname>Harish</surname><given-names>G.</given-names></name><name><surname>Mythri</surname><given-names>R. B.</given-names></name><name><surname>Mahadevan</surname><given-names>A.</given-names></name><name><surname>Bharath</surname><given-names>M. M. S.</given-names></name><name><surname>Shankar</surname><given-names>S. K.</given-names></name></person-group><article-title>Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurochemical Research</italic></source><year>2012</year><volume>37</volume><issue>2</issue><fpage>358</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/s11064-011-0619-7</pub-id><pub-id pub-id-type="other">2-s2.0-84856372105</pub-id><?supplied-pmid 21971758?><pub-id pub-id-type="pmid">21971758</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukae</surname><given-names>J.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name></person-group><article-title>Mitochondrial dysfunction in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Mitochondrion</italic></source><year>2007</year><volume>7</volume><issue>1-2</issue><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17300997</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>E. L. G.</given-names></name><name><surname>Rial</surname><given-names>D.</given-names></name><name><surname>Aguiar</surname><given-names>A. S.</given-names></name><etal/></person-group><article-title>Proanthocyanidin-rich fraction from <italic>Croton celtidifolius</italic> Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>2010</year><volume>117</volume><issue>12</issue><fpage>1337</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1007/s00702-010-0464-x</pub-id><pub-id pub-id-type="other">2-s2.0-78651237799</pub-id><?supplied-pmid 20931248?><pub-id pub-id-type="pmid">20931248</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayton</surname><given-names>S.</given-names></name><name><surname>Lei</surname><given-names>P.</given-names></name><name><surname>Hare</surname><given-names>D. J.</given-names></name><etal/></person-group><article-title>Parkinson&#x02019;s disease iron deposition caused by nitric oxide-induced loss of <italic>&#x003b2;</italic>-amyloid precursor protein</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2015</year><volume>35</volume><issue>8</issue><fpage>3591</fpage><lpage>3597</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3439-14.2015</pub-id><pub-id pub-id-type="other">2-s2.0-84923347844</pub-id><?supplied-pmid 25716857?><pub-id pub-id-type="pmid">25716857</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>J. M.</given-names></name><name><surname>Paley</surname><given-names>M. N.</given-names></name><name><surname>Gr&#x000fc;newald</surname><given-names>R. A.</given-names></name><name><surname>Hoggard</surname><given-names>N.</given-names></name><name><surname>Griffiths</surname><given-names>P. D.</given-names></name></person-group><article-title>Brain iron deposition in Parkinson&#x02019;s disease imaged using the PRIME magnetic resonance sequence</article-title><source><italic toggle="yes">Brain</italic></source><year>2000</year><volume>123</volume><issue>12</issue><fpage>2423</fpage><lpage>2431</lpage><pub-id pub-id-type="pmid">11099445</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Mallen</surname><given-names>P.</given-names></name><name><surname>Gatenby</surname><given-names>C.</given-names></name><name><surname>Friend</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2017</year><volume>378</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2017.04.035</pub-id><pub-id pub-id-type="other">2-s2.0-85018258880</pub-id><?supplied-pmid 28566175?><pub-id pub-id-type="pmid">28566175</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>M.</given-names></name><name><surname>Bergamasco</surname><given-names>B.</given-names></name><name><surname>Lopiano</surname><given-names>L.</given-names></name></person-group><article-title>Is neuromelanin changed in Parkinson&#x02019;s disease? Investigations by magnetic spectroscopies</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>2006</year><volume>113</volume><issue>6</issue><fpage>769</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">16755381</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>K. C. M.</given-names></name><name><surname>Ang</surname><given-names>E.-T.</given-names></name><name><surname>Tai</surname><given-names>Y. K.</given-names></name><etal/></person-group><article-title>Enhanced autophagy from chronic toxicity of iron and mutant A53T <italic>&#x003b1;</italic>-synuclein implications for neuronal cell death in Parkinson disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2011</year><volume>286</volume><issue>38</issue><fpage>33380</fpage><lpage>33389</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.268409</pub-id><pub-id pub-id-type="other">2-s2.0-80052989037</pub-id><?supplied-pmid 21795716?><pub-id pub-id-type="pmid">21795716</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochstrasser</surname><given-names>H.</given-names></name><name><surname>Tomiuk</surname><given-names>J.</given-names></name><name><surname>Walter</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Functional relevance of ceruloplasmin mutations in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">The FASEB Journal</italic></source><year>2005</year><volume>19</volume><issue>13</issue><fpage>1851</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1096/fj.04-3486fje</pub-id><pub-id pub-id-type="other">2-s2.0-27744446323</pub-id><?supplied-pmid 16150804?><pub-id pub-id-type="pmid">16150804</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivieri</surname><given-names>S.</given-names></name><name><surname>Conti</surname><given-names>A.</given-names></name><name><surname>Iannaccone</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Ceruloplasmin oxidation, a feature of Parkinson&#x02019;s disease CSF, inhibits ferroxidase activity and promotes cellular iron retention</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2011</year><volume>31</volume><issue>50</issue><fpage>18568</fpage><lpage>18577</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3768-11.2011</pub-id><pub-id pub-id-type="other">2-s2.0-83455177604</pub-id><?supplied-pmid 22171055?><pub-id pub-id-type="pmid">22171055</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>B. N.</given-names></name><name><surname>Dunn</surname><given-names>R. J.</given-names></name><name><surname>Jeong</surname><given-names>S. Y.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Julien</surname><given-names>J. P.</given-names></name><name><surname>David</surname><given-names>S.</given-names></name></person-group><article-title>Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2002</year><volume>22</volume><issue>15</issue><fpage>6578</fpage><lpage>6586</lpage><pub-id pub-id-type="pmid">12151537</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpenko</surname><given-names>M. N.</given-names></name><name><surname>Ilyicheva</surname><given-names>E. Y.</given-names></name><name><surname>Muruzheva</surname><given-names>Z. M.</given-names></name><name><surname>Milyukhina</surname><given-names>I. V.</given-names></name><name><surname>Orlov</surname><given-names>Y. A.</given-names></name><name><surname>Puchkova</surname><given-names>L. V.</given-names></name></person-group><article-title>Role of copper dyshomeostasis in the pathogenesis of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Bulletin of Experimental Biology and Medicine</italic></source><year>2018</year><volume>164</volume><issue>5</issue><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">29577200</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in MPTP-induced Parkinson&#x02019;s disease in mice</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2019</year><volume>152</volume><issue>3</issue><fpage>397</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">31442326</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B.</given-names></name><name><surname>Gutteridge</surname><given-names>J. M. C.</given-names></name></person-group><article-title>Role of free radicals and catalytic metal ions in human disease: an overview</article-title><source><italic toggle="yes">Methods Enzymology</italic></source><year>1999</year><volume>186</volume><fpage>1</fpage><lpage>85</lpage></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>N. B.</given-names></name><name><surname>Murphy</surname><given-names>D. D.</given-names></name><name><surname>Lebowitz</surname><given-names>J.</given-names></name><name><surname>Di Noto</surname><given-names>L.</given-names></name><name><surname>Levine</surname><given-names>L. R.</given-names></name><name><surname>Nusbaum</surname><given-names>R. L.</given-names></name></person-group><article-title>Metal-catalyzed oxidation of <italic>&#x003b1;</italic>-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>10</issue><fpage>9678</fpage><lpage>9690</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409946200</pub-id><pub-id pub-id-type="other">2-s2.0-15744402739</pub-id><?supplied-pmid 15615715?><pub-id pub-id-type="pmid">15615715</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Qu</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Le</surname><given-names>W.</given-names></name></person-group><article-title>Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2005</year><volume>333</volume><issue>2</issue><fpage>544</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">15950935</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carboni</surname><given-names>E.</given-names></name><name><surname>Lingor</surname><given-names>P.</given-names></name></person-group><article-title>Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Metallomics</italic></source><year>2015</year><volume>7</volume><issue>3</issue><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">25648629</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>M. S.</given-names></name><name><surname>Schumacher-Schuh</surname><given-names>A.</given-names></name><name><surname>Cardoso</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Iron and oxidative stress in Parkinson&#x02019;s disease: an observational study of injury biomarkers</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2016</year><volume>11</volume><issue>1, article e0146129</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0146129</pub-id><pub-id pub-id-type="other">2-s2.0-84954488860</pub-id><?supplied-pmid 26751079?><pub-id pub-id-type="pmid">26751079</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangania</surname><given-names>M. K.</given-names></name><name><surname>Batra</surname><given-names>J.</given-names></name><name><surname>Kushwaha</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Role of iron and copper in the pathogenesis of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Indian Journal of Clinical Biochemistry</italic></source><year>2017</year><volume>32</volume><issue>3</issue><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">28811697</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Hsu</surname><given-names>L. J.</given-names></name><name><surname>Rockenstein</surname><given-names>E.</given-names></name><name><surname>Takenouchi</surname><given-names>T.</given-names></name><name><surname>Mallory</surname><given-names>M.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>
<italic>&#x003b1;</italic>-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>13</issue><fpage>11465</fpage><lpage>11472</lpage><pub-id pub-id-type="pmid">11790792</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Lesuisse</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Stabilization of <italic>&#x003b1;</italic>-synuclein protein with aging and familial Parkinson&#x02019;s disease-linked A53T mutation</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2004</year><volume>24</volume><issue>33</issue><fpage>7400</fpage><lpage>7409</lpage><pub-id pub-id-type="pmid">15317865</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeney</surname><given-names>P. M.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Capaldi</surname><given-names>R. A.</given-names></name><name><surname>Bennett</surname><given-names>J. P.</given-names></name></person-group><article-title>Parkinson&#x02019;s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2006</year><volume>26</volume><issue>19</issue><fpage>5256</fpage><lpage>5264</lpage><pub-id pub-id-type="pmid">16687518</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bay&#x00131;r</surname><given-names>H.</given-names></name><name><surname>Kapralov</surname><given-names>A. A.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome <italic>c.</italic> Protection against apoptosis versus delayed oxidative stress in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2009</year><volume>284</volume><issue>23</issue><fpage>15951</fpage><lpage>15969</lpage><pub-id pub-id-type="doi">10.1074/jbc.M900418200</pub-id><pub-id pub-id-type="other">2-s2.0-67650156461</pub-id><pub-id pub-id-type="pmid">19351880</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>M.</given-names></name><name><surname>Deleersnijder</surname><given-names>A.</given-names></name><name><surname>Daniels</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Inhibition of FK506 binding proteins reduces <italic>&#x003b1;</italic>-synuclein aggregation and Parkinson&#x02019;s disease-like pathology</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2010</year><volume>30</volume><issue>7</issue><fpage>2454</fpage><lpage>2463</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5983-09.2010</pub-id><pub-id pub-id-type="other">2-s2.0-77249126934</pub-id><?supplied-pmid 20164329?><pub-id pub-id-type="pmid">20164329</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F. T.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y. J.</given-names></name><etal/></person-group><article-title>Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant <italic>&#x003b1;</italic>-synuclein</article-title><source><italic toggle="yes">Brain Research</italic></source><year>2015</year><volume>1604</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2015.01.050</pub-id><pub-id pub-id-type="other">2-s2.0-84925633576</pub-id><?supplied-pmid 25665531?><pub-id pub-id-type="pmid">25665531</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostovtseva</surname><given-names>T. K.</given-names></name><name><surname>Gurnev</surname><given-names>P. A.</given-names></name><name><surname>Protchenko</surname><given-names>O.</given-names></name><etal/></person-group><article-title>
<italic>&#x003b1;</italic>-Synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2015</year><volume>290</volume><issue>30</issue><fpage>18467</fpage><lpage>18477</lpage><pub-id pub-id-type="pmid">26055708</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahnawaz</surname><given-names>M.</given-names></name><name><surname>Tokuda</surname><given-names>T.</given-names></name><name><surname>Waragai</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development of a biochemical diagnosis of Parkinson disease by detection of <italic>&#x003b1;</italic>-synuclein misfolded aggregates in cerebrospinal fluid</article-title><source><italic toggle="yes">JAMA Neurology</italic></source><year>2017</year><volume>74</volume><issue>2</issue><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.4547</pub-id><pub-id pub-id-type="other">2-s2.0-85014678606</pub-id><pub-id pub-id-type="pmid">27918765</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name><name><surname>Tong</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Iron chelation nanoparticles with delayed saturation as an effective therapy for Parkinson disease</article-title><source><italic toggle="yes">Biomacromolecules</italic></source><year>2016</year><volume>18</volume><issue>2</issue><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">27989126</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Protective effects of a new metalloporphyrin on paraquat-induced oxidative stress and apoptosis in N27 cells</article-title><source><italic toggle="yes">Acta Biochimica et Biophysica Sinica</italic></source><year>2008</year><volume>40</volume><issue>2</issue><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7270.2008.00386.x</pub-id><pub-id pub-id-type="other">2-s2.0-39749122913</pub-id><?supplied-pmid 18235974?><pub-id pub-id-type="pmid">18235974</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadava</surname><given-names>N.</given-names></name><name><surname>Nicholls</surname><given-names>D. G.</given-names></name></person-group><article-title>Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2007</year><volume>27</volume><issue>27</issue><fpage>7310</fpage><lpage>7317</lpage><pub-id pub-id-type="pmid">17611283</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>I. A.</given-names></name><name><surname>Khan</surname><given-names>H. A.</given-names></name></person-group><article-title>Environmental toxins and Parkinson&#x02019;s disease: putative roles of impaired electron transport chain and oxidative stress</article-title><source><italic toggle="yes">Toxicology and Industrial Health</italic></source><year>2010</year><volume>26</volume><issue>2</issue><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20207656</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marella</surname><given-names>M.</given-names></name><name><surname>Seo</surname><given-names>B. B.</given-names></name><name><surname>Yagi</surname><given-names>T.</given-names></name><name><surname>Matsuno-Yagi</surname><given-names>A.</given-names></name></person-group><article-title>Parkinson&#x02019;s disease and mitochondrial complex I: a perspective on the Ndi1 therapy</article-title><source><italic toggle="yes">Journal of Bioenergetics and Biomembranes</italic></source><year>2009</year><volume>41</volume><issue>6</issue><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">19904590</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betarbet</surname><given-names>R.</given-names></name><name><surname>Sherer</surname><given-names>T. B.</given-names></name><name><surname>Mackenzie</surname><given-names>G.</given-names></name><name><surname>Garcia-Osuna</surname><given-names>M.</given-names></name><name><surname>Panov</surname><given-names>A. V.</given-names></name><name><surname>Greenamyre</surname><given-names>J. T.</given-names></name></person-group><article-title>Chronic systemic pesticide exposure reproduces features of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Nature Neuroscience</italic></source><year>2000</year><volume>3</volume><issue>12</issue><fpage>1301</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">11100151</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>T. B.</given-names></name><name><surname>Betarbet</surname><given-names>R.</given-names></name><name><surname>Testa</surname><given-names>C. M.</given-names></name><etal/></person-group><article-title>Mechanism of toxicity in rotenone models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2003</year><volume>23</volume><issue>34</issue><fpage>10756</fpage><lpage>10764</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-34-10756.2003</pub-id><?supplied-pmid 14645467?><pub-id pub-id-type="pmid">14645467</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danielson</surname><given-names>S. R.</given-names></name><name><surname>Held</surname><given-names>J. M.</given-names></name><name><surname>Oo</surname><given-names>M.</given-names></name><name><surname>Riley</surname><given-names>R.</given-names></name><name><surname>Gibson</surname><given-names>B. W.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group><article-title>Quantitative mapping of reversible mitochondrial Complex I cysteine oxidation in a Parkinson disease mouse model</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2011</year><volume>286</volume><issue>9</issue><fpage>7601</fpage><lpage>7608</lpage><pub-id pub-id-type="pmid">21196577</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>H. D.</given-names></name><name><surname>Guan</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>Rotenone impairs autophagic flux and lysosomal functions in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2015</year><volume>284</volume><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">25446361</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C. C.</given-names></name><name><surname>Yeh</surname><given-names>T. H.</given-names></name><name><surname>Lai</surname><given-names>S. C.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism</article-title><source><italic toggle="yes">Experimental Neurology</italic></source><year>2015</year><volume>263</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2014.09.016</pub-id><pub-id pub-id-type="other">2-s2.0-84910684941</pub-id><?supplied-pmid 25263579?><pub-id pub-id-type="pmid">25263579</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatt</surname><given-names>A. P.</given-names></name><name><surname>Duncan</surname><given-names>O. F.</given-names></name><name><surname>Attems</surname><given-names>J.</given-names></name><name><surname>Francis</surname><given-names>P. T.</given-names></name><name><surname>Ballard</surname><given-names>C. G.</given-names></name><name><surname>Bateman</surname><given-names>J. M.</given-names></name></person-group><article-title>Dementia in Parkinson&#x02019;s disease is associated with enhanced mitochondrial complex I deficiency</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2016</year><volume>31</volume><issue>3</issue><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">26853899</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Hulette</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease</article-title><source><italic toggle="yes">Molecular &#x00026; Cellular Proteomics</italic></source><year>2006</year><volume>5</volume><issue>7</issue><fpage>1193</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">16565515</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadhwa</surname><given-names>R.</given-names></name><name><surname>Ryu</surname><given-names>J.</given-names></name><name><surname>Ahn</surname><given-names>H. M.</given-names></name><etal/></person-group><article-title>Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2015</year><volume>290</volume><issue>13</issue><fpage>8447</fpage><lpage>8456</lpage><pub-id pub-id-type="pmid">25645922</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>T. J.</given-names></name><name><surname>Hoekstra</surname><given-names>J. G.</given-names></name><name><surname>Eaton</surname><given-names>D. L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Mortalin is expressed by astrocytes and decreased in the midbrain of Parkinson&#x02019;s disease patients</article-title><source><italic toggle="yes">Brain Pathology</italic></source><year>2016</year><volume>26</volume><issue>1</issue><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26095919</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>M. A.</given-names></name><name><surname>Collins</surname><given-names>J. L.</given-names></name><name><surname>Hod</surname><given-names>Y.</given-names></name><name><surname>Ringe</surname><given-names>D.</given-names></name><name><surname>Petsko</surname><given-names>A. G.</given-names></name></person-group><article-title>The 1.1-&#x000c5; resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2003</year><volume>100</volume><issue>16</issue><fpage>9256</fpage><lpage>9261</lpage></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R. H.</given-names></name><name><surname>Smith</surname><given-names>P. D.</given-names></name><name><surname>Aleyasin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2005</year><volume>102</volume><issue>14</issue><fpage>5215</fpage><lpage>5220</lpage></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleyasin</surname><given-names>H.</given-names></name><name><surname>Rousseaux</surname><given-names>M. W. C.</given-names></name><name><surname>Phillips</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The Parkinson&#x02019;s disease gene DJ-1 is also a key regulator of stroke-induced damage</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2007</year><volume>104</volume><issue>47</issue><fpage>18748</fpage><lpage>18753</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709379104</pub-id><pub-id pub-id-type="other">2-s2.0-36749013055</pub-id><?supplied-pmid 18003894?><pub-id pub-id-type="pmid">18003894</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Chin</surname><given-names>L. S.</given-names></name></person-group><article-title>Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage</article-title><source><italic toggle="yes">Human Molecular Genetics</italic></source><year>2010</year><volume>19</volume><issue>12</issue><fpage>2395</fpage><lpage>2408</lpage><pub-id pub-id-type="pmid">20304780</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irrcher</surname><given-names>I.</given-names></name><name><surname>Aleyasin</surname><given-names>H.</given-names></name><name><surname>Seifert</surname><given-names>E. L.</given-names></name><etal/></person-group><article-title>Loss of the Parkinson&#x02019;s disease-linked gene DJ-1 perturbs mitochondrial dynamics</article-title><source><italic toggle="yes">Human Molecular Genetics</italic></source><year>2010</year><volume>19</volume><issue>19</issue><fpage>3734</fpage><lpage>3746</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq288</pub-id><pub-id pub-id-type="other">2-s2.0-77956522541</pub-id><?supplied-pmid 20639397?><pub-id pub-id-type="pmid">20639397</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Bercury</surname><given-names>K.</given-names></name><name><surname>Cummiskey</surname><given-names>J.</given-names></name><name><surname>Luong</surname><given-names>N.</given-names></name><name><surname>Lebin</surname><given-names>J.</given-names></name><name><surname>Freed</surname><given-names>C. R.</given-names></name></person-group><article-title>Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2011</year><volume>286</volume><issue>17</issue><fpage>14941</fpage><lpage>14951</lpage><pub-id pub-id-type="pmid">21372141</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joselin</surname><given-names>A. P.</given-names></name><name><surname>Hewitt</surname><given-names>S. J.</given-names></name><name><surname>Callaghan</surname><given-names>S. M.</given-names></name><etal/></person-group><article-title>ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons</article-title><source><italic toggle="yes">Human Molecular Genetics</italic></source><year>2012</year><volume>21</volume><issue>22</issue><fpage>4888</fpage><lpage>4903</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds325</pub-id><pub-id pub-id-type="other">2-s2.0-84868087279</pub-id><?supplied-pmid 22872702?><pub-id pub-id-type="pmid">22872702</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lev</surname><given-names>N.</given-names></name><name><surname>Barhum</surname><given-names>Y.</given-names></name><name><surname>Pilosof</surname><given-names>N. S.</given-names></name><etal/></person-group><article-title>DJ-1 protects against dopamine toxicity: implications for Parkinson&#x02019;s disease and aging</article-title><source><italic toggle="yes">The Journals of Gerontology Series A: Biological Sciences and Medical Sciences</italic></source><year>2013</year><volume>68</volume><issue>3</issue><fpage>215</fpage><lpage>225</lpage></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zondler</surname><given-names>L.</given-names></name><name><surname>Miller-Fleming</surname><given-names>L.</given-names></name><name><surname>Repici</surname><given-names>M.</given-names></name><etal/></person-group><article-title>DJ-1 interactions with a-synuclein attenuate aggregation and cellular toxicity in models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Cell Death &#x00026; Disease</italic></source><year>2014</year><volume>5</volume><issue>7</issue><fpage>p. e1350</fpage></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canet-Avil&#x000e9;s</surname><given-names>R. M.</given-names></name><name><surname>Wilson</surname><given-names>M. A.</given-names></name><name><surname>Miller</surname><given-names>D. W.</given-names></name><etal/></person-group><article-title>The Parkinson&#x02019;s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2004</year><volume>101</volume><issue>24</issue><fpage>9103</fpage><lpage>9108</lpage></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Freed</surname><given-names>C. R.</given-names></name></person-group><article-title>DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T <italic>&#x003b1;</italic>-synuclein toxicity</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>52</issue><fpage>43150</fpage><lpage>43158</lpage><pub-id pub-id-type="pmid">16227205</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steckley</surname><given-names>D.</given-names></name><name><surname>Karajgikar</surname><given-names>M.</given-names></name><name><surname>Dale</surname><given-names>L. B.</given-names></name><etal/></person-group><article-title>Puma is a dominant regulator of oxidative stress induced Bax activation and neuronal apoptosis</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2007</year><volume>27</volume><issue>47</issue><fpage>12989</fpage><lpage>12999</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3400-07.2007</pub-id><pub-id pub-id-type="other">2-s2.0-36348989734</pub-id><pub-id pub-id-type="pmid">18032672</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Davis</surname><given-names>B.</given-names></name><name><surname>Chiang</surname><given-names>Y. H.</given-names></name><etal/></person-group><article-title>Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson&#x02019;s disease model</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2016</year><volume>138</volume><issue>5</issue><fpage>746</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1111/jnc.13706</pub-id><pub-id pub-id-type="other">2-s2.0-84983670770</pub-id><?supplied-pmid 27317935?><pub-id pub-id-type="pmid">27317935</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>C.</given-names></name><name><surname>Xing</surname><given-names>D.</given-names></name></person-group><article-title>A<italic>&#x003b2;</italic> induces PUMA activation: a new mechanism for A<italic>&#x003b2;</italic>-mediated neuronal apoptosis</article-title><source><italic toggle="yes">Neurobiology of Aging</italic></source><year>2015</year><volume>36</volume><issue>2</issue><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">25457551</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P.-C.</given-names></name><name><surname>Vargas</surname><given-names>M. R.</given-names></name><name><surname>Pani</surname><given-names>A. K.</given-names></name><etal/></person-group><article-title>Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson&#x02019;s disease: critical role for the astrocyte</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2009</year><volume>106</volume><issue>8</issue><fpage>2933</fpage><lpage>2938</lpage></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haskew-Layton</surname><given-names>R. E.</given-names></name><name><surname>Payappilly</surname><given-names>J. B.</given-names></name><name><surname>Smirnova</surname><given-names>N. A.</given-names></name><etal/></person-group><article-title>Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2010</year><volume>107</volume><issue>40</issue><fpage>17385</fpage><lpage>17390</lpage><pub-id pub-id-type="doi">10.1073/pnas.1003996107</pub-id><pub-id pub-id-type="other">2-s2.0-78049233238</pub-id><?supplied-pmid 20855618?><pub-id pub-id-type="pmid">20855618</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagda</surname><given-names>R. K.</given-names></name><name><surname>Cherra</surname><given-names>S. J.</given-names></name><name><surname>Kulich</surname><given-names>S. M.</given-names></name><name><surname>Tandon</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>D.</given-names></name><name><surname>Chu</surname><given-names>C. T.</given-names></name></person-group><article-title>Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2009</year><volume>284</volume><issue>20</issue><fpage>13843</fpage><lpage>13855</lpage><pub-id pub-id-type="pmid">19279012</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>C.</given-names></name><name><surname>Stetler</surname><given-names>C.</given-names></name><name><surname>Petrucelli</surname><given-names>L.</given-names></name></person-group><article-title>Disruption of protein quality control in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Cold Spring Harbor Perspectives in Medicine</italic></source><year>2012</year><volume>2</volume><issue>5, article a009423</issue></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>M.</given-names></name><name><surname>Berlin</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2012</year><volume>32</volume><issue>19</issue><fpage>6561</fpage><lpage>6569</lpage><pub-id pub-id-type="pmid">22573678</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafourifar</surname><given-names>P.</given-names></name><name><surname>Colton</surname><given-names>C. A.</given-names></name></person-group><article-title>Mitochondria and nitric oxide</article-title><source><italic toggle="yes">Antioxidants &#x00026; Redox Signaling</italic></source><year>2003</year><volume>5</volume><issue>3</issue><fpage>249</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">12889472</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>D.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Nitrosative stress linked to sporadic Parkinson&#x02019;s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2004</year><volume>101</volume><issue>29</issue><fpage>10810</fpage><lpage>10814</lpage><pub-id pub-id-type="doi">10.1073/pnas.0404161101</pub-id><pub-id pub-id-type="other">2-s2.0-3242733689</pub-id><?supplied-pmid 15252205?><pub-id pub-id-type="pmid">15252205</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavya</surname><given-names>R.</given-names></name><name><surname>Saluja</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Dikshit</surname><given-names>M.</given-names></name></person-group><article-title>Nitric oxide synthase regulation and diversity: implications in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Nitric Oxide</italic></source><year>2006</year><volume>15</volume><issue>4</issue><fpage>280</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">16934505</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>S. H.</given-names></name><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Piao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2011</year><volume>187</volume><issue>2</issue><fpage>960</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">21685323</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>P. K. K.</given-names></name><name><surname>Lai</surname><given-names>A. K. W.</given-names></name><name><surname>Son</surname><given-names>H. J.</given-names></name><etal/></person-group><article-title>Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Aging</italic></source><year>2017</year><volume>50</volume><fpage>119</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">27960106</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>J. S.</given-names></name><name><surname>Koppenol</surname><given-names>W. H.</given-names></name></person-group><article-title>Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly</article-title><source><italic toggle="yes">American Journal of Physiology-Cell Physiology</italic></source><year>1996</year><volume>271</volume><issue>5</issue><fpage>C1424</fpage><lpage>C1437</lpage></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehmer</surname><given-names>T.</given-names></name><name><surname>Lindenau</surname><given-names>J.</given-names></name><name><surname>Haid</surname><given-names>S.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name><name><surname>Schulz</surname><given-names>J. B.</given-names></name></person-group><article-title>Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2000</year><volume>74</volume><issue>5</issue><fpage>2213</fpage><lpage>2216</lpage><pub-id pub-id-type="pmid">10800968</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolanza</surname><given-names>M.</given-names></name><name><surname>Cavalcanti-Kiwiatkoski</surname><given-names>R.</given-names></name><name><surname>Padovan-Neto</surname><given-names>F. E.</given-names></name><etal/></person-group><article-title>Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2015</year><volume>73</volume><fpage>377</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.10.017</pub-id><pub-id pub-id-type="other">2-s2.0-84909580553</pub-id><?supplied-pmid 25447229?><pub-id pub-id-type="pmid">25447229</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebadi</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name></person-group><article-title>Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease</article-title><source><italic toggle="yes">Experimental Biology and Medicine</italic></source><year>2006</year><volume>231</volume><issue>9</issue><fpage>1576</fpage><lpage>1583</lpage><pub-id pub-id-type="pmid">17018883</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotharius</surname><given-names>J.</given-names></name><name><surname>Barg</surname><given-names>S.</given-names></name><name><surname>Wiekop</surname><given-names>P.</given-names></name><name><surname>Lundberg</surname><given-names>C.</given-names></name><name><surname>Raymon</surname><given-names>H. K.</given-names></name><name><surname>Brundin</surname><given-names>P.</given-names></name></person-group><article-title>Effect of mutant <italic>&#x003b1;</italic>-synuclein on dopamine homeostasis in a new human mesencephalic cell line</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>41</issue><fpage>38884</fpage><lpage>38894</lpage><pub-id pub-id-type="pmid">12145295</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.-W.</given-names></name><name><surname>Chen</surname><given-names>G. Y. J.</given-names></name><etal/></person-group><article-title>A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson&#x02019;s disease models</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2014</year><volume>5</volume><issue>1, article 3276</issue><pub-id pub-id-type="doi">10.1038/ncomms4276</pub-id><pub-id pub-id-type="other">2-s2.0-84928096894</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotz</surname><given-names>M. E.</given-names></name><name><surname>Kunig</surname><given-names>G.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group><article-title>Oxidative stress: free radical production in neural degeneration</article-title><source><italic toggle="yes">Pharmacology &#x00026; Therapeutics</italic></source><year>1994</year><volume>63</volume><issue>1</issue><fpage>37</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">7972344</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burbulla</surname><given-names>L. F.</given-names></name><name><surname>Song</surname><given-names>P.</given-names></name><name><surname>Mazzulli</surname><given-names>J. R.</given-names></name><etal/></person-group><article-title>Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Science</italic></source><year>2017</year><volume>357</volume><issue>6357</issue><fpage>1255</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1126/science.aam9080</pub-id><pub-id pub-id-type="other">2-s2.0-85029038928</pub-id><?supplied-pmid 28882997?><pub-id pub-id-type="pmid">28882997</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gesi</surname><given-names>M.</given-names></name><name><surname>Santinami</surname><given-names>A.</given-names></name><name><surname>Ruffoli</surname><given-names>R.</given-names></name></person-group><article-title>Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties)</article-title><source><italic toggle="yes">Pharmacology &#x00026; Toxicology: MiniReview</italic></source><year>2001</year><volume>89</volume><issue>5</issue><fpage>217</fpage><lpage>224</lpage></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>A. H.</given-names></name><name><surname>Hastings</surname><given-names>T. G.</given-names></name><name><surname>Vrana</surname><given-names>K. E.</given-names></name></person-group><article-title>Cytotoxic and genotoxic potential of dopamine</article-title><source><italic toggle="yes">Journal of Neuroscience Research</italic></source><year>1999</year><volume>55</volume><issue>6</issue><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">10220107</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>S. B.</given-names></name><name><surname>Hastings</surname><given-names>T. G.</given-names></name></person-group><article-title>Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1997</year><volume>69</volume><issue>3</issue><fpage>1185</fpage><lpage>1195</lpage><pub-id pub-id-type="pmid">9282942</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>S. B.</given-names></name><name><surname>Hastings</surname><given-names>T. G.</given-names></name></person-group><article-title>Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1999</year><volume>73</volume><fpage>1127</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">10461904</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>D. M.</given-names></name><name><surname>Arthur Junior</surname><given-names>R. E.</given-names></name><name><surname>Thomas</surname><given-names>D. M.</given-names></name><name><surname>Elferink</surname><given-names>L. A.</given-names></name></person-group><article-title>Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1999</year><volume>73</volume><issue>3</issue><fpage>1309</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">10461926</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofic</surname><given-names>E.</given-names></name><name><surname>Lange</surname><given-names>K. W.</given-names></name><name><surname>Jellinger</surname><given-names>K.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group><article-title>Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuroscience Letters</italic></source><year>1992</year><volume>142</volume><issue>2</issue><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">1454205</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sian</surname><given-names>J.</given-names></name><name><surname>Dexter</surname><given-names>D. T.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name><etal/></person-group><article-title>Alterations in glutathione levels in Parkinson&#x02019;s disease and other neurodegenerative disorders affecting basal ganglia</article-title><source><italic toggle="yes">Annals of Neurology</italic></source><year>1994</year><volume>36</volume><issue>3</issue><fpage>348</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1002/ana.410360305</pub-id><pub-id pub-id-type="other">2-s2.0-0028075410</pub-id><pub-id pub-id-type="pmid">8080242</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Sofic</surname><given-names>E.</given-names></name><name><surname>Rausch</surname><given-names>W. D.</given-names></name></person-group><article-title>Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1989</year><volume>52</volume><issue>2</issue><fpage>515</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1989.tb09150.x</pub-id><pub-id pub-id-type="other">2-s2.0-0024557734</pub-id><?supplied-pmid 2911028?><pub-id pub-id-type="pmid">2911028</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Dudek</surname><given-names>E.</given-names></name><name><surname>Reddan</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>A.</given-names></name></person-group><article-title>Vitamin C and vitamin E restore the resistance of GSH-depleted lens cells to H<sub>2</sub>O<sub>2</sub></article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>2003</year><volume>34</volume><issue>5</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(02)01304-7</pub-id><pub-id pub-id-type="other">2-s2.0-0037373024</pub-id><?supplied-pmid 12614841?><pub-id pub-id-type="pmid">12614841</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitch</surname><given-names>J. A.</given-names></name><name><surname>D'amato</surname><given-names>R. J.</given-names></name><name><surname>Strittmatter</surname><given-names>S. M.</given-names></name><name><surname>Snyder</surname><given-names>S. H.</given-names></name></person-group><article-title>Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>1985</year><volume>82</volume><issue>7</issue><fpage>2173</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.7.2173</pub-id><pub-id pub-id-type="other">2-s2.0-0000340348</pub-id><?supplied-pmid 3872460?><pub-id pub-id-type="pmid">3872460</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>H. G.</given-names></name><name><surname>Hwang</surname><given-names>L.</given-names></name></person-group><article-title>Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson&#x02019;s disease by blocking microglial activation</article-title><source><italic toggle="yes">Neurotoxicity Research</italic></source><year>2009</year><volume>15</volume><issue>4</issue><fpage>332</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1007/s12640-009-9037-x</pub-id><pub-id pub-id-type="other">2-s2.0-70449527787</pub-id><?supplied-pmid 19384567?><pub-id pub-id-type="pmid">19384567</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Kim</surname><given-names>S. R.</given-names></name><name><surname>Jin</surname><given-names>B. K.</given-names></name></person-group><article-title>Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2010</year><volume>185</volume><issue>2</issue><fpage>1230</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000208</pub-id><pub-id pub-id-type="other">2-s2.0-77955504380</pub-id><?supplied-pmid 20566832?><pub-id pub-id-type="pmid">20566832</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Bok</surname><given-names>E.</given-names></name><name><surname>Huh</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title>Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2011</year><volume>187</volume><issue>12</issue><fpage>6508</fpage><lpage>6517</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102435</pub-id><pub-id pub-id-type="other">2-s2.0-83755178512</pub-id><?supplied-pmid 22079984?><pub-id pub-id-type="pmid">22079984</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tz</surname><given-names>M. E.</given-names></name><name><surname>Gerstner</surname><given-names>A.</given-names></name><name><surname>Harth</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Altered redox state of platelet coenzyme Q10 in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>2000</year><volume>107</volume><issue>1</issue><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s007020050003</pub-id><pub-id pub-id-type="other">2-s2.0-0033969735</pub-id><?supplied-pmid 10809402?><pub-id pub-id-type="pmid">10809402</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>D. H.</given-names></name></person-group><article-title>Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>1997</year><volume>104</volume><issue>6-7</issue><fpage>649</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1007/BF01291883</pub-id><pub-id pub-id-type="other">2-s2.0-0030666415</pub-id><?supplied-pmid 9444565?><pub-id pub-id-type="pmid">9444565</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofic</surname><given-names>E.</given-names></name><name><surname>Paulus</surname><given-names>W.</given-names></name><name><surname>Jellinger</surname><given-names>K.</given-names></name></person-group><article-title>Selective increase of iron in substantia nigra zona compacta of parkinsonian brains</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1991</year><volume>56</volume><issue>3</issue><fpage>978</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb02017.x</pub-id><pub-id pub-id-type="other">2-s2.0-0025963530</pub-id><?supplied-pmid 1704426?><pub-id pub-id-type="pmid">1704426</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharath</surname><given-names>S.</given-names></name><name><surname>Hsu</surname><given-names>M.</given-names></name><name><surname>Kaur</surname><given-names>D.</given-names></name><name><surname>Rajagopalan</surname><given-names>S.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group><article-title>Glutathione, iron and Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Biochemical Pharmacology</italic></source><year>2002</year><volume>64</volume><issue>5-6</issue><fpage>1037</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(02)01174-7</pub-id><pub-id pub-id-type="other">2-s2.0-0036710567</pub-id><?supplied-pmid 12213603?><pub-id pub-id-type="pmid">12213603</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoritaka</surname><given-names>A.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Stadtman</surname><given-names>E. R.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name></person-group><article-title>Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>1996</year><volume>93</volume><issue>7</issue><fpage>2696</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.7.2696</pub-id><pub-id pub-id-type="other">2-s2.0-0029917194</pub-id><?supplied-pmid 8610103?><pub-id pub-id-type="pmid">8610103</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>Z. I.</given-names></name><name><surname>Jenner</surname><given-names>A.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><etal/></person-group><article-title>Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>1997</year><volume>69</volume><issue>3</issue><fpage>1196</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.69031196.x</pub-id><?supplied-pmid 9282943?><pub-id pub-id-type="pmid">9282943</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campolo</surname><given-names>J.</given-names></name><name><surname>De Maria</surname><given-names>R.</given-names></name><name><surname>Cozzi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2016</year><volume>370</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2016.09.050</pub-id><pub-id pub-id-type="other">2-s2.0-84989223278</pub-id><?supplied-pmid 27772753?><pub-id pub-id-type="pmid">27772753</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>B. T.</given-names></name></person-group><article-title>CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">International Journal of Molecular Medicine</italic></source><year>2004</year><volume>13</volume><issue>3</issue><fpage>343</fpage><lpage>353</lpage><?supplied-pmid 14767563?><pub-id pub-id-type="pmid">14767563</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevas</surname><given-names>G. P.</given-names></name><name><surname>Kapaki</surname><given-names>E.</given-names></name><name><surname>Petropoulou</surname><given-names>O.</given-names></name><name><surname>Anagnostouli</surname><given-names>M.</given-names></name><name><surname>Vagenas</surname><given-names>V.</given-names></name><name><surname>Papageorgiou</surname><given-names>C.</given-names></name></person-group><article-title>Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2003</year><volume>215</volume><issue>1-2</issue><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(03)00184-9</pub-id><pub-id pub-id-type="other">2-s2.0-0142026191</pub-id><?supplied-pmid 14568128?><pub-id pub-id-type="pmid">14568128</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>R. K.</given-names></name><name><surname>Shukla</surname><given-names>S.</given-names></name><name><surname>Seth</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2006</year><volume>22</volume><issue>2</issue><fpage>421</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.12.008</pub-id><pub-id pub-id-type="other">2-s2.0-33646137778</pub-id><?supplied-pmid 16480889?><pub-id pub-id-type="pmid">16480889</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J. H.</given-names></name><name><surname>Du</surname><given-names>M.</given-names></name><name><surname>Bai</surname><given-names>Y. H.</given-names></name></person-group><article-title>Correlations of melatonin and glutathione levels with oxidative stress mechanism in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Acta Academiae Medicinae Sinicae</italic></source><year>2019</year><volume>41</volume><issue>2</issue><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">31060672</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zampol</surname><given-names>M. A.</given-names></name><name><surname>Barros</surname><given-names>M. H.</given-names></name></person-group><article-title>Melatonin improves survival and respiratory activity of yeast cells challenged by alpha-synuclein and menadione</article-title><source><italic toggle="yes">Yeast</italic></source><year>2018</year><volume>35</volume><issue>3</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/yea.3296</pub-id><pub-id pub-id-type="other">2-s2.0-85043322350</pub-id><?supplied-pmid 29143358?><pub-id pub-id-type="pmid">29143358</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patki</surname><given-names>G.</given-names></name><name><surname>Lau</surname><given-names>Y. S.</given-names></name></person-group><article-title>Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Pharmacology Biochemistry and Behavior</italic></source><year>2011</year><volume>99</volume><issue>4</issue><fpage>704</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2011.06.026</pub-id><pub-id pub-id-type="other">2-s2.0-79960334940</pub-id><?supplied-pmid 21741988?><pub-id pub-id-type="pmid">21741988</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>R.</given-names></name><name><surname>Phukan</surname><given-names>B. C.</given-names></name><name><surname>Thenmozhi</surname><given-names>A. J.</given-names></name><name><surname>Manivasagam</surname><given-names>T.</given-names></name><name><surname>Bhattacharya</surname><given-names>P.</given-names></name><name><surname>Borah</surname><given-names>A.</given-names></name></person-group><article-title>Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Life Sciences</italic></source><year>2018</year><volume>192</volume><fpage>238</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2017.11.016</pub-id><pub-id pub-id-type="other">2-s2.0-85034447953</pub-id><pub-id pub-id-type="pmid">29138117</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S. M.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Effects of melatonin levels on neurotoxicity of the medial prefrontal cortex in a rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Chinese Medical Journal</italic></source><year>2017</year><volume>130</volume><issue>22</issue><fpage>p. 2726</fpage><pub-id pub-id-type="pmid">29133763</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>M. Z.</given-names></name><name><surname>Andrabi</surname><given-names>S. S.</given-names></name><name><surname>Salman</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Melatonin improves behavioral and biochemical outcomes in a rotenone-induced rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Environmental Pathology, Toxicology and Oncology</italic></source><year>2018</year><volume>37</volume><issue>2</issue><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.2018025666</pub-id><pub-id pub-id-type="other">2-s2.0-85050891931</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassani</surname><given-names>T. B.</given-names></name><name><surname>Gradowski</surname><given-names>R. W.</given-names></name><name><surname>Zaminelli</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson&#x02019;s disease model in rats</article-title><source><italic toggle="yes">Brain Research</italic></source><year>2014</year><volume>1593</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2014.09.068</pub-id><pub-id pub-id-type="other">2-s2.0-84916595528</pub-id><?supplied-pmid 25301688?><pub-id pub-id-type="pmid">25301688</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsoy</surname><given-names>O.</given-names></name><name><surname>Yildirim</surname><given-names>F. B.</given-names></name><name><surname>Ogut</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model</article-title><source><italic toggle="yes">Free Radical Research</italic></source><year>2015</year><volume>49</volume><issue>8</issue><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.3109/10715762.2015.1027198</pub-id><pub-id pub-id-type="other">2-s2.0-84938385734</pub-id><?supplied-pmid 25791066?><pub-id pub-id-type="pmid">25791066</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>G. G.</given-names></name><name><surname>Mor&#x000e1;les-S&#x000e1;nchez</surname><given-names>E. W.</given-names></name><name><surname>Pacheco-Mois&#x000e9;s</surname><given-names>F. P.</given-names></name><etal/></person-group><article-title>Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Gaceta medica de Mexico</italic></source><year>2017</year><volume>153</volume><issue>Supl. 2</issue><supplement>Supplement 2</supplement><fpage>S72</fpage><lpage>S81</lpage><pub-id pub-id-type="doi">10.24875/GMM.M000008</pub-id><pub-id pub-id-type="other">2-s2.0-85059140687</pub-id><?supplied-pmid 29099102?><pub-id pub-id-type="pmid">29099102</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naskar</surname><given-names>A.</given-names></name><name><surname>Prabhakar</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Dutta</surname><given-names>D.</given-names></name><name><surname>Mohanakumar</surname><given-names>K. P.</given-names></name></person-group><article-title>Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice</article-title><source><italic toggle="yes">Journal of Pineal Research</italic></source><year>2015</year><volume>58</volume><issue>3</issue><fpage>262</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1111/jpi.12212</pub-id><pub-id pub-id-type="other">2-s2.0-84924707221</pub-id><pub-id pub-id-type="pmid">25626558</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belaid</surname><given-names>H.</given-names></name><name><surname>Adrien</surname><given-names>J.</given-names></name><name><surname>Karachi</surname><given-names>C.</given-names></name><name><surname>Hirsch</surname><given-names>E. C.</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>C.</given-names></name></person-group><article-title>Effect of melatonin on sleep disorders in a monkey model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Sleep Medicine</italic></source><year>2015</year><volume>16</volume><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">26429753</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Ran</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a <italic>Drosophila</italic> model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2016</year><volume>13</volume><issue>5</issue><fpage>3936</fpage><lpage>3944</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.4991</pub-id><pub-id pub-id-type="other">2-s2.0-84964711891</pub-id><?supplied-pmid 26985725?><pub-id pub-id-type="pmid">26985725</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>G. A.</given-names></name><name><surname>Mastick</surname><given-names>J.</given-names></name><name><surname>Colling</surname><given-names>E.</given-names></name><name><surname>Carter</surname><given-names>J. H.</given-names></name><name><surname>Singer</surname><given-names>C. M.</given-names></name><name><surname>Aminoff</surname><given-names>M. J.</given-names></name></person-group><article-title>Melatonin for sleep disturbances in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Sleep Medicine</italic></source><year>2005</year><volume>6</volume><issue>5</issue><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2005.04.004</pub-id><pub-id pub-id-type="other">2-s2.0-24344486006</pub-id><?supplied-pmid 16084125?><pub-id pub-id-type="pmid">16084125</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilat</surname><given-names>M.</given-names></name><name><surname>Jackson</surname><given-names>A. C.</given-names></name><name><surname>Marshall</surname><given-names>N. S.</given-names></name><etal/></person-group><article-title>Melatonin for rapid eye movement sleep behavior disorder in Parkinson&#x02019;s disease: a randomised controlled trial</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2020</year><volume>35</volume><issue>2</issue><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1002/mds.27886</pub-id><?supplied-pmid 31674060?><pub-id pub-id-type="pmid">31674060</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prolonged-release melatonin in Parkinson&#x02019;s disease patients with a poor sleep quality: a randomized trial</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2020</year><volume>16</volume><fpage>50</fpage><lpage>54</lpage></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X. Y.</given-names></name><name><surname>Su</surname><given-names>S. W.</given-names></name><etal/></person-group><article-title>Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials</article-title><source><italic toggle="yes">Neurological Sciences</italic></source><year>2016</year><volume>37</volume><issue>1</issue><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s10072-015-2357-0</pub-id><pub-id pub-id-type="other">2-s2.0-84955725894</pub-id><?supplied-pmid 26255301?><pub-id pub-id-type="pmid">26255301</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebadi</surname><given-names>M.</given-names></name><name><surname>Govitrapong</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Muralikrishnan</surname><given-names>D.</given-names></name><name><surname>Shavali</surname><given-names>S.</given-names></name><name><surname>Pellett</surname><given-names>L.</given-names></name></person-group><article-title>Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurosignals</italic></source><year>2001</year><volume>10</volume><issue>3-4</issue><fpage>224</fpage><lpage>253</lpage></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonakdar</surname><given-names>R. A.</given-names></name><name><surname>Guarneri</surname><given-names>E.</given-names></name></person-group><article-title>Coenzyme Q10</article-title><source><italic toggle="yes">American Family Physician</italic></source><year>2005</year><volume>72</volume><issue>6</issue><fpage>1065</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">16190504</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echtay</surname><given-names>K. S.</given-names></name><name><surname>Roussel</surname><given-names>D.</given-names></name><name><surname>St-Pierre</surname><given-names>J.</given-names></name><name><surname>Jekabsons</surname><given-names>M. B.</given-names></name><name><surname>Cadenas</surname><given-names>S.</given-names></name><name><surname>Stuart</surname><given-names>J. A.</given-names></name></person-group><article-title>Superoxide activates mitochondrial uncoupling proteins</article-title><source><italic toggle="yes">Nature</italic></source><year>2002</year><volume>415</volume><issue>6867</issue><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11780125</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>R. T.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Browne</surname><given-names>S.</given-names></name><name><surname>Baik</surname><given-names>M.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group><article-title>Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>1998</year><volume>95</volume><issue>15</issue><fpage>8892</fpage><lpage>8897</lpage></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdin</surname><given-names>A. A.</given-names></name><name><surname>Hamouda</surname><given-names>H. E.</given-names></name></person-group><article-title>Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2008</year><volume>55</volume><fpage>1340</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">18817789</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleren</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Lorenzo</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Therapeutic effects of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) and reduced CoQ<sub>10</sub> in the MPTP model of parkinsonism</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2008</year><volume>104</volume><fpage>113</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">17995936</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Matthews</surname><given-names>R. T.</given-names></name><name><surname>Tieleman</surname><given-names>A.</given-names></name><name><surname>Shults</surname><given-names>C. W.</given-names></name></person-group><article-title>Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice</article-title><source><italic toggle="yes">Brain Research</italic></source><year>1998</year><volume>783</volume><issue>1</issue><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">9479058</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>T. L.</given-names></name><name><surname>Diano</surname><given-names>S.</given-names></name><name><surname>Leranth</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Endocrinology</italic></source><year>2003</year><volume>144</volume><issue>7</issue><fpage>2757</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1210/en.2003-0163</pub-id><pub-id pub-id-type="other">2-s2.0-0038336912</pub-id><?supplied-pmid 12810526?><pub-id pub-id-type="pmid">12810526</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S. K.</given-names></name><name><surname>El ReFaey</surname><given-names>H.</given-names></name><name><surname>Ebadi</surname><given-names>M.</given-names></name></person-group><article-title>Complex-1 activity and <sup>18</sup>F-DOPA uptake in genetically engineered mouse model of Parkinson&#x02019;s disease and the neuroprotective role of coenzyme Q<sub>10</sub></article-title><source><italic toggle="yes">Brain Research Bulletin</italic></source><year>2006</year><volume>70</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16750479</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><collab>The Parkinson&#x02019;s Study Group QE3</collab><article-title>A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease. No evidence of benefit</article-title><source><italic toggle="yes">JAMA Neurology</italic></source><year>2014</year><volume>71</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">24664227</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negida</surname><given-names>A.</given-names></name><name><surname>Menshawy</surname><given-names>A.</given-names></name><name><surname>El Ashal</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Coenzyme Q10 for patients with Parkinson&#x02019;s disease: a systematic review and meta-analysis</article-title><source><italic toggle="yes">CNS &#x00026; Neurological Disorders &#x02013; Drug Targets</italic></source><year>2016</year><volume>15</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">26553164</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>M.</given-names></name><name><surname>Riise</surname><given-names>T.</given-names></name><name><surname>Engeland</surname><given-names>A.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>Bj&#x000f8;rnevik</surname><given-names>K.</given-names></name></person-group><article-title>Urate and the risk of Parkinson&#x02019;s disease in men and women</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2018</year><volume>52</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">29615298</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarukhani</surname><given-names>M. R.</given-names></name><name><surname>Haghdoost-Yazdi</surname><given-names>H.</given-names></name><name><surname>Khandan-Chelarci</surname><given-names>G.</given-names></name></person-group><article-title>Changes in the serum urate level can predict the development of Parkinsonism in the 6-hydroxydopamine animal model</article-title><source><italic toggle="yes">Neurochemical Research</italic></source><year>2018</year><volume>43</volume><issue>5</issue><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">29616443</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coolen</surname><given-names>E. J. C. M.</given-names></name><name><surname>Arts</surname><given-names>I. C. W.</given-names></name><name><surname>Bekers</surname><given-names>O.</given-names></name><name><surname>Vervaet</surname><given-names>C.</given-names></name><name><surname>Bast</surname><given-names>A.</given-names></name><name><surname>Dagnelie</surname><given-names>P. C.</given-names></name></person-group><article-title>Oral bioavailability of ATP after prolonged administration</article-title><source><italic toggle="yes">British Journal of Nutrition</italic></source><year>2011</year><volume>105</volume><issue>3</issue><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">21129239</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreadou</surname><given-names>E.</given-names></name><name><surname>Nikolaou</surname><given-names>C.</given-names></name><name><surname>Gournaras</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Serum uric acid levels in patients with Parkinson&#x02019;s disease: their relationship to treatment and disease duration</article-title><source><italic toggle="yes">Clinical Neurology and Neurosurgery</italic></source><year>2009</year><volume>111</volume><issue>9</issue><fpage>724</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2009.06.012</pub-id><pub-id pub-id-type="other">2-s2.0-70349487220</pub-id><?supplied-pmid 19632030?><pub-id pub-id-type="pmid">19632030</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>A.</given-names></name><name><surname>Yamauchi</surname><given-names>A.</given-names></name><name><surname>Matsumoto</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Behavioural Pharmacology</italic></source><year>2019</year><volume>30</volume><issue>1</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/FBP.0000000000000413</pub-id><pub-id pub-id-type="other">2-s2.0-85059829003</pub-id><?supplied-pmid 29847340?><pub-id pub-id-type="pmid">29847340</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T. T.</given-names></name><name><surname>Hao</surname><given-names>D. L.</given-names></name><name><surname>Wu</surname><given-names>B. N.</given-names></name><name><surname>Mao</surname><given-names>L. L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Uric acid demonstrates neuroprotective effect on Parkinson&#x02019;s disease mice through Nrf2-ARE signaling pathway</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2017</year><volume>493</volume><issue>4</issue><fpage>1443</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">28986252</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwaki</surname><given-names>H.</given-names></name><name><surname>Ando</surname><given-names>R.</given-names></name><name><surname>Miyaue</surname><given-names>N.</given-names></name><etal/></person-group><article-title>One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson&#x02019;s disease in Japan</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2017</year><volume>383</volume><fpage>75</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2017.10.030</pub-id><pub-id pub-id-type="other">2-s2.0-85032296412</pub-id><?supplied-pmid 29246629?><pub-id pub-id-type="pmid">29246629</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdin</surname><given-names>E.</given-names></name></person-group><article-title>NAD<sup>+</sup> in aging, metabolism, and neurodegeneration</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>350</volume><issue>6265</issue><fpage>1208</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1126/science.aac4854</pub-id><pub-id pub-id-type="other">2-s2.0-84949036094</pub-id><?supplied-pmid 26785480?><pub-id pub-id-type="pmid">26785480</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>C.</given-names></name><name><surname>Gong</surname><given-names>Y. L.</given-names></name><name><surname>Zhuang</surname><given-names>Q. Q.</given-names></name><etal/></person-group><article-title>Protective effects of <italic>&#x003b2;</italic>-nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>2019</year><volume>94</volume><fpage>p. 109670</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2019.109670</pub-id><pub-id pub-id-type="other">2-s2.0-85067579813</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>F. S.</given-names></name><name><surname>Biasibetti-Brendler</surname><given-names>H.</given-names></name><name><surname>Pierozan</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Kynurenic acid restores Nrf2 levels and prevents quinolinic acid-induced toxicity in rat striatal slices</article-title><source><italic toggle="yes">Molecular Neurobiology</italic></source><year>2018</year><volume>55</volume><issue>11</issue><fpage>8538</fpage><lpage>8549</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1003-2</pub-id><pub-id pub-id-type="other">2-s2.0-85044184871</pub-id><pub-id pub-id-type="pmid">29564809</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>E. L.</given-names></name><name><surname>Raman</surname><given-names>S.</given-names></name><name><surname>Yost</surname><given-names>R. A.</given-names></name><name><surname>Garrett</surname><given-names>T. J.</given-names></name><name><surname>Vedam-Mai</surname><given-names>V.</given-names></name></person-group><article-title>L-Carnitine inhibits lipopolysaccharide-induced nitric oxide production of SIM-A9 microglia cells</article-title><source><italic toggle="yes">ACS Chemical Neuroscience</italic></source><year>2018</year><volume>9</volume><issue>5</issue><fpage>901</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.7b00468</pub-id><pub-id pub-id-type="other">2-s2.0-85047225188</pub-id><?supplied-pmid 29370524?><pub-id pub-id-type="pmid">29370524</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Glutamine protects against oxidative stress injury through inhibiting the activation of PI3K/Akt signaling pathway in parkinsonian cell model</article-title><source><italic toggle="yes">Environmental Health and Preventive Medicine</italic></source><year>2019</year><volume>24</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30611201</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernando</surname><given-names>S.</given-names></name><name><surname>Requejo</surname><given-names>C.</given-names></name><name><surname>Herran</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Beneficial effects of <italic>n</italic>-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson&#x02019;s disease: the role of glia and NRf2 regulation</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2019</year><volume>121</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.10.001</pub-id><pub-id pub-id-type="other">2-s2.0-85055029070</pub-id><?supplied-pmid 30296616?><pub-id pub-id-type="pmid">30296616</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>L.</given-names></name><name><surname>Witt</surname><given-names>E. H.</given-names></name><name><surname>Tritschler</surname><given-names>H. J.</given-names></name></person-group><article-title>Alpha-lipoic acid as a biological antioxidant</article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>1995</year><volume>19</volume><issue>2</issue><fpage>227</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(95)00017-R</pub-id><pub-id pub-id-type="other">2-s2.0-0029070687</pub-id><pub-id pub-id-type="pmid">7649494</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>L.</given-names></name><name><surname>Tritschler</surname><given-names>H. J.</given-names></name><name><surname>Wessel</surname><given-names>k.</given-names></name></person-group><article-title>Neuroprotection by the metabolic antioxidant <italic>&#x003b1;</italic>-lipoic acid</article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>1997</year><volume>22</volume><issue>1-2</issue><fpage>359</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(96)00269-9</pub-id><pub-id pub-id-type="other">2-s2.0-0029909010</pub-id><?supplied-pmid 8958163?><pub-id pub-id-type="pmid">8958163</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maczurek</surname><given-names>A.</given-names></name><name><surname>Hager</surname><given-names>K.</given-names></name><name><surname>Kenklies</surname><given-names>M.</given-names></name><name><surname>Sharman</surname><given-names>M.</given-names></name><name><surname>Martins</surname><given-names>R.</given-names></name><name><surname>Engel</surname><given-names>J.</given-names></name></person-group><article-title>Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer&#x02019;s disease</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2008</year><volume>60</volume><issue>13-14</issue><fpage>1463</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.04.015</pub-id><pub-id pub-id-type="other">2-s2.0-51449084024</pub-id><?supplied-pmid 18655815?><pub-id pub-id-type="pmid">18655815</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilska</surname><given-names>A.</given-names></name><name><surname>Dubiel</surname><given-names>M.</given-names></name><name><surname>Sokolowska-Jez&#x02019;ewicz</surname><given-names>M.</given-names></name><name><surname>Lorenc-koci</surname><given-names>E.</given-names></name><name><surname>Wlodek</surname><given-names>L.</given-names></name></person-group><article-title>Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2007</year><volume>146</volume><issue>4</issue><fpage>1758</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.04.002</pub-id><pub-id pub-id-type="other">2-s2.0-34249039316</pub-id><?supplied-pmid 17478054?><pub-id pub-id-type="pmid">17478054</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Wen</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Alpha lipoamide ameliorates motor deficits and mitochondrial dynamics in the Parkinson&#x02019;s disease model induced by 6-hydroxydopamine</article-title><source><italic toggle="yes">Neurotoxicity Research</italic></source><year>2018</year><volume>33</volume><issue>4</issue><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1007/s12640-017-9819-5</pub-id><pub-id pub-id-type="other">2-s2.0-85030845773</pub-id><pub-id pub-id-type="pmid">29019159</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Alpha-lipoic acid alleviated 6-OHDA-induced cell damage by inhibiting AMPK/mTOR mediated autophagy</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2019</year><volume>155</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.04.009</pub-id><pub-id pub-id-type="other">2-s2.0-85066315365</pub-id><?supplied-pmid 30986422?><pub-id pub-id-type="pmid">30986422</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulikova</surname><given-names>O. I.</given-names></name><name><surname>Berezhnoy</surname><given-names>D. S.</given-names></name><name><surname>Stvolinsky</surname><given-names>S. L.</given-names></name><name><surname>Lopachev</surname><given-names>A. V.</given-names></name><name><surname>Orlova</surname><given-names>V. S.</given-names></name><name><surname>Fedorova</surname><given-names>T. N.</given-names></name></person-group><article-title>Neuroprotective effect of the carnosine&#x02013;<italic>&#x003b1;</italic>-lipoic acid nanomicellar complex in a model of early-stage Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Regulatory Toxicology and Pharmacology</italic></source><year>2018</year><volume>95</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">29601911</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S. F.</given-names></name><name><surname>Xie</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Wang</surname><given-names>M. H.</given-names></name><name><surname>Wang</surname><given-names>X. J.</given-names></name><name><surname>Liu</surname><given-names>Z. G.</given-names></name></person-group><article-title>Lipoic acid alleviates L-DOPA-induced dyskinesia in 6-OHDA parkinsonian rats via anti-oxidative stress</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>1118</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">29115484</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdin</surname><given-names>A. A.</given-names></name><name><surname>Sarhan</surname><given-names>N. I.</given-names></name></person-group><article-title>Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of <italic>&#x003b1;</italic>-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity</article-title><source><italic toggle="yes">Neuroscience Research</italic></source><year>2011</year><volume>71</volume><fpage>387</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">21889550</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumaswala</surname><given-names>U. J.</given-names></name><name><surname>Zhuo</surname><given-names>L.</given-names></name><name><surname>Mahajan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs</article-title><source><italic toggle="yes">American Journal of Physiology-Cell Physiology</italic></source><year>2001</year><volume>280</volume><issue>4</issue><fpage>C867</fpage><lpage>C873</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.2001.280.4.C867</pub-id><?supplied-pmid 11245604?><pub-id pub-id-type="pmid">11245604</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glosli</surname><given-names>H.</given-names></name><name><surname>Tronstad</surname><given-names>K. J.</given-names></name><name><surname>Wergedal</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Human TNF-<italic>&#x003b1;</italic> in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes</article-title><source><italic toggle="yes">The FASEB Journal</italic></source><year>2002</year><volume>16</volume><issue>11</issue><fpage>1450</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1096/fj.01-0948fje</pub-id><?supplied-pmid 12205044?><pub-id pub-id-type="pmid">12205044</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Sawada</surname><given-names>H.</given-names></name><name><surname>Izumi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2007</year><volume>282</volume><issue>7</issue><fpage>4364</fpage><lpage>4372</lpage><pub-id pub-id-type="pmid">17158454</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harish</surname><given-names>G.</given-names></name><name><surname>Venkateshappa</surname><given-names>C.</given-names></name><name><surname>Mythri</surname><given-names>R. B.</given-names></name><etal/></person-group><article-title>Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Bioorganic &#x00026; Medicinal Chemistry</italic></source><year>2010</year><volume>18</volume><issue>7</issue><fpage>2631</fpage><lpage>2638</lpage><pub-id pub-id-type="pmid">20227282</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>Dalton</surname><given-names>T. P.</given-names></name><name><surname>Nebert</surname><given-names>D. W.</given-names></name><name><surname>Shertzer</surname><given-names>H. G.</given-names></name></person-group><article-title>Glutathione redox state regulates mitochondrial reactive oxygen production</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>27</issue><fpage>25305</fpage><lpage>25312</lpage><pub-id pub-id-type="pmid">15883162</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>N.</given-names></name><name><surname>Jurma</surname><given-names>O.</given-names></name><name><surname>Lalli</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pettus</surname><given-names>E. H.</given-names></name><name><surname>Greenamyre</surname><given-names>J. T.</given-names></name></person-group><article-title>Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>34</issue><fpage>26096</fpage><lpage>26101</lpage><pub-id pub-id-type="pmid">10846169</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinta</surname><given-names>S. J.</given-names></name><name><surname>Kumar</surname><given-names>M. J.</given-names></name><name><surname>Hsu</surname><given-names>M.</given-names></name><name><surname>Rajagopalan</surname><given-names>S.</given-names></name><name><surname>Kaur</surname><given-names>D.</given-names></name><name><surname>Rane</surname><given-names>A.</given-names></name></person-group><article-title>Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2007</year><volume>27</volume><issue>51</issue><fpage>13997</fpage><lpage>14006</lpage><pub-id pub-id-type="pmid">18094238</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>J. B.</given-names></name><name><surname>Lindenau</surname><given-names>J.</given-names></name><name><surname>Seyfried</surname><given-names>J.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name></person-group><article-title>Glutathione, oxidative stress and neurodegeneration</article-title><source><italic toggle="yes">European Journal of Biochemistry</italic></source><year>2000</year><volume>267</volume><issue>16</issue><fpage>4904</fpage><lpage>4911</lpage><pub-id pub-id-type="pmid">10931172</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sechi</surname><given-names>G.</given-names></name><name><surname>Deledda</surname><given-names>M. G.</given-names></name><name><surname>Bua</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Reduced intravenous glutathione in the treatment of early Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>1996</year><volume>20</volume><issue>7</issue><fpage>1159</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">8938817</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Sakamoto</surname><given-names>N.</given-names></name><name><surname>Iwai</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats</article-title><source><italic toggle="yes">Research Communications in Chemical Pathology and Pharmacology</italic></source><year>1993</year><volume>81</volume><issue>2</issue><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">8210700</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wassef</surname><given-names>R.</given-names></name><name><surname>Haenold</surname><given-names>R.</given-names></name><name><surname>Hansel</surname><given-names>A.</given-names></name><name><surname>Brot</surname><given-names>N.</given-names></name><name><surname>Heinemann</surname><given-names>S. H.</given-names></name><name><surname>Hoshi</surname><given-names>T.</given-names></name></person-group><article-title>Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson&#x02019;s-like symptoms</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>2007</year><volume>27</volume><issue>47</issue><fpage>12808</fpage><lpage>12816</lpage><pub-id pub-id-type="pmid">18032652</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>J.</given-names></name><name><surname>Clore</surname><given-names>E. L.</given-names></name><name><surname>Zheng</surname><given-names>K.</given-names></name><name><surname>Adame</surname><given-names>A.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Simon</surname><given-names>D. K.</given-names></name></person-group><article-title>Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in <italic>&#x003b1;</italic>-synuclein overexpressing mice</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2010</year><volume>5</volume><issue>8</issue><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarukhani</surname><given-names>M.</given-names></name><name><surname>Haghdoost-Yazdi</surname><given-names>H.</given-names></name><name><surname>Sarbazi Golezari</surname><given-names>A.</given-names></name><name><surname>Babayan-Tazehkand</surname><given-names>A.</given-names></name><name><surname>Dargahi</surname><given-names>T.</given-names></name><name><surname>Rastgoo</surname><given-names>N.</given-names></name></person-group><article-title>Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson&#x02019;s disease: behavioral, histological and biochemical studies</article-title><source><italic toggle="yes">Neurological Research</italic></source><year>2018</year><volume>40</volume><issue>7</issue><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">29726751</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virel</surname><given-names>A.</given-names></name><name><surname>Dudka</surname><given-names>I.</given-names></name><name><surname>Laterveer</surname><given-names>R.</given-names></name><name><surname>af Bjerk&#x000e9;n</surname><given-names>S.</given-names></name></person-group><article-title>1H NMR profiling of the 6-OHDA parkinsonian rat brain reveals metabolic alterations and signs of recovery after N-acetylcysteine treatment</article-title><source><italic toggle="yes">Molecular and Cellular Neuroscience</italic></source><year>2019</year><volume>98</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">31200101</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonilla-Porras</surname><given-names>A. R.</given-names></name><name><surname>Jimenez-Del-Rio</surname><given-names>M.</given-names></name><name><surname>Velez-Pardo</surname><given-names>C.</given-names></name></person-group><article-title>N-Acetyl-cysteine blunts 6-hydroxydopamine-and l-buthionine-sulfoximine-induced apoptosis in human mesenchymal stromal cells</article-title><source><italic toggle="yes">Molecular Biology Reports</italic></source><year>2019</year><volume>46</volume><issue>4</issue><fpage>4423</fpage><lpage>4435</lpage><pub-id pub-id-type="pmid">31147858</pub-id></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname><given-names>L. D.</given-names></name><name><surname>Tuite</surname><given-names>P. J.</given-names></name><name><surname>&#x000d6;z</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Repeated-dose oral N-acetylcysteine in Parkinson&#x02019;s disease: pharmacokinetics and effect on brain glutathione and oxidative stress</article-title><source><italic toggle="yes">The Journal of Clinical Pharmacology</italic></source><year>2018</year><volume>58</volume><issue>2</issue><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/jcph.1008</pub-id><pub-id pub-id-type="other">2-s2.0-85030160901</pub-id><pub-id pub-id-type="pmid">28940353</pub-id></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>Y.</given-names></name><name><surname>Fukushima</surname><given-names>W.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Dietary intake of antioxidant vitamins and risk of Parkinson&#x02019;s disease: a case&#x02013;control study in Japan</article-title><source><italic toggle="yes">European Journal of Neurology</italic></source><year>2011</year><volume>18</volume><issue>1</issue><fpage>106</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03088.x</pub-id><pub-id pub-id-type="other">2-s2.0-78650134461</pub-id><?supplied-pmid 20491891?><pub-id pub-id-type="pmid">20491891</pub-id></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Rijk</surname><given-names>M. C.</given-names></name><name><surname>Breteler</surname><given-names>M. M. B.</given-names></name><name><surname>den Breeijen</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title>Dietary antioxidants and Parkinson disease: the Rotterdam Study</article-title><source><italic toggle="yes">Archives of Neurology</italic></source><year>1997</year><volume>54</volume><issue>6</issue><fpage>762</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1001/archneur.1997.00550180070015</pub-id><pub-id pub-id-type="other">2-s2.0-0030943863</pub-id><?supplied-pmid 9193212?><pub-id pub-id-type="pmid">9193212</pub-id></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Hernan</surname><given-names>M. A.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Willett</surname><given-names>W. C.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group><article-title>Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk</article-title><source><italic toggle="yes">Neurology</italic></source><year>2002</year><volume>59</volume><issue>8</issue><fpage>1161</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">12391343</pub-id></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etminan</surname><given-names>M.</given-names></name><name><surname>Gill</surname><given-names>S. S.</given-names></name><name><surname>Samii</surname><given-names>A.</given-names></name></person-group><article-title>Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson&#x02019;s disease: a meta-analysis</article-title><source><italic toggle="yes">The Lancet Neurology</italic></source><year>2005</year><volume>4</volume><issue>6</issue><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">15907740</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirinzi</surname><given-names>T.</given-names></name><name><surname>Martella</surname><given-names>G.</given-names></name><name><surname>Imbriani</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Dietary vitamin E as a protective factor for Parkinson&#x02019;s disease: clinical and experimental evidence</article-title><source><italic toggle="yes">Frontiers in Neurology</italic></source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fneur.2019.00148</pub-id><pub-id pub-id-type="other">2-s2.0-85064813570</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>McDermott</surname><given-names>M.</given-names></name><name><surname>Como</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurology</italic></source><year>1994</year><volume>44</volume><issue>9</issue><fpage>1756</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1212/WNL.44.9.1756</pub-id><?supplied-pmid 7936311?><pub-id pub-id-type="pmid">7936311</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morens</surname><given-names>D. M.</given-names></name><name><surname>Grandinetti</surname><given-names>A.</given-names></name><name><surname>Waslien</surname><given-names>C. I.</given-names></name><name><surname>Park</surname><given-names>C. B.</given-names></name><name><surname>Ross</surname><given-names>G. W.</given-names></name><name><surname>White</surname><given-names>L. R.</given-names></name></person-group><article-title>Case-control study of idiopathic Parkinson&#x02019;s disease and dietary vitamin E intake</article-title><source><italic toggle="yes">Neurology</italic></source><year>1996</year><volume>46</volume><issue>5</issue><fpage>1270</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">8628465</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheider</surname><given-names>W. L.</given-names></name><name><surname>Hershey</surname><given-names>L. A.</given-names></name><name><surname>Vena</surname><given-names>J. E.</given-names></name><name><surname>Holmlund</surname><given-names>T.</given-names></name><name><surname>Marshall</surname><given-names>J. R.</given-names></name><name><surname>Freudenheim</surname><given-names>J. L.</given-names></name></person-group><article-title>Dietary antioxidants and other dietary factors in the etiology of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>1997</year><volume>12</volume><issue>2</issue><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">9087977</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C.</given-names></name><name><surname>Checkoway</surname><given-names>H.</given-names></name><name><surname>Franklin</surname><given-names>G. M.</given-names></name><name><surname>Beresford</surname><given-names>S.</given-names></name><name><surname>Smith-Weller</surname><given-names>T.</given-names></name><name><surname>Swanson</surname><given-names>P. D.</given-names></name></person-group><article-title>Dietary factors in Parkinson&#x02019;s disease: the role of food groups and specific foods</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>1999</year><volume>14</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9918340</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellenbrand</surname><given-names>W.</given-names></name><name><surname>Boeing</surname><given-names>H.</given-names></name><name><surname>Robra</surname><given-names>B. P.</given-names></name><etal/></person-group><article-title>Diet and Parkinson&#x02019;s disease. II. A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study</article-title><source><italic toggle="yes">Neurology</italic></source><year>1996</year><volume>47</volume><issue>3</issue><fpage>644</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.3.644</pub-id><pub-id pub-id-type="other">2-s2.0-9544227379</pub-id><?supplied-pmid 8797457?><pub-id pub-id-type="pmid">8797457</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>K. C.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>I. Y.</given-names></name><etal/></person-group><article-title>Intake of antioxidant vitamins and risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2016</year><volume>31</volume><issue>12</issue><fpage>1909</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1002/mds.26819</pub-id><pub-id pub-id-type="other">2-s2.0-84999723790</pub-id><?supplied-pmid 27787934?><pub-id pub-id-type="pmid">27787934</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Yamada</surname><given-names>M.</given-names></name></person-group><article-title>Vitamin A potently destabilizes preformed <italic>&#x003b1;</italic>-synuclein fibrils in vitro: implications for Lewy body diseases</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2007</year><volume>25</volume><issue>2</issue><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">17169566</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahn</surname><given-names>S.</given-names></name></person-group><article-title>A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Annals of Neurology</italic></source><year>1992</year><volume>32</volume><issue>S1</issue><fpage>S128</fpage><lpage>S132</lpage><pub-id pub-id-type="pmid">1510371</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roghani</surname><given-names>M.</given-names></name><name><surname>Behzadi</surname><given-names>G.</given-names></name></person-group><article-title>Neuroprotective effect of vitamin E on the early model of Parkinson&#x02019;s disease in rat: behavioral and histochemical evidence</article-title><source><italic toggle="yes">Brain Research</italic></source><year>2001</year><volume>892</volume><issue>1</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">11172767</pub-id></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Moreno</surname><given-names>J. C.</given-names></name><name><surname>de la Riva</surname><given-names>M. P.</given-names></name><name><surname>Mart&#x000ed;nez-Lara</surname><given-names>E.</given-names></name><name><surname>Siles</surname><given-names>E.</given-names></name><name><surname>Ca&#x000f1;uelo</surname><given-names>A.</given-names></name></person-group><article-title>Tyrosol, a simple phenol from EVOO, targets multiple pathogenic mechanisms of neurodegeneration in a <italic>C. elegans</italic> model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Aging</italic></source><year>2019</year><volume>82</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">31404721</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson&#x02019;s disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway</article-title><source><italic toggle="yes">Toxicology and Applied Pharmacology</italic></source><year>2019</year><volume>378, article 114617</volume><pub-id pub-id-type="doi">10.1016/j.taap.2019.114617</pub-id><pub-id pub-id-type="other">2-s2.0-85067845285</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goes</surname><given-names>A. T. R.</given-names></name><name><surname>Jesse</surname><given-names>C. R.</given-names></name><name><surname>Antunes</surname><given-names>M. S.</given-names></name><etal/></person-group><article-title>Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson&#x02019;s disease: involvement of neuroinflammation and neurotrophins</article-title><source><italic toggle="yes">Chemico-Biological Interactions</italic></source><year>2018</year><volume>279</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2017.10.019</pub-id><pub-id pub-id-type="other">2-s2.0-85034736766</pub-id><?supplied-pmid 29054324?><pub-id pub-id-type="pmid">29054324</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamoorthy</surname><given-names>A.</given-names></name><name><surname>Sevanan</surname><given-names>M.</given-names></name><name><surname>Mani</surname><given-names>S.</given-names></name><name><surname>Balu</surname><given-names>M.</given-names></name><name><surname>Balaji</surname><given-names>S.</given-names></name><name><surname>P</surname><given-names>R.</given-names></name></person-group><article-title>Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson&#x02019;s disease mouse model</article-title><source><italic toggle="yes">Neuroscience Letters</italic></source><year>2019</year><volume>709, article 134382</volume><pub-id pub-id-type="doi">10.1016/j.neulet.2019.134382</pub-id><pub-id pub-id-type="other">2-s2.0-85069828038</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group><article-title>Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway</article-title><source><italic toggle="yes">Food and Chemical Toxicology</italic></source><year>2018</year><volume>119</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">29906474</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Tang</surname><given-names>B.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson&#x02019;s disease models through Nrf2 induction</article-title><source><italic toggle="yes">Journal of Agricultural and Food Chemistry</italic></source><year>2018</year><volume>66</volume><issue>31</issue><fpage>8307</fpage><lpage>8318</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.8b02607</pub-id><pub-id pub-id-type="other">2-s2.0-85049501351</pub-id><?supplied-pmid 29961319?><pub-id pub-id-type="pmid">29961319</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. L.</given-names></name><name><surname>Ju</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Y. Z.</given-names></name><etal/></person-group><article-title>Protective effect of curcumin against oxidative stress-induced injury in rats with Parkinson&#x02019;s disease through the Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway</article-title><source><italic toggle="yes">Cellular Physiology and Biochemistry</italic></source><year>2017</year><volume>43</volume><issue>6</issue><fpage>2226</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1159/000484302</pub-id><pub-id pub-id-type="other">2-s2.0-85032330846</pub-id><?supplied-pmid 29069652?><pub-id pub-id-type="pmid">29069652</pub-id></element-citation></ref><ref id="B221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T. T.</given-names></name><name><surname>Vuu</surname><given-names>M. D.</given-names></name><name><surname>Huynh</surname><given-names>M. A.</given-names></name><name><surname>Yamaguchi</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>L. T.</given-names></name><name><surname>Dang</surname><given-names>T. P. T.</given-names></name></person-group><article-title>Curcumin effectively rescued Parkinson&#x02019;s disease-like phenotypes in a novel <italic>Drosophila melanogaster</italic> model with dUCH knockdown</article-title><source><italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic></source><year>2018</year><volume>2018</volume><fpage>12</fpage><pub-id pub-id-type="publisher-id">2038267</pub-id><pub-id pub-id-type="doi">10.1155/2018/2038267</pub-id><pub-id pub-id-type="other">2-s2.0-85055156545</pub-id></element-citation></ref><ref id="B222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramkumar</surname><given-names>M.</given-names></name><name><surname>Rajasankar</surname><given-names>S.</given-names></name><name><surname>Swaminathan</surname><given-names>J. W.</given-names></name><name><surname>Prabu</surname><given-names>K.</given-names></name><name><surname>Venkatesh</surname><given-names>G. V.</given-names></name></person-group><article-title>Demethoxycurcumin ameliorates rotenone-induced toxicity in rats</article-title><source><italic toggle="yes">Frontiers in Bioscience (Elite Edition)</italic></source><year>2019</year><volume>11</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30468633</pub-id></element-citation></ref><ref id="B223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poetini</surname><given-names>M. R.</given-names></name><name><surname>Araujo</surname><given-names>S. M.</given-names></name><name><surname>de Paula</surname><given-names>M. T.</given-names></name><etal/></person-group><article-title>Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in <italic>Drosophila melanogaster</italic> model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Chemico-Biological Interactions</italic></source><year>2018</year><volume>279</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2017.11.018</pub-id><pub-id pub-id-type="other">2-s2.0-85036542631</pub-id><?supplied-pmid 29191452?><pub-id pub-id-type="pmid">29191452</pub-id></element-citation></ref><ref id="B224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>S.</given-names></name><name><surname>Sekar</surname><given-names>S.</given-names></name><name><surname>Barathidasan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Naringenin decreases <italic>&#x003b1;</italic>-synuclein expression and neuroinflammation in MPTP-induced Parkinson&#x02019;s disease model in mice</article-title><source><italic toggle="yes">Neurotoxicity Research</italic></source><year>2018</year><volume>33</volume><issue>3</issue><fpage>656</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s12640-018-9869-3</pub-id><pub-id pub-id-type="other">2-s2.0-85041848100</pub-id><?supplied-pmid 29427283?><pub-id pub-id-type="pmid">29427283</pub-id></element-citation></ref><ref id="B225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugumar</surname><given-names>M.</given-names></name><name><surname>Sevanan</surname><given-names>M.</given-names></name><name><surname>Sekar</surname><given-names>S.</given-names></name></person-group><article-title>Neuroprotective effect of naringenin against MPTP-induced oxidative stress</article-title><source><italic toggle="yes">International Journal of Neuroscience</italic></source><year>2019</year><volume>129</volume><issue>6</issue><fpage>534</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">30433834</pub-id></element-citation></ref><ref id="B226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L. F.</given-names></name><name><surname>Yu</surname><given-names>X. L.</given-names></name><name><surname>Ji</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T <italic>&#x003b1;</italic>-synuclein mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Food &#x00026; Function</italic></source><year>2018</year><volume>9</volume><issue>12</issue><fpage>6414</fpage><lpage>6426</lpage><pub-id pub-id-type="doi">10.1039/C8FO00964C</pub-id><pub-id pub-id-type="other">2-s2.0-85058604929</pub-id><?supplied-pmid 30462117?><pub-id pub-id-type="pmid">30462117</pub-id></element-citation></ref><ref id="B227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abolaji</surname><given-names>A. O.</given-names></name><name><surname>Adedara</surname><given-names>A. O.</given-names></name><name><surname>Adie</surname><given-names>M. A.</given-names></name><name><surname>Vicente-Crespo</surname><given-names>M.</given-names></name><name><surname>Farombi</surname><given-names>E. O.</given-names></name></person-group><article-title>Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in <italic>Drosophila melanogaster</italic></article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2018</year><volume>503</volume><issue>2</issue><fpage>1042</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">29935183</pub-id></element-citation></ref><ref id="B228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Resveratrol suppresses rotenone-induced neurotoxicity through activation of SIRT1/Akt1 signaling pathway</article-title><source><italic toggle="yes">The Anatomical Record</italic></source><year>2018</year><volume>301</volume><issue>6</issue><fpage>1115</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1002/ar.23781</pub-id><pub-id pub-id-type="other">2-s2.0-85042150442</pub-id><pub-id pub-id-type="pmid">29350822</pub-id></element-citation></ref><ref id="B229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Z.-L.</given-names></name><name><surname>Wu</surname><given-names>H.-C.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of genistein on SH-SY5Y cells overexpressing A53T mutant <italic>&#x003b1;</italic>-synuclein</article-title><source><italic toggle="yes">Neural Regeneration Research</italic></source><year>2018</year><volume>13</volume><issue>8</issue><fpage>p. 1375</fpage></element-citation></ref><ref id="B230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name></person-group><article-title>Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced <italic>&#x003b1;</italic>-synuclein aggregation</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2019</year><volume>144</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">30342981</pub-id></element-citation></ref><ref id="B231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D.-M.</given-names></name><name><surname>Han</surname><given-names>X.-R.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Salidroside protection against oxidative stress injury through the Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway in rats with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Cellular Physiology and Biochemistry</italic></source><year>2018</year><volume>46</volume><issue>5</issue><fpage>1793</fpage><lpage>1806</lpage><pub-id pub-id-type="pmid">29705802</pub-id></element-citation></ref><ref id="B232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros-Linard</surname><given-names>C. F. B.</given-names></name><name><surname>da Silveira Andrade-da-Costa</surname><given-names>B. L.</given-names></name><name><surname>Augusto</surname><given-names>R. L.</given-names></name><etal/></person-group><article-title>Anacardic acids from cashew nuts prevent behavioral changes and oxidative stress induced by rotenone in a rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurotoxicity Research</italic></source><year>2018</year><volume>34</volume><issue>2</issue><fpage>250</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s12640-018-9882-6</pub-id><pub-id pub-id-type="other">2-s2.0-85043364237</pub-id><?supplied-pmid 29520721?><pub-id pub-id-type="pmid">29520721</pub-id></element-citation></ref><ref id="B233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javed</surname><given-names>H.</given-names></name><name><surname>Azimullah</surname><given-names>S.</given-names></name><name><surname>Meeran</surname><given-names>M. F.</given-names></name><name><surname>Ansari</surname><given-names>S. A.</given-names></name><name><surname>Ojha</surname><given-names>S.</given-names></name></person-group><article-title>Neuroprotective effects of thymol, a dietary monoterpene against dopaminergic neurodegeneration in rotenone-induced rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2019</year><volume>20</volume><issue>7</issue><fpage>p. 1538</fpage></element-citation></ref><ref id="B234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Mo</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson&#x02019;s disease mouse model</article-title><source><italic toggle="yes">International Immunopharmacology</italic></source><year>2019</year><volume>75, article 105651</volume><pub-id pub-id-type="doi">10.1016/j.intimp.2019.05.036</pub-id><pub-id pub-id-type="other">2-s2.0-85070223977</pub-id><?supplied-pmid 31401385?><pub-id pub-id-type="pmid">31401385</pub-id></element-citation></ref><ref id="B235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddadi</surname><given-names>H.</given-names></name><name><surname>Rajaei</surname><given-names>Z.</given-names></name><name><surname>Alaei</surname><given-names>H.</given-names></name><name><surname>Shahidani</surname><given-names>S.</given-names></name></person-group><article-title>Chronic treatment with carvacrol improves passive avoidance memory in a rat model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Arquivos de Neuro-Psiquiatria</italic></source><year>2018</year><volume>76</volume><issue>2</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">29489959</pub-id></element-citation></ref><ref id="B236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C. C.</given-names></name><name><surname>Chang</surname><given-names>C. H.</given-names></name><name><surname>Liao</surname><given-names>V. H. C.</given-names></name></person-group><article-title>Anti-Parkinsonian effects of <italic>&#x003b2;</italic>-amyrin are regulated via LGG-1 involved autophagy pathway in <italic>Caenorhabditis elegans</italic></article-title><source><italic toggle="yes">Phytomedicine</italic></source><year>2017</year><volume>36</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">29157804</pub-id></element-citation></ref><ref id="B237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Asiatic acid prevents oxidative stress and apoptosis by inhibiting the translocation of <italic>&#x003b1;</italic>-synuclein into mitochondria</article-title><source><italic toggle="yes">Frontiers in Neuroscience</italic></source><year>2018</year><volume>12</volume><fpage>p. 431</fpage></element-citation></ref><ref id="B238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rekha</surname><given-names>K. R.</given-names></name><name><surname>Sivakamasundari</surname><given-names>R. I.</given-names></name></person-group><article-title>Geraniol protects against the protein and oxidative stress induced by rotenone in an in vitro model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurochemical Research</italic></source><year>2018</year><volume>43</volume><issue>10</issue><fpage>1947</fpage><lpage>1962</lpage><pub-id pub-id-type="pmid">30141137</pub-id></element-citation></ref><ref id="B239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name><name><surname>Sigears</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group><article-title>Grape skin extract improves muscle function and extends lifespan of a <italic>Drosophila</italic> model of Parkinson&#x02019;s disease through activation of mitophagy</article-title><source><italic toggle="yes">Experimental Gerontology</italic></source><year>2018</year><volume>113</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">30248358</pub-id></element-citation></ref><ref id="B240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teerapattarakan</surname><given-names>N.</given-names></name><name><surname>Benya-Aphikul</surname><given-names>H.</given-names></name><name><surname>Tansawat</surname><given-names>R.</given-names></name><name><surname>Wanakhachornkrai</surname><given-names>O.</given-names></name><name><surname>Tantisira</surname><given-names>M. H.</given-names></name><name><surname>Rodsiri</surname><given-names>R.</given-names></name></person-group><article-title>Neuroprotective effect of a standardized extract of <italic>Centella asiatica</italic> ECa233 in rotenone-induced parkinsonism rats</article-title><source><italic toggle="yes">Phytomedicine</italic></source><year>2018</year><volume>44</volume><fpage>65</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">29895494</pub-id></element-citation></ref><ref id="B241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.-Y.</given-names></name><name><surname>Karthivashan</surname><given-names>G.</given-names></name><name><surname>Ko</surname><given-names>H. M.</given-names></name><etal/></person-group><article-title>Aqueous extract of <italic>Dendropanax morbiferus</italic> leaves effectively alleviated neuroinflammation and behavioral impediments in MPTP-induced Parkinson&#x02019;s mouse model</article-title><source><italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic></source><year>2018</year><volume>2018</volume><fpage>14</fpage><pub-id pub-id-type="publisher-id">3175214</pub-id><pub-id pub-id-type="doi">10.1155/2018/3175214</pub-id><pub-id pub-id-type="other">2-s2.0-85055071263</pub-id></element-citation></ref><ref id="B242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Mao</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Anti-oxidative and anti-apoptotic neuroprotective effects of <italic>Azadirachta indica</italic> in Parkinson-induced functional damage</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2018</year><volume>17</volume><issue>6</issue><fpage>7959</fpage><lpage>7965</lpage><pub-id pub-id-type="pmid">29620282</pub-id></element-citation></ref><ref id="B243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V.</given-names></name><name><surname>Essa</surname><given-names>M. M.</given-names></name><name><surname>Guizani</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Protective effect of <italic>Zizyphus spinachristi</italic> on MPP<sup>+</sup>-induced oxidative stress</article-title><source><italic toggle="yes">Frontiers in Bioscience</italic></source><year>2018</year><volume>10</volume><fpage>285</fpage><lpage>299</lpage></element-citation></ref><ref id="B244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chonpathompikunlert</surname><given-names>P.</given-names></name><name><surname>Boonruamkaew</surname><given-names>P.</given-names></name><name><surname>Sukketsiri</surname><given-names>W.</given-names></name><name><surname>Hutamekalin</surname><given-names>P.</given-names></name><name><surname>Sroyraya</surname><given-names>M.</given-names></name></person-group><article-title>The antioxidant and neurochemical activity of <italic>Apium graveolens</italic> L. and its ameliorative effect on MPTP-induced Parkinson-like symptoms in mice</article-title><source><italic toggle="yes">BMC Complementary and Alternative Medicine</italic></source><year>2018</year><volume>18</volume><issue>1</issue><fpage>p. 103</fpage><pub-id pub-id-type="pmid">29558946</pub-id></element-citation></ref><ref id="B245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>P.</given-names></name><name><surname>Montes</surname><given-names>S.</given-names></name><name><surname>Serrano-Garc&#x000ed;a</surname><given-names>N.</given-names></name><name><surname>Rojas-Casta&#x000f1;eda</surname><given-names>J.</given-names></name></person-group><article-title>Effect of EGb761 supplementation on the content of copper in mouse brain in an animal model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Nutrition</italic></source><year>2009</year><volume>25</volume><issue>4</issue><fpage>482</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">19091511</pub-id></element-citation></ref><ref id="B246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Effects of <italic>Ginkgo biloba</italic> extract on A53T <italic>&#x003b1;</italic>-synuclein transgenic mouse models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Canadian Journal of Neurological Sciences</italic></source><year>2018</year><volume>45</volume><issue>2</issue><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1017/cjn.2017.268</pub-id><pub-id pub-id-type="other">2-s2.0-85043294062</pub-id><?supplied-pmid 29506601?><pub-id pub-id-type="pmid">29506601</pub-id></element-citation></ref><ref id="B247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Ara&#x000fa;jo</surname><given-names>D. P.</given-names></name><name><surname>Nogueira</surname><given-names>P. C. N.</given-names></name><name><surname>Santos</surname><given-names>A. D. C.</given-names></name><etal/></person-group><article-title>
<italic>Aspidosperma pyrifolium</italic> Mart: neuroprotective, antioxidant and anti-inflammatory effects in a Parkinson&#x02019;s disease model in rats</article-title><source><italic toggle="yes">Journal of Pharmacy and Pharmacology</italic></source><year>2018</year><volume>70</volume><issue>6</issue><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1111/jphp.12866</pub-id><pub-id pub-id-type="other">2-s2.0-85046540424</pub-id><?supplied-pmid 29490425?><pub-id pub-id-type="pmid">29490425</pub-id></element-citation></ref><ref id="B248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbishegi</surname><given-names>M.</given-names></name><name><surname>Gorgich</surname><given-names>E. A. C.</given-names></name><name><surname>Khajavi</surname><given-names>O.</given-names></name><name><surname>Komeili</surname><given-names>G.</given-names></name><name><surname>Salimi</surname><given-names>S.</given-names></name></person-group><article-title>The neuroprotective effects of hydro-alcoholic extract of olive (<italic>Olea europaea</italic> L.) leaf on rotenone-induced Parkinson&#x02019;s disease in rat</article-title><source><italic toggle="yes">Metabolic Brain Disease</italic></source><year>2018</year><volume>33</volume><issue>1</issue><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">29039078</pub-id></element-citation></ref><ref id="B249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>B.</given-names></name><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Yadav</surname><given-names>S. K.</given-names></name><name><surname>Verma</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>S. P.</given-names></name><name><surname>Mahdi</surname><given-names>A. A.</given-names></name></person-group><article-title>Role of ethanolic extract of <italic>Bacopa monnieri</italic> against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons</article-title><source><italic toggle="yes">Brain Research Bulletin</italic></source><year>2017</year><volume>135</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">29032054</pub-id></element-citation></ref><ref id="B250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hritcu</surname><given-names>L.</given-names></name><name><surname>Foyet</surname><given-names>H. S.</given-names></name><name><surname>Stefan</surname><given-names>M.</given-names></name><name><surname>Mihasan</surname><given-names>M.</given-names></name><name><surname>Asongalem</surname><given-names>A. E.</given-names></name><name><surname>Kamtchouing</surname><given-names>P.</given-names></name></person-group><article-title>Neuroprotective effect of the methanolic extract of <italic>Hibiscus asper</italic> leaves in 6-hydroxydopamine-lesioned rat model of Parkinson's disease</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2011</year><volume>137</volume><issue>1</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">21704692</pub-id></element-citation></ref><ref id="B251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. G.</given-names></name><name><surname>Ju</surname><given-names>M. S.</given-names></name><name><surname>Shim</surname><given-names>J. S.</given-names></name><etal/></person-group><article-title>Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson&#x02019;s disease models</article-title><source><italic toggle="yes">British Journal of Nutrition</italic></source><year>2010</year><volume>104</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1017/S0007114510000218</pub-id><pub-id pub-id-type="other">2-s2.0-77954687171</pub-id><?supplied-pmid 20187987?><pub-id pub-id-type="pmid">20187987</pub-id></element-citation></ref><ref id="B252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beserra-Filho</surname><given-names>J. I. A.</given-names></name><name><surname>de Mac&#x000ea;do</surname><given-names>A. M.</given-names></name><name><surname>Le&#x000e3;o</surname><given-names>A. H. F. F.</given-names></name><etal/></person-group><article-title>
<italic>Eplingiella fruticosa</italic> leaf essential oil complexed with <italic>&#x003b2;</italic>-cyclodextrin produces a superior neuroprotective and behavioral profile in a mice model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Food and Chemical Toxicology</italic></source><year>2019</year><volume>124</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2018.11.056</pub-id><pub-id pub-id-type="other">2-s2.0-85057311207</pub-id><?supplied-pmid 30481574?><pub-id pub-id-type="pmid">30481574</pub-id></element-citation></ref><ref id="B253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaafan</surname><given-names>M. A.</given-names></name><name><surname>Abdelhamid</surname><given-names>A. M.</given-names></name><name><surname>Ibrahim</surname><given-names>S. M.</given-names></name></person-group><article-title>The protective effect of Korean red ginseng against rotenone-induced Parkinson&#x02019;s disease in rat model: modulation of nuclear factor-<italic>&#x003ba;&#x003b2;</italic> and caspase-3</article-title><source><italic toggle="yes">Current Pharmaceutical Biotechnology</italic></source><year>2019</year><volume>20</volume><issue>7</issue><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">31198107</pub-id></element-citation></ref><ref id="B254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>R.-H.</given-names></name><name><surname>Harn</surname><given-names>H.-J.</given-names></name><name><surname>Liu</surname><given-names>S.-P.</given-names></name><etal/></person-group><article-title>n-Butylidenephthalide protects against dopaminergic neuron degeneration and <italic>&#x003b1;</italic>-synuclein accumulation in <italic>Caenorhabditis elegans</italic> models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>1</issue></element-citation></ref><ref id="B255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>J.</given-names></name><name><surname>Alves</surname><given-names>C.</given-names></name><name><surname>Freitas</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Antioxidant and neuroprotective potential of the brown seaweed <italic>Bifurcaria bifurcata</italic> in an in vitro Parkinson&#x02019;s disease model</article-title><source><italic toggle="yes">Marine Drugs</italic></source><year>2019</year><volume>17</volume><issue>2</issue><fpage>p. 85</fpage><pub-id pub-id-type="doi">10.3390/md17020085</pub-id><pub-id pub-id-type="other">2-s2.0-85061143511</pub-id><?supplied-pmid 30717087?><pub-id pub-id-type="pmid">30717087</pub-id></element-citation></ref><ref id="B256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>S. H.</given-names></name><name><surname>Heo</surname><given-names>S. J.</given-names></name><name><surname>Jeon</surname><given-names>Y. J.</given-names></name><name><surname>Park</surname><given-names>S. M.</given-names></name></person-group><article-title>Dieckol, an edible seaweed polyphenol, retards rotenone-induced neurotoxicity and <italic>&#x003b1;</italic>-synuclein aggregation in human dopaminergic neuronal cells</article-title><source><italic toggle="yes">RSC Advances</italic></source><year>2016</year><volume>6</volume><issue>111</issue><fpage>110040</fpage><lpage>110046</lpage></element-citation></ref><ref id="B257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C. Y.</given-names></name><name><surname>Kuo</surname><given-names>C. H.</given-names></name><name><surname>Chen</surname><given-names>P. W.</given-names></name></person-group><article-title>Compressional-puffing pretreatment enhances neuroprotective effects of fucoidans from the brown seaweed <italic>Sargassum hemiphyllum</italic> on 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells</article-title><source><italic toggle="yes">Molecules</italic></source><year>2018</year><volume>23</volume><issue>1</issue><fpage>p. 78</fpage></element-citation></ref><ref id="B258"><label>258</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Banskota</surname><given-names>A. H.</given-names></name><name><surname>Critchley</surname><given-names>A. T.</given-names></name><name><surname>Hafting</surname><given-names>J.</given-names></name><name><surname>Prithiviraj</surname><given-names>B.</given-names></name></person-group><article-title>Neuroprotective effects of the cultivated <italic>Chondrus crispus</italic> in a <italic>C. elegans</italic> model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Marine Drugs</italic></source><year>2015</year><volume>13</volume><issue>4</issue><fpage>2250</fpage><lpage>2266</lpage><pub-id pub-id-type="pmid">25874922</pub-id></element-citation></ref><ref id="B259"><label>259</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Diosgenin attenuates lipopolysaccharide-induced Parkinson&#x02019;s disease by inhibiting the TLR/NF-<italic>&#x003ba;</italic>B pathway</article-title><source><italic toggle="yes">Journal of Alzheimer's Disease</italic></source><year>2018</year><volume>64</volume><issue>3</issue><fpage>943</fpage><lpage>955</lpage></element-citation></ref><ref id="B260"><label>260</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardah</surname><given-names>M. T.</given-names></name><name><surname>Merghani</surname><given-names>M. M.</given-names></name><name><surname>Haque</surname><given-names>M. E.</given-names></name></person-group><article-title>Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates <italic>&#x003b1;</italic>-synuclein aggregation in vitro</article-title><source><italic toggle="yes">Neurochemistry International</italic></source><year>2019</year><volume>128</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">31028778</pub-id></element-citation></ref><ref id="B261"><label>261</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>M. Q.</given-names></name><name><surname>Chen</surname><given-names>Z. Y.</given-names></name><etal/></person-group><article-title>Sulforaphane prevents PC12 cells from oxidative damage via the Nrf2 pathway</article-title><source><italic toggle="yes">Molecular Medicine Reports</italic></source><year>2019</year><volume>19</volume><issue>6</issue><fpage>4890</fpage><lpage>4896</lpage><pub-id pub-id-type="doi">10.3892/mmr.2019.10148</pub-id><pub-id pub-id-type="other">2-s2.0-85066115002</pub-id><?supplied-pmid 31059012?><pub-id pub-id-type="pmid">31059012</pub-id></element-citation></ref><ref id="B262"><label>262</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadzadeh</surname><given-names>L.</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name><name><surname>Abnous</surname><given-names>K.</given-names></name><name><surname>Razavi</surname><given-names>B. M.</given-names></name></person-group><article-title>Neuroprotective potential of crocin against malathion-induced motor deficit and neurochemical alterations in rats</article-title><source><italic toggle="yes">Environmental Science and Pollution Research</italic></source><year>2018</year><volume>25</volume><issue>5</issue><fpage>4904</fpage><lpage>4914</lpage><pub-id pub-id-type="pmid">29204935</pub-id></element-citation></ref><ref id="B263"><label>263</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Deshmukh</surname><given-names>R.</given-names></name></person-group><article-title>Neuroprotective potential of spermidine against rotenone induced Parkinson&#x02019;s disease in rats</article-title><source><italic toggle="yes">Neurochemistry International</italic></source><year>2018</year><volume>116</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">29501454</pub-id></element-citation></ref><ref id="B264"><label>264</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddadi</surname><given-names>R.</given-names></name><name><surname>Poursina</surname><given-names>M.</given-names></name><name><surname>Zeraati</surname><given-names>F.</given-names></name><name><surname>Nadi</surname><given-names>F.</given-names></name></person-group><article-title>Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc</article-title><source><italic toggle="yes">Inflammopharmacology</italic></source><year>2018</year><volume>26</volume><issue>5</issue><fpage>1305</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">29616453</pub-id></element-citation></ref><ref id="B265"><label>265</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Pharmacological Sciences</italic></source><year>2018</year><volume>138</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">30241783</pub-id></element-citation></ref><ref id="B266"><label>266</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motyl</surname><given-names>J.</given-names></name><name><surname>Przykaza</surname><given-names>&#x00141;.</given-names></name><name><surname>Boguszewski</surname><given-names>P. M.</given-names></name><name><surname>Kosson</surname><given-names>P.</given-names></name><name><surname>Strosznajder</surname><given-names>J. B.</given-names></name></person-group><article-title>Pramipexole and fingolimod exert neuroprotection in a mouse model of Parkinson&#x02019;s disease by activation of sphingosine kinase 1 and Akt kinase</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2018</year><volume>135</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">29481916</pub-id></element-citation></ref><ref id="B267"><label>267</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Mai</surname><given-names>D.</given-names></name><name><surname>Qu</surname><given-names>S.</given-names></name></person-group><article-title>Simvastatin inhibits activation of NADPH oxidase/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models</article-title><source><italic toggle="yes">Frontiers in Molecular Neuroscience</italic></source><year>2018</year><volume>11</volume><fpage>p. 165</fpage></element-citation></ref><ref id="B268"><label>268</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhurtel</surname><given-names>S.</given-names></name><name><surname>Katila</surname><given-names>N.</given-names></name><name><surname>Neupane</surname><given-names>S.</given-names></name><name><surname>Srivastav</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>P. H.</given-names></name><name><surname>Choi</surname><given-names>D. Y.</given-names></name></person-group><article-title>Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor</article-title><source><italic toggle="yes">Annals of the New York Academy of Sciences</italic></source><year>2018</year><volume>1431</volume><issue>1</issue><fpage>58</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">29882218</pub-id></element-citation></ref><ref id="B269"><label>269</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussaoui</surname><given-names>S.</given-names></name><name><surname>Obinu</surname><given-names>M.</given-names></name><name><surname>Daniel</surname><given-names>N.</given-names></name><name><surname>Reibaud</surname><given-names>M.</given-names></name><name><surname>Blanchard</surname><given-names>V.</given-names></name><name><surname>Imperato</surname><given-names>A.</given-names></name></person-group><article-title>The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Experimental Neurology</italic></source><year>2000</year><volume>166</volume><issue>2</issue><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">11085889</pub-id></element-citation></ref><ref id="B270"><label>270</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Teng</surname><given-names>J.</given-names></name></person-group><article-title>Pretreatment of glial cell-derived neurotrophic factor and geranylgeranylacetone ameliorates brain injury in Parkinson&#x02019;s disease by its anti-apoptotic and anti-oxidative property</article-title><source><italic toggle="yes">Journal of Cellular Biochemistry</italic></source><year>2018</year><volume>119</volume><issue>7</issue><fpage>5491</fpage><lpage>5502</lpage><pub-id pub-id-type="pmid">29377238</pub-id></element-citation></ref><ref id="B271"><label>271</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson&#x02019;s disease model</article-title><source><italic toggle="yes">Redox Biology</italic></source><year>2019</year><volume>22, article 101134</volume></element-citation></ref><ref id="B272"><label>272</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>k. I.</given-names></name><name><surname>Chung</surname><given-names>Y. C.</given-names></name><name><surname>Jin</surname><given-names>B. K.</given-names></name></person-group><article-title>Norfluoxetine prevents degeneration of dopamine neurons by inhibiting microglia-derived oxidative stress in an MPTP mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Mediators of inflammation</italic></source><year>2018</year><volume>2018</volume><fpage>8</fpage><pub-id pub-id-type="publisher-id">4591289</pub-id><pub-id pub-id-type="doi">10.1155/2018/4591289</pub-id><pub-id pub-id-type="other">2-s2.0-85060649037</pub-id></element-citation></ref><ref id="B273"><label>273</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapias</surname><given-names>V.</given-names></name><name><surname>McCoy</surname><given-names>J. L.</given-names></name><name><surname>Greenamyre</surname><given-names>J. T.</given-names></name></person-group><article-title>Phenothiazine normalizes the NADH/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Redox Biology</italic></source><year>2019</year><volume>24, article 101164</volume></element-citation></ref><ref id="B274"><label>274</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Hydralazine protects nigrostriatal dopaminergic neurons from MPP<sup>+</sup> and MPTP induced neurotoxicity: roles of Nrf2-ARE signaling pathway</article-title><source><italic toggle="yes">Frontiers in Neurology</italic></source><year>2019</year><volume>10</volume><fpage>p. 271</fpage><pub-id pub-id-type="doi">10.3389/fneur.2019.00271</pub-id><pub-id pub-id-type="pmid">30949126</pub-id></element-citation></ref><ref id="B275"><label>275</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname><given-names>R. M.</given-names></name><name><surname>Ahmed</surname><given-names>M. A. E.</given-names></name><name><surname>El-Sahar</surname><given-names>A. E.</given-names></name><name><surname>El Sayed</surname><given-names>N. S.</given-names></name></person-group><article-title>Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: possible role of its antioxidant, anti-inflammatory and antiapoptotic effects</article-title><source><italic toggle="yes">Toxicology and Applied Pharmacology</italic></source><year>2018</year><volume>358</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">30222980</pub-id></element-citation></ref><ref id="B276"><label>276</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.-L.</given-names></name><name><surname>Wu</surname><given-names>Y.-F.</given-names></name><name><surname>Yan</surname><given-names>F.</given-names></name><etal/></person-group><article-title>5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson&#x02019;s disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress</article-title><source><italic toggle="yes">Free Radical Biology and Medicine</italic></source><year>2019</year><volume>134</volume><fpage>288</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">30615919</pub-id></element-citation></ref><ref id="B277"><label>277</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. A.</given-names></name><name><surname>Son</surname><given-names>H. J.</given-names></name><name><surname>Choi</surname><given-names>J. W.</given-names></name><etal/></person-group><article-title>Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220</article-title><source><italic toggle="yes">Neurochemistry International</italic></source><year>2018</year><volume>112</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.11.006</pub-id><pub-id pub-id-type="other">2-s2.0-85034668850</pub-id><pub-id pub-id-type="pmid">29158022</pub-id></element-citation></ref><ref id="B278"><label>278</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biosa</surname><given-names>A.</given-names></name><name><surname>Sanchez-Martinez</surname><given-names>A.</given-names></name><name><surname>Filograna</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss</article-title><source><italic toggle="yes">Human Molecular Genetics</italic></source><year>2018</year><volume>27</volume><issue>9</issue><fpage>1618</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy069</pub-id><pub-id pub-id-type="other">2-s2.0-85047013237</pub-id><?supplied-pmid 29529199?><pub-id pub-id-type="pmid">29529199</pub-id></element-citation></ref><ref id="B279"><label>279</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Seo</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Angewandte Chemie International Edition</italic></source><year>2018</year><volume>57</volume><issue>30</issue><fpage>9408</fpage><lpage>9412</lpage><pub-id pub-id-type="doi">10.1002/anie.201805052</pub-id><pub-id pub-id-type="other">2-s2.0-85050028860</pub-id><pub-id pub-id-type="pmid">29862623</pub-id></element-citation></ref><ref id="B280"><label>280</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>R.</given-names></name><name><surname>Wairkar</surname><given-names>S.</given-names></name><name><surname>Sridhar</surname><given-names>V.</given-names></name><name><surname>Gaud</surname><given-names>R.</given-names></name></person-group><article-title>Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity</article-title><source><italic toggle="yes">International Journal of Biological Macromolecules</italic></source><year>2018</year><volume>109</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">29247729</pub-id></element-citation></ref><ref id="B281"><label>281</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Dang</surname><given-names>S.</given-names></name><name><surname>Nigam</surname><given-names>K.</given-names></name><name><surname>Ali</surname><given-names>J.</given-names></name><name><surname>Baboota</surname><given-names>S.</given-names></name></person-group><article-title>Selegiline nanoformulation in attenuation of oxidative stress and upregulation of dopamine in the brain for the treatment of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Rejuvenation Research</italic></source><year>2018</year><volume>21</volume><issue>5</issue><fpage>464</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1089/rej.2017.2035</pub-id><pub-id pub-id-type="other">2-s2.0-85055071057</pub-id><?supplied-pmid 29717617?><pub-id pub-id-type="pmid">29717617</pub-id></element-citation></ref><ref id="B282"><label>282</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agim</surname><given-names>Z. S.</given-names></name><name><surname>Cannon</surname><given-names>J. R.</given-names></name></person-group><article-title>Dietary factors in the etiology of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">BioMed Research International</italic></source><year>2015</year><volume>2015</volume><fpage>16</fpage><pub-id pub-id-type="publisher-id">672838</pub-id><pub-id pub-id-type="doi">10.1155/2015/672838</pub-id><pub-id pub-id-type="other">2-s2.0-84922351025</pub-id></element-citation></ref><ref id="B283"><label>283</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J. A.</given-names></name><name><surname>Shukitt-Hale</surname><given-names>B.</given-names></name><name><surname>Denisova</surname><given-names>N. A.</given-names></name><etal/></person-group><article-title>Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation</article-title><source><italic toggle="yes">Journal of Neuroscience</italic></source><year>1999</year><volume>19</volume><issue>18</issue><fpage>8114</fpage><lpage>8121</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-18-08114.1999</pub-id><pub-id pub-id-type="pmid">10479711</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Sources of oxidative stress in Parkinson's disease.</p></caption><graphic xlink:href="OMCL2020-2360872.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mechanisms of free radical involvement in Parkinson's disease.</p></caption><graphic xlink:href="OMCL2020-2360872.002"/></fig></floats-group></article>